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The National Disease Surveillance Centre became the Health
Protection Surveillance Centre on moving into the Health
Service Executive on 1st January 2005.
The establishment of the HSE - which is responsible for the
running of the health services in Ireland - has meant that it is
no longer necessary to have a board at HPSC. It has been a
great honour for me to have served on the board since the
foundation of the centre in 1998. On behalf of all those who
have served on the board over the last seven years,
I wish HPSC well within the new structures.
Since its foundation in 1998 the centre has worked tirelessly
in partnership with health service providers and sister
organisations around the world, to provide up to date
information for the effective control of infectious diseases.
During this time the HPSC has rightly won the respect of the
international medical community through sheer hard work
and strict adherence to best practice. I am confident that it
can continue to enhance its well-earned reputation for
excellence at the forefront of the global fight against
communicable disease.
HPSC will continue to make a valuable contribution to public
health in Ireland, through the provision of expert advice,
epidemiological investigation, scientific research, data
collection and participation in health promotion and training.
As in previous years this report reflects the diligence, vision
and professionalism of the Director, Dr Darina O'Flanagan and
her staff.
The health services in Ireland are facing an exciting and
challenging future. HPSC can face the future with great
confidence and will continue to make a significant
contribution to improving the health of the Irish population.
It remains for me to thank the outgoing Board members, our
Director, and all the staff whose efforts have made such a
huge contribution to the ongoing success of HPSC.
Dr Elizabeth Keane
Chairperson
Board of the National Disease Surveillance Centre
Foreword
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Introduction
Since the 1st January 2005 the newly established Health
Services Executive has been responsible for the running of the
health services in Ireland. The National Disease Surveillance
Centre welcomed the opportunity to lend our expertise to the
new body and as our agency is now part of the Health
Protection division, it was appropriate that our name reflected
the key role we have to play in improving the health of the
Irish population.
The publication of this annual report marks our transition
from the National Disease Surveillance Centre to the Health
Protection Surveillance Centre. Our role and responsibilities
remain the same.
This is the centre's sixth annual report.
2004 saw the emergence of the H5N1 strain of avian
influenza which has spread rapidly amongst birds in Asia and
has now reached Eastern Europe. While it shows no sign of
becoming humanly transmissible its emergence re-enforces
the need to remain vigilant for any indications of a new
influenza pandemic.
There was a marked decrease in illness due to Norovirus,
because of a combination of short-term immunity amongst
the population and the use of guidelines - produced by NDSC
- to combat the disease. There were 1744 outbreak cases in
2003, compared with 7650 in 2002. Unfortunately 2004 saw
the emergence of a new strain across Europe. The so-called
'jam strain', a new variant of Norovirus, was originally
detected from an outbreak at an international scout jamboree
in the Netherlands in the summer of 2004. This led again to
an increase in Ireland in 2004 up to 2388 outbreak cases.
Untreated water supplies, particularly from private wells may
pose a significant threat to public health. During 2004, they
continued to be associated with outbreaks of VTEC such as
E.coli O157. Two of the four VTEC associated HUS cases in
children in 2004 were caused by non O157 VTEC. This
highlights the importance for clinicians to look closely for
other types of VTEC apart from E.coli O157 in cases of severe
illness such as HUS.
Data supplied to the European Antimicrobial Resistance
Surveillance System (EARSS) in 2004 covered 98% of the Irish
population providing information on MRSA and other
pathogens which are associated with resistance concerns both
in the hospital and the community setting. This coverage of
population in this European surveillance system compares
favourably with other EU countries (e.g.16% coverage in the
UK and 19% coverage in Spain). Extensions of surveillance of
MRSA and other hospital acquired infections needs to be
resourced at both national and local levels. Antibiotic usage
in 2004 increased and the trend is rising year on year. It is
crucial to link in the data on antibiotic usage to the problem
of increasing antimicrobial resistance.
HPSC Annual Report 2004 5
Ireland had the second highest rate of measles among 16
other EU countries which reported complete data for 2004.
We also suffered a mumps outbreak which saw a 10-fold
increase highlighting the need for investment in approved
infrastructure, especially the development of a national
computerised childhood immunisation registry. However the
continued rise in immunisation uptake was very welcome and
reached 89% in 2004 for the five primary antigens and 81%
for MMR. MMR uptake in particular is still far below the
internationally recommended level of 95% and the deficit
needs to be tackled through a catch-up campaign.
There were 1154 cases of Hepatitis C notified in 2004, which
was the first year that Hepatitis C became a notifiable disease
in its own right. The development of a comprehensive
strategy to respond to this serious problem is urgently
required.
The number of new HIV diagnoses in 2004 highlights the
need for maintaining harm reduction measures. There
continues to be a need for culturally appropriate messages for
heterosexual transmission. 38 of the 356 cases newly
diagnosed were late diagnosis in that AIDS was diagnosed at
the time of HIV diagnosis. This reinforces the need for
members of the general public to seek testing if they consider
they may have placed themselves at risk.
Between August and December 2004 there was an increase in
the number of Hib vaccine failures in children. Six failures
occurred in 2004 compared with three in 2003 and four in
2002. This increase continued into 2005 and a catch up
campaign with the introduction of a booster dose has begun
to address the problem. The national immunisation schedule
is prioritised according to the epidemiology of diseases
occurring in the country. Surveillance of infectious disease is
one of the cornerstones of all immunisation programs.
Finally, I would like to thank everyone who serves voluntarily
on HPSC's scientific advisory committees. They are a great
example of what can be achieved through multi disciplinary
collaboration between professionals working to reduce the
burden of illness from communicable disease. Thanks also to
all the staff at HPSC whose commitment and professionalism
is reflected in this report.
Dr Darina O'Flanagan
Director
Health Protection Surveillance Centre
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Epidemiology of Cryptosporidiosis 
in Ireland, 2004
Key Points
• In 2004, under S.I.707, Cryptosporidiosis became a
notifiable disease
• The crude incidence rate in Ireland in 2004 was 11.0 per
100,000 population
• The highest reported incidence was in children under the
age of 5 years
• A large proportion of the cases were reported between
April and June
• The lowest incidence was reported by the ERHA.
Introduction
Cryptosporidium is a protozoal parasite that causes a
diarrhoeal illness in humans known as cryptosporidiosis. In
2004, under the Infectious Diseases (Amendment) (No 3)
Regulations 2003 (S.I. 707 of 2003), cryptosporidiosis became
a notifiable disease in Ireland in all age groups, permitting us
for the first time to report on the national incidence of
cryptosporidiosis in Ireland.
Cryptosporidium was first recognised in the 1980s as a cause
of severe diarrhoeal illness in patients with AIDS, but more
recently it has been established that it is a major cause of
diarrhoeal illness in healthy individuals. In immunocompetent
patients it causes watery non-bloody diarrhoea, sometimes
accompanied by abdominal pain, nausea, anorexia, fever and
weight loss. In immunocompromised individuals, especially
those with AIDS, diarrhoea can be chronic and persistent,
causing clinically significant fluid and electrolyte depletion.
Weight loss, wasting and abdominal pain may be severe.
C. parvum (formerly known as C. parvum type II) and C.
hominis (formerly known as C. parvum type I) are the main
species associated with human infection, although a minority
of infections have been linked with other species such as C.
felis and C. meleagridis. The primary reservoir for C. hominis is
humans while both livestock (calves and lambs in particular)
and humans serve as reservoirs for C. parvum. Thus, speciation
can be used to indicate a likely source of infection for
individual cases.
With both humans and animals serving as potential reservoirs,
multiple routes of transmission are possible. The consumption
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of contaminated water is regarded as being an important
transmission route,1 but infection can also occur as a result of
recreational bathing,2 consumption of contaminated foods,
and animal-person3 and person-to-person transmission. A
primary public health concern regarding Cryptosporidium is its
relative resistance to chlorination.
Several reports have indicated the importance of
cryptosporidiosis as a cause of gastroenteritis in Ireland.4 5 6 A
number of outbreaks in Ireland have also served to heighten
concerns regarding cryptosporidiosis.7 8
Methods
Cases of cryptosporidiosis were notified by both clinicians and
laboratory directors to the medical officer of health in each
health board, and data were collated and forwarded to HPSC
on a weekly basis. These weekly notifications form the basis of
the analyses presented here. The case definition for
cryptosporidiosis in Ireland is based on the EU case definition
and is as follows:
Clinical description
Clinical picture compatible with cryptosporidiosis,
characterised by diarrhoea, abdominal cramps, loss of
appetite, nausea and vomiting.
Laboratory criteria for diagnosis
One of the following:
• Demonstration of Cryptosporidium oocysts in stool
• Demonstration of Cryptosporidium sp. in intestinal fluid or
small-bowel biopsy specimens
• Demonstration of Cryptosporidium antigen in stool
Case classification
Possible: N/A
Probable: A clinically compatible case with an epidemiological
link
Confirmed: A case that is laboratory confirmed.
Census data from 2002 (CSO) were used to calculate
incidence rates.
Results
Incidence 
In 2004, 432 cases of cryptosporidiosis were notified, an
incidence rate of 11.0 per 100,000 population.
Geographical distribution 
The crude incidence rates by health board for 2004 are
reported in table 1. There was a wide variation in rates
reported between health boards that, in addition to a true
difference in incidence, may also reflect regional variation in
laboratory screening and case-finding policies. An outbreak in
the MHB in May 2004 contributed in part to it being the
health board with the highest incidence rate in 2004 (27.5 per
100,000). Other health board that had incidence rates higher
than the national rate were the WHB, SEHB, NWHB, MWHB
and SHB. The lowest rate was reported by the ERHA.
Age distribution 
The highest reported incidence was in children under the age
of 5 years (figure 1).
The majority of health boards reported a similar age profile
for cases. However, the age profile for the ERHA was atypical
Table 1. Number of notified cases and crude incidence rates of cryptosporidiosis by health 
board, 2004
Health Board No. of notifications CIR (95% C.I.)
ERHA 23 1.6 (0.9-2.3)
MHB 62 27.5 (20.7-34.3)
MWHB 45 13.3 (9.4-17.2)
NEHB 30 8.7 (5.6-11.8)
NWHB 41 18.5 (12.8-24.2)
SEHB 80 18.9 (14.8-23.0)
SHB 74 12.8 (9.9-15.7)
WHB 77 20.2 (15.7-24.7)
Total 432 11.0 (10.0-12.0)
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with a much larger proportion of adult cases. The SEHB also
reported a higher proportion of adult cases (table 2).
Seasonality
The largest number of cases was notified during the month of
April, and 49% of all cases were reported during the 3 months
April to June (figure 2).
Outbreaks of cryptosporidiosis in Ireland 2004
Five outbreaks of cryptosporidiosis were reported in 2004:
four general outbreaks [SEHB (2), MHB (1) and NEHB (1)] and
one family outbreak (SEHB). The suspected mode of
transmission for all four general outbreaks was waterborne. In
the MHB, epidemiological evidence was obtained linking the
outbreak with tap water consumption.8 The family outbreak
was reported as being due to person-to-person transmission.
Discussion
The establishment of cryptosporidiosis as a notifiable disease
in 2004 was an important first step in understanding the
epidemiology of cryptosporidiosis in Ireland, providing a
baseline against which subsequent data can be evaluated. In
2004, Cryptosporidium imposed a considerable burden of
illness in Ireland, with over 400 cases notified
(CIR=11.0/100,000) making it the most common protozoal
gastrointestinal pathogen notified. This is slightly higher than
in the UK, where the rates were 6.8/100,000 in England and
Wales (personal communication HPS, London), and 9.1 per
100,000 in Scotland,9 in 2004.
There is a large variation in incidence between health boards.
Some of the difference may reflect different diagnostic
policies and case finding procedures between regions. In two
studies of cryptosporidiosis in Irish children, a higher incidence
among children from rural backgrounds was noted.10 11 The low
rate of cryptosporidiosis among the ERHA population is
consistent with this observation. In the UK, London has
historically also had a low rate of cryptosporidiosis reported.12
The age profile of cases in the ERHA was also distinctive, with
only 4/22 (18%) reported cases being less than 15 years,
compared to 64-96% in other parts of the country. It was
reported that many of these cases were travel-associated.
The seasonal effect reported here is consistent with that
reported previously for Ireland6 but differs significantly from
the pattern reported in England and Wales where between
1996 and 2000, there was a bimodal pattern in human
cryptosporidiosis cases with a peak in the number of cases in
early May and late September.13 C. parvum was more common
in the spring while C. hominis was significantly more common
in patients infected during late summer/autumn.14 The spring
peak in human infections in the UK concurred with that of
infection in farm animals, co-incident with calving and
lambing. This pattern changed significantly in 2001 and
subsequent years when the May peak in human infections
was considerably reduced.13 Initially the observed reduction in
England and Wales in 2001 was thought to be due to the
restrictions imposed during the foot and mouth outbreak that
year.12 However, the sustained reduction in the number of
spring cases in the North West of England, an area that had
contributed a disproportionate number of cases to national
surveillance during quarter 2 1997 to 2000,13 has more
recently been attributed to a major programme of
development in a public water supply in that region.
Table 2. Number of cryptosporidiosis notifications by health board and age group in 2004
Age Group (years) ERHA MHB MWHB NEHB NWHB SEHB SHB WHB Total
Less than 1  1 3 1 3 3 9 8 10 38
1-4  1 36 29 15 21 30 44 45 221
5-9  0 11 10 5 8 10 10 15 69
10-14  2 3 2 2 2 2 5 3 21
>=15  18 9 2 5 6 29 7 3 79
N/K 1 0 1 0 1 0 0 1 4
Total 23 62 45 30 41 80 74 77 432
% <15  18% 85% 95% 83% 85% 64% 91% 96% 80%
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Figure 2. Seasonal distribution of cryptosporidiosis cases 2004 
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From the seasonal distribution of cases reported here, it is
likely that the epidemiology of the disease differs from that
seen currently in England and Wales. For outbreaks, water has
been shown to be an important transmission route here.
However, the transmission route for sporadic cases remains
unconfirmed. It is likely that transmission from animal
reservoirs is of primary importance for sporadic cases, with
perhaps animal contact and water source contamination by
livestock being central.
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Key Points
• There were 407 new cases of TB notified in 2003, giving
a crude incidence rate of 10.4 per 100,000 population
• Two hundred and sixty two (64.4%) of the cases were
culture confirmed. M. tuberculosis was isolated in 250
cases and M. bovis in five cases 
• Of the 407 cases reported in 2003, 299 cases (73.4%)
had a pulmonary component of which 146 (48.8%) were
smear positive
• Eighty nine (21.9%) of the cases were born outside
Ireland
• Outcome data were reported in 84.8% of TB cases (345
cases)
• Six deaths were attributed to TB in 2003
• There were 437 cases of TB provisionally notified 
in 2004
Introduction
Since 1998, all information concerning TB notifications in
Ireland has been reported by each of the health boards to the
Health Protection Surveillance Centre (HPSC), known formerly
as the National Disease Surveillance Centre (NDSC) for
analysis. Beginning on January 1st 2000, this information has
included enhanced surveillance data based on the minimum
dataset reported to EuroTB, the European agency that collates
national TB data within Europe and contributes that data to
the WHO global TB control programme.1 The resulting
National Tuberculosis Surveillance System (NTBSS) was set up
following consultation between HPSC, the eight health boards
and the National Tuberculosis (TB) Advisory Group.
Materials and Methods
For each individual case of tuberculosis notified in 2003, an
enhanced notification form was completed by public health
doctors, using the available clinical, microbiological,
histological and epidemiological data. These forms were then
collated in the regional Departments of Public Health. In each
regional Public Health department, data were also entered
onto an Epi Info 2000 database. From this database, an
anonymised dataset was submitted to HPSC on a quarterly
basis where the data were collated nationally. Reports
summarising results were produced on a quarterly basis by
the HPSC. Information on all 2003 cases was updated in
early/mid 2005 by each health board to include outcome
data.
Population figures, used as the denominator, were taken from
the 2002 census of population. In order to compare rates
between groups of interest, 95% confidence intervals were
Tuberculosis in Ireland, 2003
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used. Direct methods of standardisation were used to allow
comparison of rates between geographical areas using the
Irish population as the standard population.
As in previous years, the case definitions used were as
recommended by the National Tuberculosis (TB) Working
Group.2
A notified case of TB refers to clinically active disease due to
infection with organisms of the Mycobacterium tuberculosis
complex (M. tuberculosis, M. bovis, M. africanum). Active
disease is presumed if the patient is commenced on a full
curative course of anti-tuberculosis chemotherapy. Persons
placed on chemoprophylaxis for preventive treatment or
infected by mycobacteria other than M. tuberculosis complex
are not included as cases.
Pulmonary TB is defined as a laboratory-confirmed case –
either a positive smear, histology or culture of a respiratory
sample – with or without radiological abnormalities
consistent with active pulmonary TB or a case where the
physician takes the decision that the patient’s clinical
symptoms and/or radiological signs are compatible with
pulmonary TB.
Extrapulmonary TB is defined as a patient with a smear,
culture or histological specimen, from an extrapulmonary site,
that is positive for M. tuberculosis complex or a case with
clinical signs of active extrapulmonary disease in conjunction
with a decision taken by the attending physician to treat the
patient with a full curative course of anti-tuberculosis
chemotherapy.
Multi drug resistance (MDR) is defined as resistance to at
least isoniazid and rifampicin with or without resistance to
other antituberculosis drugs.
Results
Four hundred and seven cases of TB were notified in 2003 in
Ireland, giving a notification rate of 10.4/100,000 population.
This compares to 408 cases notified in 2002 and 381 cases
notified in 2001 (table 1).
Age standardised rates by health board are provided in table
2. The highest age standardised TB incidence rate was
reported in the SHB at 16.0 per 100,000 population. This was
significantly higher than the national age standardised
incidence rate (10.3/100,000). The next highest rates were
reported in the MWHB (12.3/100,000) and the ERHA
(11.8/100,000). The NWHB had the lowest rate at 3.8 per
100,000 population. The rates in the NWHB, MHB and WHB
were significantly lower than the national age standardised
incidence rate.
Age and sex distribution
Two hundred and fifty two cases were male (61.9%) and 154
were female (37.8%), giving a male to female ratio of 1.6:1.
The gender of one case was not recorded. The average age of
those diagnosed with TB was 43.1 years with a range from
less than one year of age to 98 years. Approximately 6% of
cases were aged less than 15 years and 23% of cases occurred
in those aged 65 and over. The highest rates were observed in
those aged 65 years and older (21.3/100,000 population). The
age- and sex-specific incidence rates per 100,000 population
in Ireland, in 2003 are illustrated in figure 1.
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Figure 1: Age- and sex-specific TB incidence rates in Ireland, 2003
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Geographic origin
Of the 407 patients diagnosed with TB in 2003, 300 (73.7%)
were born in Ireland, 89 (21.9%) were born outside Ireland
and for the remaining 18 cases, the country of birth was
unknown. Of the 89 born outside Ireland in 2003, 38 cases
were born in Asia, 22 in Europe, 21 in Africa, two in North
America and one in South America. The country of birth was
unknown for five of the cases born outside Ireland. The crude
rate of TB notifications in the indigenous population only in
2003 was 8.7/100,000 population while the national crude
rate for all cases notified in 2003 was 10.4/100,000
population.
Diagnostic details
Of the 407 TB notifications, 262 (64.4%) were definite cases
which were culture confirmed. Of the 262 culture-confirmed
cases, 250 (95.4%) of the isolates were M. tuberculosis and
five (1.9%) were M. bovis. The isolate was not specified in
seven culture positive cases.
Two hundred and sixty five cases were pulmonary (65.1%),
105 cases were extrapulmonary (25.8%) and 34 cases were
pulmonary and extrapulmonary TB (8.4%). In three cases, the
TB site was unspecified (0.7%). The diagnostic breakdown in
each health board is shown in table 3. Of the 299 TB cases
with a pulmonary disease component, 211 (70.1%) were
culture positive and 150 (50.2%) were sputum positive by
microscopy. One hundred and forty six (48.8%) of the
pulmonary TB cases were smear positive.1
TB meningitis
There were eight cases of TB meningitis reported in 2003
giving an incidence rate of 2.0 per million. Between 1998 and
2003, 35 cases of TB meningitis have been reported giving a
cumulative incidence rate of 8.9 per million population. Four
of the 35 TB meningitis cases reported between 1998 and
2003 were in children aged 0-4 years.
Resistance
Resistance was documented in 12 cases out of a total of 250
M. tuberculosis isolates (4.8% of M. tuberculosis isolates).
There was one multi-drug resistant TB (MDR-TB) case, which
was resistant to isoniazid, rifampicin, pyrazinamide,
ethambutol and streptomycin. Mono-resistance to isoniazid
was recorded in eight cases and mono-resistance to
streptomycin in one case. Two further cases were resistant to
both isoniazid and streptomycin. Five of the 12 drug-resistant
cases were born outside Ireland.
Outcome
Of the 407 cases notified in 2003, the outcome was recorded
in 345 cases (84.8%). Of the 345 cases, 264 (76.5 %)
completed treatment, 32 (9.3%) died, 30 (8.7%) were
recorded as being lost to follow up, treatment was interrupted
in 12 cases (3.5%) and seven cases were continuing to receive
treatment at time of reporting (2.0%). Of the 32 deaths
reported, six were attributed to TB.
Of the 146 smear positive cases of pulmonary TB notified in
2003, 92 completed treatment, 12 died, seven were lost to
follow up, treatment was interrupted in five cases and two
were still on treatment at time of reporting. The outcome was
unknown in 28 of the cases.
Table 1. Notified TB cases in Ireland, 1991 – 2003, with 3-year moving averages, 
1992 - 2002
Year  Number    Crude rate per 100,000pop.  3 year moving average
1991 640 18.2 
1992 604 17.1 612
1993 598 17.0 581
1994 524 14.5 526
1995 458 12.6 469
1996 434 12.0 436
1997 416 11.5 423
1998 424 11.7 433
1999 469 12.9 439
2000 395 10.1 410
2001 381 9.7 391
2002 408 10.4 401
2003 407 10.4 
 
Table 2: Number of cases of TB in Ireland and age standardised incidence rates with 95% 
confidence intervals (CI) by health board , 2003
Health Board  TB cases  Age standardised incidence rate  95% CI
ERHA 167 11.8 10.0-13.6
MHB 12 5.4 2.3-8.5
MWHB 42 12.4 8.6-16.1
NEHB 26 7.7 4.8-10.7
NWHB 9 3.8 1.3-6.4
SEHB 35 8.3 5.6-11.1
SHB 93 16.0 12.7-19.3
WHB 23 5.9 3.4-8.3
Ireland 407 10.3 9.3-11.4
Age was unknown for one case in the WHB and one case in the ERHA
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A summary profile of the epidemiology of TB in Ireland from
2000 to 2003 is shown in table 4.
Provisional 2004 data
There were 437 cases of TB provisionally notified in 2004. It is
important to note that these data are provisional and may
change significantly following validation and some cases may
also be denotified.
• Of the 437 cases provisionally notified, pulmonary TB was
diagnosed in 274 cases (62.7%), extrapulmonary TB in 117
cases (26.8%) and pulmonary and extrapulmonary TB in 26
cases (6.0%).
• Provisionally, of the 300 TB cases with a pulmonary
component, 165 (55.0%) were culture positive and 134
(44.7%) were sputum smear positive.
• One hundred and twenty (27.5%) of the cases were born
outside Ireland, 282 cases (64.5%) were born in Ireland and
country of birth was unavailable for 35 cases (8.0%).
• Of the 437 cases, 258 (59.0%) were male and 175 (40.0%)
were female. The gender was unknown for four cases.
• One hundred and seventeen (26.8%) of the cases
provisionally notified in 2004 were aged between 25 and 34
and 101 (23.1%) were aged 65 years and older.
• There were six cases of TB meningitis provisionally notified
in 2004
Discussion
In 2003, 407 cases of TB were notified to HPSC giving a
national crude incidence rate of 10.4 per 100,000 population.
This compares to 408 cases notified in 2002 (10.4/100,000)
and 381 cases in 2001 (9.7/100,000). The three year moving 
average, which removes some of the fluctuation from year to
year, showed an increase (table 1).
Differences in age standardised TB incidence rates persist
between health board areas. In 2003, the SHB had the highest
rate of TB followed by the MWHB and the ERHA. In 2002, the
highest rates were seen in the SHB, the SEHB and the ERHA
while in 2001, TB rates were highest in the ERHA and the
SHB. In 2003, the NWHB reported the lowest age
standardised incidence rate.
Those aged 65 and over had the highest age specific rate in
2003. This was similar to the rate observed in this age group
in 2002 (20.6/100,000 population). The male to female ratio
reported in 2003 was also comparable with the rate reported
in 2002 (1.8:1).
Eighty nine of the TB cases (21.9%) diagnosed in 2003 were
born outside Ireland compared to 123 cases (30.1%) in 2002,
63 cases (16.5%) in 2001 and 45 cases (11.1%) in 2000. In
2002, among the 24 countries in the EU who reported data to
the EuroTB network, 28% of notifications were in foreign born
patients.3 In the United Kingdom, France, Germany and
Belgium, where crude incidence rates are similar to those
reported in Ireland, the percentage of cases of foreign origin in
2002 ranged from 38-56%.3
In recent years, the quality of the data, and in particular data
on treatment outcome, has improved. In 2003, information on
treatment outcome was provided for 84.8% of cases as
compared to 77.2% in 2002 and 59.8% in 2001. It is critical
to TB control in Ireland that surveillance of TB and reporting
Table 4. Summary of epidemiology of TB in Ireland, 2000 – 2003
  2000 2001 2002 2003  
Total number of cases 395 381 408 407
Notification rate per 100,000 population 10.1 9.7 10.4 10.4
Foreign born TB patients 44 63 123 89
% Culture positive patients 58 58.8 61.0 64.4
M. tuberculosis 222 204 234 250
M. bovis  2 7 5 5
M. africanum 3 1 0 0
% smear positive pulmonary cases 47.2 44.4 38.4 48.8
Monoresistance to isoniazid 2 4 8 8
Monoresistance to streptomycin 1 3 1 1
Monoresistance to pyrizinamide 1 1 0 0
Multi drug resistant cases  2 2 0 1
Deaths attributed to TB 6 5 5 6
Table 3: Diagnostic categories of TB cases notified in 2003, by health board
Health Board  Pulmonary Extrapulmonary P+E Unknown Total
ERHA 102 43 22 - 167
MHB 9 2 - 1 12
MWHB 29 12 1 - 42
NEHB 18 6 1 1 26
NWHB 8 1 - - 9
SEHB 21 11 3 - 35
SHB 60 26 7 - 93
WHB 18 4 - 1 23
Total 265 105 34 3 407
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of outcome data be maintained at a high level, particularly in
monitoring multi-drug resistant tuberculosis. In 2003, there
was one multi-drug resistant case of TB reported in Ireland
(0.3% of TB cases in 2003). In Western Europe, 1.8% of new
cases of TB in 2003 were multi drug resistant.4 
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Key Points
• During 2004, there were 356 newly diagnosed cases of
HIV infection, a 10% decrease on the number of cases
diagnosed in 2003
• Of the 356 cases, 178 were among heterosexuals, 71
among IDUs and 64 among MSM. Incomplete data were
received for 42 (11.7%) of the newly diagnosed cases  
• Of the 356 cases, 192 (53.9%) were male and 161
(45.2%) were female. Information on gender is
unavailable for three cases
• Of the 356 cases, 136 were born in Ireland, 130 were
born in sub-Saharan Africa and 25 were born in other
countries in Western Europe. Information on geographic
origin is unavailable for 51 of the newly diagnosed cases
• Thirty eight of the 356 cases newly diagnosed with HIV
in 2004 were late diagnoses, i.e. they were diagnosed
with AIDS at the time of HIV diagnosis 
• The cumulative total of HIV infections reported in
Ireland to the end of December 2004 is 3,764
• A total of 38 AIDS cases and four deaths among
HIV/AIDS cases were reported to the HPSC during 2004.
A total of 855 AIDS cases and 393 deaths among
HIV/AIDS cases have been reported to the HPSC up to
the end of June 2005 
Introduction
Worldwide, HIV kills more than 8,000 people every day.
Nearly 5 million people are newly infected with the HIV virus
every year and the vast majority of these people live in
developing countries.1
AIDS surveillance was introduced in Ireland in the mid 1980s
and HIV case based reporting was introduced in mid 2001.
The aims of HIV case based reporting are to ensure the
collection of timely data on the distribution and mode of
transmission of HIV infection, to accurately monitor trends in
the epidemic and to enable linkage between reports of HIV
infection and AIDS.
Methods
HIV and AIDS surveillance in Ireland is voluntary and
anonymous and operates in cooperation with laboratories,
clinicians and Departments of Public Health. For every newly
diagnosed HIV infection, a HIV/AIDS surveillance report form
is sent by the laboratory which confirms the diagnosis, to the
treating clinician. Forms are completed by the clinician and
forwarded to the appropriate Department of Public Health
who in turn forwards them to the HPSC where national
figures are collated. Analysis of HIV data is carried out by the
HPSC every six months and a report is published on the HPSC
website and sent to a large mailing list including clinicians,
microbiologists, public health personnel, DoHC, non-
governmental organizations (NGOs) and other interested
parties. Clinicians are also asked to report all cases of AIDS
and deaths among HIV/AIDS patients to the HPSC using the
HIV/AIDS surveillance report forms. A summary of the HIV
and AIDS data are forwarded twice yearly to the European
HIVand AIDS in Ireland, 2004
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Centre for the Epidemiological Monitoring of AIDS (EuroHIV).
Results
Newly diagnosed HIV infections
During 2004, a total of 356 HIV infections were newly
diagnosed. This compares to 399 diagnosed in 2003 and
represents a 10.8% decrease. The cumulative total number of
HIV infections reported up to the end of December 2004 is
3,764. Table 1 shows HIV infections newly diagnosed in 2004
by probable route of transmission. The cumulative total of
cases by probable route of transmission is also provided.
Figure 1 shows the number of cases diagnosed annually in
Ireland from 1990 to 2004.
Probable route of transmission
Figure 2 shows the trends in newly diagnosed cases among
the three major risk groups, heterosexual contact, men who
have sex with men (MSM) and injecting drug users (IDUs)
since 1994.
Between 1998 and 2002, there was a steep increase in the
number of newly diagnosed cases acquired through
heterosexual contact, from 47 in 1998 to 232 in 2002.
Between 2002 and 2004, the number of cases acquired
through heterosexual contact decreased but still remains the
most common route of transmission. Information on probable
route of transmission was unavailable for 10% of the cases
diagnosed in 2004.
There were 64 new HIV infections diagnosed among MSM
during 2004. This compares with 75 during 2003 and 46 in
2002.
Among IDUs, there were 71 HIV infections newly diagnosed
during 2004 compared to 49 in 2003 and 50 in 2002.
HIV infection was newly diagnosed in five children during
2004. Of the five, three were infected through Mother-to-
Child transmission (MCT). During 2004, there were 113 babies
born to HIV positive mothers. Of the 113 babies, one was
diagnosed with HIV infection and the status of the remaining
112 is indeterminate (they do not meet the criteria for HIV
infection and are <18 months at time of test).
Sex and Age Distribution 
Of the 356 cases newly diagnosed in 2004, 192 (53.9%) were
male and 161 (45.2%) were female. Information on gender is
unavailable for three cases. Among females, the most frequent
route of transmission was heterosexual contact, which
accounted for 72% of newly diagnosed infections. Among
males, the most frequent routes of transmission were sex
between men (33%) and heterosexual contact (32%).
Of the 161 females who were diagnosed with HIV infection in
2004, 46 were reported to be pregnant at HIV diagnosis.
Information relating to pregnancy status is unavailable for 30
of the female cases.
Most of the newly diagnosed cases (78.1%) were aged
between 20 and 40 years. The mean age at HIV diagnosis was
31.5 years. The mean age at HIV diagnosis was 28.8 years in
females and 33.7 years in males, a difference of 4.9 years. The
mean age at HIV diagnosis was 30.1 years in IDUs, 31.3 years
in heterosexuals and 35.7 years in MSM.
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Figure 1: Annual number of HIV infections (1990 to 2004)
Table 1: HIV infected patients in Ireland by probable route of transmission (up to end 
December 2004) 
Probable route of transmission 2004 Cumulative Total (to end 
  Dec. 2004)
Heterosexual 178 1344
IDU 71 1204
MSM 64 828
Haemophiliac - 106
Children 5 82
Transfusion Recipient - 7
Occupational/Hospital Staff  - 8
Haemophiliac contact - 4
Other 3 80
Unknown 35 101
Total 356 3764
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Geographic Origin 
Analysis of 2004 cases by geographic origin is presented in
figure 3. Classification by geographic origin is as used by
EuroHIV. Geographic origin is based on country of birth for
adult cases and country of birth of the mother for children.
Of the 356 cases diagnosed in 2004, 136 were born in Ireland,
130 were born in sub-Saharan Africa and 25 were born in
other countries in Western Europe. Information on geographic
origin is unavailable for 51 of the newly diagnosed cases.
Of the 178 cases acquired through heterosexual contact, 122
were born in sub-Saharan Africa (85 female and 37 male) and
35 were born in Ireland (20 female and 15 male).
Area of residence
Of the 356 cases newly diagnosed in 2004, 223 were resident
in the Eastern Region (i.e. Dublin, Kildare and Wicklow) and 73
were resident elsewhere in the country at the time of HIV
diagnosis. Information on area of residence is unavailable for
60 of the 356 cases. By category, 84.5% of IDUs, 63% of
heterosexuals and 58% of MSM were resident in the Eastern
region at HIV diagnosis.
Stage of infection
Information on stage of infection at time of HIV diagnosis
was available for 305 of the newly diagnosed cases. Of the
305 cases, 232 were asymptomatic at HIV diagnosis and 38
were diagnosed with AIDS at the time of HIV diagnosis. Of
the 38 late diagnoses, 24 were among heterosexuals, six
among IDUs and four among MSM. Of the 24 heterosexuals,
13 were born in sub-Saharan Africa, nine were born in Ireland
and two were born in Western Europe.
AIDS cases and deaths among HIV/AIDS cases
A total of 38 AIDS cases and four deaths among HIV/AIDS
cases were reported to the HPSC during 2004. The cumulative
total of AIDS cases reported to the HPSC up to the end of
June 2005, is 855. A total of 393 deaths among HIV/AIDS
cases have also been reported to the HPSC up to the end of
June 2005.
Figure 4 shows the number of AIDS cases and deaths among
HIV/AIDS cases by year of diagnosis and year of death
(includes all cases reported up to the end of June 2005). AIDS
cases are analysed by year of diagnosis as recommended by
NASC.2 It is important to note that there is significant
underreporting and delays in reporting of AIDS cases and
deaths among HIV/AIDS cases. It is likely that further reports
particularly relating to recent years, will be received and the
number of cases of AIDS and deaths among HIV/AIDS cases
will be revised upwards for some years, in particular for the
later years.
Figure 5 shows AIDS cases by probable route of transmission
and year of diagnosis.
Discussion
Between 1998 and 2003, there was a dramatic increase in the
number of newly diagnosed HIV infections in Ireland, from
116 cases in 1998 to 399 cases in 2003 (a 3.4 fold increase).
While there has been a decrease in the overall number of HIV
infections diagnosed in 2004, the data should be interpreted
with caution as the downward trend may not continue in
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Figure 3: Newly diagnosed HIV infections in Ireland by probable route of transmission and 
geographic origin (2004)
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future years. It is also important to note that data for
reported HIV diagnoses do not represent HIV incidence. The
data includes individuals who were infected in previous years
and depend on uptake of HIV testing. In addition, incomplete
data were received for 42 (11.8%) of the newly diagnosed
cases, which makes analysis of the data and interpretation of
trends difficult.
The number of new diagnoses among IDUs increased in 2004
and highlights the need for maintaining harm reduction
measures in order to prevent transmission of blood borne
viruses among needle sharing drug users. The number of
newly diagnosed infections reported among MSM, while
showing a slight downward trend on the 2003 data, is an
increase on the numbers reported in 2002. This is of concern
in the context of the continuing endemicity of syphilis in
Ireland following the syphilis outbreak among MSM which
began in Dublin in 2000.3 Syphilis and other genital ulcer
diseases facilitate the transmission and acquisition of HIV.4
It has been clearly shown that vertical transmission of HIV
from mother to child can be dramatically reduced or
prevented by appropriate intervention and treatment
measures.5 However, such measures can only be offered if HIV
infection is diagnosed before or during pregnancy. A policy to
recommend and offer routine antenatal HIV testing to all
women was introduced in Ireland in 1999. Since 2002, the
HPSC has collected quarterly data on the uptake of the
antenatal HIV test from all maternity hospitals/units in
Ireland. Further information on the antenatal HIV screening
programme can be found on the HPSC website (www.hpsc.ie).
During 2004, a total of 113 babies were born to HIV infected
mothers and of these, only one was diagnosed with HIV
infection. The status of the remaining 112 is indeterminate
(they do not meet the criteria for HIV infection and are <18
months at time of test). This illustrates the effectiveness of
the antenatal screening programme in Ireland.
Of the 178 cases acquired through heterosexual contact, the
majority (122) were born in sub-Saharan Africa and 35 were
born in Ireland. The number of cases of HIV infection in
Ireland diagnosed among people of sub-Saharan African origin
is not unexpected, considering the prevalence of HIV in that
region of the world. There is a need for culturally appropriate
prevention messages to be developed in partnership with
ethnic minority communities in Ireland.
The usefulness of AIDS surveillance data depends on the
extent to which case reporting is complete and it is felt that
there is considerable under-reporting and late reporting of
AIDS cases and HIV/AIDS related deaths in Ireland. Highly
active antiretroviral therapy (HAART) was introduced in
Ireland in 1996. The efficacy of the treatment led to a fall in
the number of patients who develop AIDS-defining conditions
and has improved outcomes for those who do develop such
conditions. Clinicians may no longer consider it meaningful to
define patients in terms of their disease stage and
consequently may be less likely to report an AIDS diagnosis.
As a result, the analysis of AIDS surveillance data and
interpretation of trends is difficult. However, it is possible that
reporting of AIDS cases, particularly where HIV and AIDS are
diagnosed simultaneously, has improved since the
introduction of HIV case based reporting in 2001.
Of concern, 38 of the 356 cases newly diagnosed with HIV in
2004 were late diagnoses, i.e. they were diagnosed with AIDS
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Figure 4: AIDS cases and HIV/AIDS related deaths, 1983 to 2004 
(reported up to June 2005)
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Figure 5: AIDS cases by year of diagnosis and probable route of transmission, 
1983 to 2004 (reported up to June 2005)
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at the time of HIV diagnosis. These individuals would not have
had the opportunity to benefit from early diagnosis and
treatment. In a recent review of newly diagnosed HIV
infections in the UK and Ireland, the authors concluded that a
substantial number of people are being diagnosed as having
HIV infection at a late stage of disease and that many
patients do not have their HIV infection diagnosed on routine
screening.6 This report highlights the need for provision of
routine HIV testing in all the appropriate settings and for
culturally information and support services to be put in place
which would encourage people to avail of testing, as diagnosis
at an early stage in the course of HIV infection facilitates
early intervention and treatment.
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Sexually Transmitted Infections 
in Ireland, 2003
Key Points
• In 2003, 11,153 cases of STIs were notified in Ireland.
This represents an increase of 6.5% when compared to
2002 (n=10,471).
• The three most commonly notified STIs in 2003 were
ano-genital warts (n=3981), non-specific urethritis
(n=2332) and Chlamydia trachomatis (n=2258).
• A total of 112 cases of hepatitis B were notified through
the STI surveillance system in 2003, compared to 57
cases in 2002. This increase is likely to be due to an
increase in the number of people attending STI clinics
with chronic infections, from areas of the world where
Hepatitis B infection is endemic.
• Genital Chlamydia trachomatis notifications increased by
17.5% in 2003 compared to 2002.
• Notifications of syphilis and gonorrhoea decreased by
22.4% and 13.1%, respectively in 2003 compared to
2002.
Introduction
Sexually transmitted infections (STIs) are a major global cause
of illness, infertility and death. Both ulcerative and non-
ulcerative STIs have been found to increase the risk of sexual
transmission of HIV and co-infections with HIV may increase
the clinical morbidity caused by each infection. Early
detection and treatment of curable STIs and management of
chronic infections is vital. Good quality surveillance data is
essential in planning public health, clinical and laboratory
service provision and in determining if prevention and
screening programmes are necessary and, if implemented,
successful.
During 2003, 14 STIs were legally notifiable in Ireland: ano-
genital warts, candidiasis, chancroid, Chlamydia trachomatis,
genital herpes simplex, gonorrhoea, granuloma inguinale,
infectious hepatitis B, lymphogranuloma venereum,
molluscum contagiosum, non-specific urethritis, Pediculosis
pubis, syphilis and trichomoniasis. This list of notifiable STIs
was updated in January 2004 (Infectious Diseases
(Amendment) (No. 3) Regulations 2003, S.I. No. 707 of 2003),
however this report details the 14 STIs that were notifiable
during 2003. An additional comprehensive report on STIs
notified in Ireland in 2003 is available on the HPSC website.1
The incidence of STIs in Ireland has increased significantly in
recent years. This trend continued in 2003, with a 6.5%
increase in the total number of notified STIs, compared to
2002. However, significant decreases were seen in syphilis
(22.4%) and gonorrhoea notifications (13.1%). This may be
attributable to interventions put in place to control the
syphilis outbreak in MSM in Dublin between 2000 and 2002.
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Although some notifications are currently received from
primary care, STI surveillance in Ireland is mainly clinic-based.
This data is sufficient to display the general trends in STIs, but
is an underestimate of true incidences. It is also likely that
the number of cases of gonorrhoea and chlamydia notified
represent a substantial underestimate due to the largely
asymptomatic nature of these diseases.
Methods
Aggregate data on the number of notified STIs from
Departments of Public Health is collated quarterly.
Departments of Public Health are notified of STIs by STI
clinics and some GPs. The number of STIs notified by quarter,
health board, age group and gender for 2003 are presented in
this report. Rates per 100,000 population are based on the
2002 population census, unless otherwise stated. It should be
noted that cases of infectious hepatitis B may also be
reported through the weekly infectious disease report
published by HPSC and although they are identified in STI
clinics may not have been sexually transmitted. Quarterly STI
data is only available from 1995 and annual STI data is only
available from 1989.
In response to a dramatic increase in syphilis amongst men
who have sex with men (MSM) in Dublin in early 2000, an
enhanced surveillance system was introduced to capture data
on all syphilis cases since January 2000.2 Case-based
demographic data, clinical data and data on sexual practices
have been collected since then. This enhanced syphilis data is
briefly summarised in this report, but has been reported more
comprehensively elsewhere.2
Results
Notified STIs between 1989 and 2002
During 2003, 11,153 STIs were notified compared to 10,471
in 2002 (6.5% increase) (table 1). Notified STIs have been
increasing each year since 1994, with an increase of 173.8%
seen between 1994 and 2003. The number of STIs notified in
2003 is the highest number reported in any year on record.
Notified cases of infectious hepatitis B, C. trachomatis, non-
specific urethritis, molluscum contagiosum, genital herpes
simplex, candidiasis and ano-genital warts increased during
2003, compared to 2002. The most significant increase was
in infectious hepatitis B notifications, which increased from 57
cases in 2002 to 112 cases in 2003. Notifications of syphilis,
trichomoniasis, gonorrhoea, and pediculosis pubis, decreased
in 2003, compared to 2002, syphilis by 22.4% and gonorrhea
by 13%. No cases of granuloma inguinale, chancroid or
lymphogranuloma venereum were notified in 2003 (table 1).
The cumulative rate per 100,000 population for all notified
STIs increased to 284.7 per 100,000 population in 2003,
compared to a rate of 267.3 per 100,000 in 2002. Annual
trends for ano-genital warts, non-specific urethritis, C.
trachomatis, genital herpes simplex, gonorrhoea, syphilis and
infectious hepatitis B are presented in figure 1(a-e) and table 4.
Notified STIs by health board, 2003
During 2003, 48.4% (n=5402) of all STI notifications were
from the ERHA, 16.3% (n=1822) were from the SHB, 13.5%
(n=1511) were from the MWHB, 9.2% (n=1021) were from
the WHB, 7.0% (n=779) were from the SEHB, 5.4% (n=599)
were from the NWHB, 0.15% (n=17) were from the NEHB
and 0.02% (n=2) were from the MHB (table 2). It is
Table 1: Notified sexually transmitted infections for 2003 and 2002
Sexually Transmitted Infection  2003 2002 Increase  % Increase
Ano-Genital Warts 3981 3932 49 1.2
Candidiasis 1370 1351 19 1.4
Chancroid 0 1 -1 -100
Chlamydia Trachomatis 2258 1922 336 17.5
Genital Herpes Simplex 375 358 17 4.7
Gonorrhoea 186 214 -28 -13.1
Granuloma Inguinale 0 0 0 0
Infectious Hepatitis B 112 57 55 96.5
Lymphogranuloma Venereum 0 1 -1 -100
Molluscum Contagiosum 169 150 19 12.7
Non-Specific Urethritis 2332 2025 307 15.2
Pediculosis Pubis 76 84 -8 -9.5
Syphilis 235 303 -68 -22.4
Trichomoniasis 59 73 -14 -19.2
Total 11153 10471 682 6.5
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Figure 1a
Figure 1(a-e): Number of notifications of ano-genital warts, non-specific urethritis, 
C. trachomatis, genital herpes simplex, gonorrhoea, syphilis and infectious hepatitis B, by 
year between 1989 and 2003.
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important to note that STI surveillance is mainly clinic based
and there are currently no STI clinics in the MHB and NEHB.
Additionally, many people use STI clinics outside their area of
residence so this data does not necessarily reflect cases
resident in each health board. The majority of most notifiable
STIs in 2003 were notified by the ERHA: ano-genital warts
(n=1879; 47.2%), C. trachomatis (n=1278; 56.6%), non-
specific urethritis (n=975; 41.8%), candidiasis (n=587; 42.9%),
genital herpes simplex (n=225; 60%), syphilis (n=170; 72.3%),
gonorrhoea (n=106; 57%), molluscum contagiosum (n=69;
40.8%), infectious hepatitis B (n=58; 51.8%) and
trichomoniasis (n=37; 62.7%). The majority of notifications of
pediculosis pubis (n=20, 26.3%) in 2003 were from the SHB.
STI notifications increased in the ERHA (21.8%), NEHB
(750%) and the SHB (12.7%) in 2003, compared to 2002.
Decreases were seen in the MHB (71.4%), MWHB (12.2%),
NWHB (6%), SEHB (14%) and the WHB (11%).
Notified STIs by age group and gender, 2003
Fifty-one point four percent (n=5734) of all notified cases of
STIs were male during 2003 and 48.1% (n=5366) were
female (table 3). Gender data were not reported for 0.5%
(n=53) of notifications. The majority of cases of gonorrhoea
(78.5%), non-specific urethritis (78.1%), pediculosis pubis
(64.5%), molluscum contagiosum (62.1%), infectious hepatitis
B (58.9%), syphilis (58.3%) and ano-genital warts (52.3%)
were males. The majority of notifications of candidiasis
(87.2%), trichomoniasis (83.1%), genital herpes simplex
(59.2%) and C. trachomatis (54.7%) were females (table 3).
In 2003, 11% (n=1226) of notified cases of STIs were 0 to 19
years old, 61.6% (n=6870) were 20 to 29 years, 17.8%
(n=1987) were 30 to 39 years, 6.6% (n=734) were aged 40
years of age or older and the age of 3% of cases was
unknown (n=336). For all of the notifiable STIs, the highest
number of cases were seen in the 20-29 year age group 
(table 3).
Disease-specific trends
Ano-genital warts
Notifications increased each year between 1992 and 2001
and levelled off in 2002 and 2003. During 2003 notifications
(n=3981, rate=101.6 per 100,000 population) increased by
1.2%, compared to 2002. Males accounted for 52.3% of cases
and females for 47.4% of cases (gender was not reported for
0.3% cases). Eleven point seven percent of cases were aged 0-
19, 63.1% of cases were 20-29, 16.5% were 30-39, 5.6% were
aged 40 years or older and the age of 3.2% of cases was not
reported. Ano-genital warts accounted for the majority
(35.7%) of all STI notifications in 2003.
Chancroid
No cases of chancroid were notified in 2003. With the
exception of the year 2000 (when 16 cases were notified), the
number of notifications of chancroid has ranged from no
cases to three cases per year since 1989.
Chlamydia trachomatis
From 1989 to 1995, the number of cases of C. trachomatis
notified remained stable fluctuating around a mean of 205
cases per year (standard deviation: 55.8). Since 1995 the
number of cases increased steadily every year, with
notifications increasing by 822% between 1995 and 2003.
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Figure 1b
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Two thousand two hundred and fifty-eight cases (57.6 per
100,000 population) were notified in 2003, representing an
increase of 17.5% compared to 2002. C. trachomatis
accounted for 20.2% of all STI notifications in 2003. Forty-
four percent of cases were male and 54.7% were female
(gender was not reported in 1.4% cases). Twelve point one
percent of cases were aged 0-19 years, 69.3% of cases were
20-29, 13.6% were 30-39, 2.8% were aged 40 years or older
and the age of 2.2% of cases was not reported.
Genital herpes simplex
Genital herpes simplex notifications increased by 381%
between 1989 and 2003. Three hundred and seventy-five
cases (9.6 per 100,000 population) were notified in 2003,
representing an increase of 4.7% compared to 2002. Forty
point three percent of cases were male and 59.2% were
female (gender was not reported in 0.5% cases). Eight point
three percent of cases were aged 0-19, 52% of cases were 20-
29, 26.1% were 30-39, 9.1% were aged 40 years or older and
the age of 4.5% of cases was not reported.
Gonorrhoea
Gonorrhoea notifications increased consistently between
1996 (n=83, rate=2.3 per 100,000 population) and 2001
(n=349, rate=8.9 per 100,000 population). Numbers have
declined in the past two years, with notifications decreasing
by 38.7% in 2002 (compared to 2001) and 13.1% in 2003
(compared to 2002). One hundred and eighty-six cases of
gonorrhoea (4.8 per 100,000 population) were notified in
2003. Seventy-eight point five percent of cases were male
and 20.4% were female (gender was not reported 1.1% cases)
in 2003. Eight point six percent of cases were aged 0-19,
52.2% of cases were 20-29, 23.7% were 30-39, 13.4% were
aged 40 years or older and the age of 2.2% of cases was not
reported.
Granuloma Inguinale
No cases of granuloma inguinale were notified during 2003.
The number of notifications has ranged from no cases to six
cases per year since 1989.
Infectious Hepatitis B
Between 1989 and 1999, infectious hepatitis B cases reported
through the STI quarterly notification system ranged from no
cases to four cases per year. The number of notifications
increased steadily from 1999 to 2003 and 112 cases were
notified in 2003 (2.9 per 100,000 population). This is the
highest yearly total on record and represents an increase of
96.5% compared to 2002. Fifty-eight point nine percent of
cases notified were male and 41.1% were female. The number
of male cases increased by 266.7% and the number of female
cases increased by 17.9% in 2003, compared to 2002. Five
point four percent of cases were aged 0-19, 48.2% of cases
were 20-29, 31.3% were 30-39, 14.3% were aged 40 years or
older and the age of 0.9% of cases was not reported.
Lymphogranuloma venereum
No cases of Lymphogranuloma venereum were notified during
2003. The number of cases of Lymphogranuloma venereum
has ranged from no cases to five cases per year since 1989.
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Table 2: Notified sexually transmitted infections by health board for 2003
Sexually Transmitted Infection ERHA MHB MWHB NEHB NWHB SEHB SHB WHB Total
Ano-Genital Warts 1879 0 383 5 257 347 644 466 3981
Candidiasis 587 0 215 0 73 37 248 210 1370
Chancroid 0 0 0 0 0 0 0 0 0
Chlamydia Trachomatis 1278 0 187 5 74 144 396 174 2258
Genital Herpes Simplex 225 0 18 1 3 22 71 35 375
Gonorrhoea 106 1 15 0 15 17 24 8 186
Granuloma Inguinale 0 0 0 0 0 0 0 0 0
Infectious Hepatitis B 58 0 27 6 0 1 18 2 112
Lymphogranuloma Venereum 0 0 0 0 0 0 0 0 0
Molluscum Contagiosum 69 0 17 0 4 23 36 20 169
Non-Specific Urethritis 975 0 619 0 169 177 317 75 2332
Pediculosis Pubis 18 0 14 0 2 5 20 17 76
Syphilis 170 1 14 0 2 5 33 10 235
Trichomoniasis 37 0 2 0 0 1 15 4 59
Total 5402 2 1511 17 599 779 1822 1021 11153
Molluscum contagiosum
Notified cases of molluscum contagiosum ranged between 31
and 59 cases per year between 1989 and 1996. Since then
the number of cases has either remained stable or increased
every year. One hundred and sixty-nine cases were notified in
2003 (4.3 per 100,000 population). This represents an increase
of 12.7%, compared to 2002. Sixty-two point one percent of
cases notified were male and 37.3% were female (gender was
not reported 0.6% cases). Fourteen point two percent of cases
were aged 0-19, 66.9% of cases were 20-29, 11.8% were 30-
39, 1.8% were aged 40 years or older and the age of 5.3% of
cases was not reported.
Non-specific urethritis 
Non-specific urethritis notifications fluctuated around a mean
of 640 per year between 1989 and 1994 (standard deviation:
78.4). Since then, the number of cases has either increased or
remained stable every year. In 2003, 2332 cases of non-
specific urethritis were notified (59.5 per 100,000 population).
This represents an increase of 15.2%, compared to 2002.
Seventy-eight point one percent of cases notified were male
and 21.8% were female (gender was not reported 0.04%
cases). Eight point eight percent of cases were aged 0-19,
58.4% of cases were 20-29, 21.3% were 30-39, 8.5% were
aged 40 years or older and the age of 3.0% of cases was not
reported. Non-specific urethritis accounted for 20.9% of all
STI notifications in 2003.
Pediculosis pubis
Pediculosis pubis notifications fluctuated around a mean of
73.8 (standard deviation: 7.3) cases per year between 1989
and 1997. Notifications increased over the subsequent three
years, with 138 cases (3.5 per 100,000 population) notified in
2000. Numbers have decreased every year since then.
Seventy-six cases of pediculosis pubis (1.9 per 100,000
population) were notified in 2003. This represented a 9.5%
decrease when compared to 2002. Sixty-four point five
percent of cases notified were male and 34.2% were female
(gender was not reported 1.3% cases). Nine point two percent
of cases were aged 0-19, 59.2% of cases were 20-29, 14.5%
were 30-39, 13.2% were aged 40 years or older and the age
of 4.0% of cases was not reported.
Syphilis
There was a dramatic increase in syphilis amongst men who
have sex with men (MSM) in Dublin in early 2000.2 This was
against a low incidence of syphilis nationally between 1989
and 1999, when the mean number of annual notifications was
14.1 (standard deviation: 4.6). Notifications peaked in 2002 at
303 cases and syphilis has remained endemic since. Two
hundred and thirty-five cases were notified in 2003 (6 per
100,000 population). This represents a decrease of 22.4%
when compared to 2002. Fifty-eight point three percent of
cases notified were male and 41.3% were female (gender was
not reported 0.4% cases). The number of male cases
decreased by 36.3% and the number of female cases
increased by 11.5%, compared to 2002. Three point eight
percent of cases were aged 0-19, 38.7% of cases were 20-29,
35.3% were 30-39, 19.2% were aged 40 years or older and
the age of 3.0% of cases was not reported. An enhanced
surveillance system was introduced by HPSC to capture data
on all syphilis cases from January 2000.
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Table 3: Notified sexually transmitted infections by age group (years) & gender for 2003
Sexually Transmitted Infection  0-19  20-29  30-39  40+  Age unknown Male Female Gender unknown  Total
Ano-Genital Warts 464 2510 658 223 126 2082 1887 12 3981
Candidiasis 184 811 223 108 44 173 1195 2 1370
Chancroid 0 0 0 0 0 0 0 0 0
Chlamydia Trachomatis 274 1564 307 63 50 993 1234 31 2258
Genital Herpes Simplex 31 195 98 34 17 151 222 2 375
Gonorrhoea 16 97 44 25 4 146 38 2 186
Granuloma Inguinale 0 0 0 0 0 0 0 0 0
Infectious Hepatitis B 6 54 35 16 1 66 46 0 112
Lymphogranuloma Venereum 0 0 0 0 0 0 0 0 0
Molluscum Contagiosum 24 113 20 3 9 105 63 1 169
Non-Specific Urethritis 205 1362 497 197 71 1822 509 1 2332
Pediculosis Pubis 7 45 11 10 3 49 26 1 76
Syphilis 9 91 83 45 7 137 97 1 235
Trichomoniasis 6 28 11 10 4 10 49 0 59
Total 1226 6870 1987 734 336 5734 5366 53 11153
Trichomoniasis
Trichomoniasis notifications fluctuated significantly between
1989 and 2003. The highest number of cases on record
occurred in 1991 when 163 notifications were made (4.6 per
100,000 population). The mean number of notifications for all
years between 1989 and 2003, excluding 1991, was 60.9.
During 2003, 59 cases (1.5 per 100,000 population) were
notified. This represents a decrease of 9.5% compared to
2002. Seventeen percent of cases notified were male and
83% were female. Ten point two percent of cases were aged
0-19, 47.5% of cases were 20-29, 18.6% were 30-39, 17%
were aged 40 years or older and the age of 6.8% of cases was
not reported.
Enhanced surveillance of syphilis 2003
A total of 195 cases of syphilis were reported to the HPSC
through the syphilis enhanced surveillance system for 2003.
Of the total cases reported, 87% (n=170) were reported by
the ERHA. Forty-eight percent of the 195 cases were early
(infectious)* syphilis and 35% were late† syphilis cases. Over
60% (62.1%) of cases were male and 37.4% were female. This
differs from 2002 and 2001 when 73.5% and 81.2% of cases
were male, respectively. The mean age for male and female
cases was 36 and 28 years, respectively. Forty percent of all
syphilis cases were amongst MSM: 88% were homosexual and
12% were bisexual. Thirty-four percent of cases were
heterosexual (45.5% male and 54.5% female) and sexual
orientation was unknown for 26% of cases (figure 2). Twenty-
five (12.8%) syphilis cases were HIV positive, 15 of which,
were early (infectious) syphilis cases, 8 were late syphilis cases
and staging was unknown for two cases. Thirty-two  percent
(n=8) of syphilis cases with HIV were newly diagnosed in
2003. Twelve percent of all syphilis cases, and 17% of early
(infectious) syphilis cases, had one or more concurrent STIs
(excluding HIV). Seventy percent of all female cases (n=23)
were identified through antenatal screening (5 early
(infectious) cases, 14 late syphilis cases and 4 unknown
stage). Seventeen of the cases identified through antenatal
screening were non-nationals, two were Irish nationals and
four were of unknown nationality.
*Early (infectious) syphilis cases refer to primary, secondary and early
latent syphilis cases.
†Late syphilis cases refer to late latent and tertiary syphilis cases
Discussion
The increase in STIs in Ireland during 2003 is likely to be
associated with a number of factors. Between 2000 and 2003
over 60% of STIs occurred in 20-29 year olds. This age group
is more likely to have higher numbers of sexual partners,
change partners more frequently and engage in high-risk
behaviour such as unprotected sex with new sex partners. It is
also likely that case identification is improving. Media
attention and public health education initiatives have lead to
increased awareness of STIs, it has become more socially
acceptable to attend STI clinics and improvements have been
made in laboratory testing for STIs. The introduction of
screening programmes such as voluntary health screening for
asylum seekers and antenatal screening in maternity hospitals
are also likely to have contributed to the observed increases.
Dramatic increases in hepatitis B (96.5%) were seen in 2003.
Hepatitis B is known to affect certain subgroups of the
population, namely intravenous drug users, prisoners and
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Table 4: Notified sexually transmitted infections from 1989 to 2003
Sexually Transmitted Infection 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
 Ano-Genital Warts 505 917 1089 1066 1432 1532 1972 2286 2514 2886 3049 3735 3993 3932 3981
 Candidiasis 688 1056 1257 1157 1400 1360 1271 1321 1521 1277 1105 1095 1150 1351 1370
 Chancroid 2 0 0 2 0 2 3 1 1 0 1 16 1 1 0
 Chlamydia Trachomatis 174 215 164 192 315 133 245 364 462 646 869 1343 1649 1922 2258
 Genital Herpes Simplex 78 123 109 125 124 173 198 181 211 243 275 269 331 358 375
 Gonorrhoea 27 90 73 51 24 98 91 83 98 125 175 290 349 214 186
 Granuloma Inguinale 0 0 0 0 6 0 0 1 1 0 1 0 0 0 0
 Infectious Hepatitis B 0 0 0 0 0 0 4 2 0 0 2 15 39 57 112
 Lymphogranuloma Venereum 0 0 0 0 0 0 0 0 5 1 2 0 0 1 0
 Molluscum Contagiosum 31 39 43 44 34 56 59 34 74 84 83 118 111 150 169
 Non-Specific Urethritis 600 738 549 585 756 610 781 823 1034 1083 1265 1726 1634 2025 2332
 Pediculosis Pubis 60 70 72 70 77 69 86 79 81 105 113 138 103 84 76
 Syphilis 12 19 20 20 8 11 11 17 16 15 6 46 279 303 235
 Trichomoniasis 51 86 163 41 57 29 60 71 94 38 47 78 64 73 59
 Total 2228 3353 3539 3353 4233 4073 4781 5263 6112 6503 6993 8869 9703 10471 11153
chronically infected immigrants from endemic areas of the
world such as Sub-Saharan Africa, Asia and parts of Eastern
and Central Europe.3 It is important to note that case
classification data was not collected prior to 2004 and we do
not know whether the reported cases of infectious hepatitis B
were acute or chronic nor do we know the country of origin
of notified cases. However, anecdotally we have learnt that
there are increasing numbers of people attending STI clinics
from countries where hepatitis B is endemic. STI clinic
attendees are routinely screened for hepatitis B markers and it
is likely that the increase in notifications in 2003 is largely
attributable to people from endemic countries who are tested
in STI clinics and whose chronic hepatitis B co-infection is a
co-incidental finding and is a result of infection acquired in
the past. Demographic, risk factor, clinical and microbiological
data are required in order to characterise the epidemiology of
this infection and to better inform prevention and control
strategies.
C. trachomatis notifications continued to increase in 2003. In
addition to a true underlying increase in the number of people
infected, this increase reflects increased testing and the use of
highly sensitive and specific DNA amplification techniques
(NAATS), which can be used on non-invasively collected
specimens, particularly urine. The numbers reported are likely
to represent a substantial underestimate of the true burden of
disease as C. trachomatis infection is asymptomatic in at least
70% of women and 50% of men.4 In women, if chlamydia is
not treated it can cause pelvic inflammatory disease (PID),
which can lead to ectopic pregnancy, chronic pelvic pain and
tubal-factor infertility.5 Due to the “silent” nature of C.
trachomatis infections and the severity of possible
complications of untreated infection, some countries routinely
screen sexually active men and women under the age of 25
and other risk groups, for infection.6,7 The STI subcommittee
of Scientific Advisory Committee (SAC) of the HPSC is
currently examining the need for chlamydia screening in
Ireland.
Between 2000 and 2002, there was a dramatic increase in
syphilis amongst men who have sex with men (MSM) in
Dublin. Similar increases were seen in the UK, several other
European countries and the US. Syphilis, like other genital
ulcer diseases, increases the risk of transmitting and acquiring
HIV. In response to this increase the Director of Public Health
in the Eastern Regional Health Authority (ERHA) established
an outbreak control team in October 2000. Intervention
measures included the provision of additional resources for
clinical services, contact tracing, educational materials, onsite
testing in MSM venues and information campaigns targeted
at the MSM community.2 These interventions may have had
an impact, as the outbreak amongst MSM in Dublin peaked in
2002 and notifications decreased by 22.4% in 2003.
However, notifications have not returned to their previous
levels and syphilis remains endemic in Ireland. The increase
observed in the number of female syphilis cases in 2003 is
partly due to cases identified through antenatal screening.
Over 30% of female cases reported through the syphilis
enhanced surveillance system between 2000 and 2003 were
identified through antenatal screening. The numbers
identified in this manner may be even higher as the reasons
for attending an STI clinic were not known for a further
52.5% of female cases and some of these women may have
been referred following antenatal screening.
The peak in gonorrhoea notifications observed in 2001
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  Figure 2: Infectious syphilis cases by sexual orientation and quarter and year of diagnosis as reported through the syphilis enhanced surveillance system (n=558)
Homosexual BisexualHeterosexual
coincided with the outbreak of syphilis amongst MSM.
Gonococcal infections tend to be concentrated in core risk
groups, such as MSM and this may be reflected in the 2003
data, in that 78% of notifications were male. The 13.1%
decrease in reported cases observed in 2003 compared to
2002, may have resulted from the interventions put in place
to control the syphilis outbreak. However, the numbers
reported are likely to represent an underestimate of the true
incidence of infection as gonorrhoea can be asymptomatic in
up to 86% of women and 55% of men.8
Ano-genital warts, the clinically visible manifestations of
infection with human papilloma virus (HPV), was the most
commonly notified STI in Ireland in 2003, with similar
numbers of cases reported to 2002. These numbers represent
a very small percentage of the overall burden of HPV infection
in the community. It is estimated that many more people
without warts have subclinical disease or latent infection with
HPV. Most visible anogenital warts are benign and caused by
HPV types 6 and 11. Infection with some other HPV types,
especially 16, 18, 31 and 45 may lead to the development of
invasive cervical cancer and other cancers of the anogenital
tract.9
STI control, prevention and policy-making requires timely
surveillance data that includes a range of. demographic,
behavioural, clinical and microbiological information. Ideally
data should be collected from all sites where STIs are
identified. Although some notifications are currently received
from primary care physicians, STI surveillance in Ireland is
mainly clinic-based. This data is sufficient to display the
general trends in STIs, but is an underestimate of true
incidences as significant proportions of specimens received by
laboratories to be tested for STIs come from sources other
than STI clinics.
The amendment to the Infectious Diseases Regulations 1981
(Infectious Diseases (Amendment) (No. 3) Regulations 2003,
S.I. No. 707 of 2003) introduced a requirement for laboratory
directors to report infectious diseases from January 2004.
This should substantially improve the accuracy with which
national data reflects the true numbers of STIs diagnosed in
Ireland. The STI subcommittee of Scientific Advisory
Committee (SAC) of HPSC is also working on agreeing a
dataset for the collection of patient-based disaggregate STI
data. The collection of this data and laboratory reporting will
be facilitated by the development of a internet-based system
(CIDR) to manage the surveillance and control of infectious
diseases in Ireland.10 It will be used by public health,
laboratory and surveillance personnel for reporting and
disseminating disaggregate infectious disease data in a timely
manner.
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Invasive Pneumococcal Disease
(IPD) in Ireland, 2004
Key Points
• Streptococcus pneumoniae is commonly associated with
pneumonia, meningitis, bacteraemia, sinusitis or otitis
media
• 400 cases of invasive pneumococcal disease (IPD) were
reported in Ireland through EARSS during 2004
• Highest incidence rates of IPD were found among the
elderly and the very young 
• Pneumococcal vaccine is recommended for individuals
at increased risk of infection, including all individuals 64
years of age or older 
Introduction
Invasive pneumococcal disease (IPD) is caused by the
organism Streptococcus pneumoniae. S. Pneumoniae is one of
the most common bacterial causes of acute otitis media and
invasive bacterial infections in children. It is commonly
associated with sinusitis, community acquired pneumonia and
conjunctivitis. It is also the second most common organism
(after N. Meningitidis) causing bacterial meningitis in Ireland
(accounting for 8% of all bacterial meningitis cases in 2004).
Those most at risk of meningitis are young children and older
age groups.
More than 90 serotypes of S. pneumoniae have been
described since the organism was first identified by Pasteur in
1881. Although most serotypes have been shown to cause
serious disease, only a few serotypes produce the majority of
pneumococcal infections. The 10 most common serotypes are
estimated to account for over 60% of invasive disease
worldwide.
The true burden of disease associated with IPD in Ireland is
evident with the information available from European
Antimicrobial Resistance Surveillance System (EARSS). EARSS
started in Ireland in 1999 and provides information on the
number of isolates of S. pneumoniae from participating
laboratories (see chapter on EARSS for additional
information). EARSS participating laboratories are now
estimated to cover approximately 98% of the Irish population.
Additionally, since January 1st 2004 all invasive S. pneumoniae
infections or laboratory confirmed diagnoses (isolation of S.
pneumoniae or detection of S. pneumoniae nucleic acid from
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a normally sterile site) should be notified to the medical
officer of health. A detailed description of the case definition
is provided in the HPSC Case Definitions booklet.1
Information on the number of isolates of invasive 
S. pneumoniae during 2004 is more accurately reported
through EARSS, therefore, the EARSS data is used in the
following discussion of the epidemiology of IPD in Ireland
during 2004. Reference is made to IPD notifications reported
through the weekly notification system. Incidence rates are
calculated using population data taken from the 2002 census.
Results
In 2004, four hundred cases of IPD were reported through
EARSS. In contrast, 159 cases were reported through the
weekly notification system. EARSS data clearly provides a
more accurate reflection of disease incidence in the country
than weekly IPD notifications made to the medical officer of
health.
The 400 IPD cases reported through EARSS during 2004
represents an estimated crude incidence rate of 10.4 cases per
100,000 population (extrapolated from EARSS laboratories
covering 98% of the population).
Males and females were similarly affected (ratio 1.06:1). The
highest age specific incidence rates (ASIR) were reported
among those greater than 64 years of age (37.6 per
1000,000; 164 cases) and among children in the 0-4 year age
(24.1 per 100,000 population; 67 cases). Incidence rates are
highest in the oldest age groups (> 85 years of age, ASIR of 
64.6 per 100,000). The number of cases of IPD and the ASIRs
are presented in Figure 1.
No serotype data was provided on any of the S. pneumoniae
isolates in 2004.
Discussion
During 2004, IPD caused substantial morbidity, with 400 IPD
cases reported through EARSS. The weekly notification system
only identified 159 IPD cases, demonstrating substantial
under-reporting to Medical Officers of Health (MoH). The
reason for this under-reporting to the MoH is unclear. It may
reflect either 1) lack of awareness among clinicians that all
IPD cases should be reported or 2) inaccurate belief amongst
clinical directors of laboratories that by reporting IPD isolates
to EARSS that they are fulfilling their statutory obligation. It is
most likely that under-reporting is related to a combination of
these two factors.
IPD rates reported in Ireland in 2004, although less than those
reported in the United States prior to introduction of a 7-
valent pneumococcal conjugate vaccine for children (average
24.3/100,000 for 1998 and 1999)2, are similar to those
reported from the UK (9.9/100,000) in 2003/04.3
Two age groups are found to have the highest incidence of
IPD, the 0-4 year age group and the over 64 year age group, a
finding reported in other countries.2,3 In recognition of the
increased risk of infection among the elderly population, all
individuals 65 years of age or older in Ireland are
recommended pneumococcal vaccine to protect against IPD
and its complications.
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Figure 1. Invasive Streptococcus pneumoniae cases and age specific incidence rates (ASIR), 
by age group, notified in 2004
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Other groups are also recognised at being at increased risk of
infection or its complications and are recommended
pneumococccal vaccination.4 Those considered to be most at
risk are those with the following conditions: no spleens or
splenic dysfunction; chronic renal disease or nephrotic
syndrome; chronic heart, lung or liver disease; diabetes
mellitus; sickle disease; CSF leaks; cochlear implants; as well as
the elderly (65 years of age or older). Two types of
pneumococcal vaccine are available, 23-valent polysaccharide
pneumococccal, recommended for those 24 months and
older, and a 7-valent conjugate vaccine, recommended for
infants and children at risk.
Currently in Ireland there are no national data available on
vaccination uptake rates amongst these risk groups. Nor do
current surveillance systems in place routinely identify
whether or not an IPD case belongs to a risk group, or
whether they were vaccinated. As information on serotypes
was not available for any of the IPD isolates in 2004 it is
difficult to estimate the potential vaccine efficacy in the Irish
population even if vaccine uptake data were available.
IPD is a potentially vaccine preventable disease. Therefore,
understanding the distribution of the disease, the risk factors
for infection, vaccination uptake and the S. pneumoniae
serotypes in circulation in Ireland is fundamental to improving
control and preventing infection among those most at risk.
Recommendations
Improving information on IPD epidemiology will more
accurately quantify the burden of disease, risk factors for
infection and missed opportunities for immunisation.
All clinicians and laboratory directors should report IPD cases
to the MoH. Additionally, laboratories should also report S.
pneumoniae isolates to EARSS according to agreed protocols.
Developing laboratory capacity so that S. pneumoniae isolates
can be serotyped is integral to any future surveillance
programme.
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Information and Communications
Technology
Information and Communication Technology staff are
responsible for the management, purchase and support of
information systems at HPSC.
Major IT developments, in conjunction with the CIDR/Health
Informatics team and other HPSC staff, during 2004 included :
• Information governance certificiation 
• On going website development
• Establishment of a business continuity solution
• Developments in health informatics
Information Governance
An information governance committee was formed 'to
establish a framework to ensure the privacy, confidentiality
and security of information within the agency and to ensure
that the policies relating to these are implemented and
complied with.'
The committee, made up of  staff from all disciplines, meets
monthly. It provides policy development and guidance in
relation to information handling and information security in
the context of the organisation's responsibilities under the
Data Protection Acts (1988 & 2003) and Freedom of
Information Acts (1997 & 2003).
During 2004 the centre obtained formal certification to the
National Standards Authority of Ireland (NSAI) recognised
Information Security standard IS17799. This certification
audits Information Security Management Systems (ISMS) and
the associated set of  policies and procedures. Certification
also confirms the implementation of the relevant policies and
procedures. The centre ensures the confidentiality, integrity
and availability of vital information, through compliance with
this standard.
Website
The website (www.hpsc.ie) continues to be one of HPSC’s
most important communications tools. A wide range of
information is published on the web site, including all reports
produced by the centre, weekly and annual infectious disease
statistics, disease specific factsheets, press releases and other
general information.
Use of the web site continued to increase in 2004. At the end
of 2003 the average number of log-ons to the site per day
was 789. During the last quarter of 2004 it averaged 1032
users per day.
During 2004 a project was initiated to re-design and update
the structure of the web site. A project team was established
to oversee the changes. The new web site was launched in
2005.
A separate web project - to provide easily accessible
anonymosied, summary data to medical professionals and the
general public through tabular, graphic and map formats- also
began in 2004.
Disaster Recovery / Business Continuity
During 2004, HPSC established a disaster recovery / business
continuity system to protect its operational integrity.
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The business continuity solution is based on use of off site
facilities provided by Network Recovery Ltd., who are
specialists in  Business Continuity and Disaster Recovery. A
scaled down IT network infrastructure providing the core
communications and software functions has been configured
and tested on the network recovery site. Eight staff can be
supported directly by the system which can also be
configured to allow remote access for additional staff as
necessary.
An equivalent solution is being being developed for CIDR in
2005.
HeBE Messaging Subgroup
The HeBE Messaging subgroup (including HPSC) continued to
work through 2004 producing HL7 version 2.4 national
implementation guides for HL7 XML Batch File Protocol,
Admission and Discharge Notifications, Appointment
Scheduling and Message Acknowledgement for
communications between primary and secondary care
information systems.
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Viral Hepatitis, 2004
Key Points
• Hepatitis A incidence remained low, with 47 cases
notified in 2004.
• The number of notifications of hepatitis B continued to
increase with 797 cases reported in 2004, compared to
547 cases in 2003. Where acute/chronic status was
known, 91% (n=553) of cases were reported as chronic
and 9% (n=58) were reported as acute.
• 2004 was the first year that hepatitis C was notifiable
in Ireland and 1,154 cases were reported. The majority
of cases occurred in young adults.
• Work is progressing on a national database for people
infected with hepatitis C though administration of
blood and blood products. By collecting medical and
demographic information on consenting patients, this
database will enable the natural history of hepatitis C
to be studied in this cohort, and will facilitate health
service planning and evaluation.
Viral Hepatitis - Type A
Introduction
Hepatitis A is an acute, usually self-limiting disease of the
liver caused by the hepatitis A virus (HAV). It is transmitted by
person-to-person contact, primarily via the faecal-oral route
and is associated with poor hygiene and sanitation and water
that is contaminated with human faecal matter.1 Blood borne
transmission of hepatitis A can occur but is not as common.
In high- and intermediate-endemicity countries (Africa, the
Middle East, Asia, Eastern Europe, Central and South America),
most adults have serological evidence of past HAV infection.
In developed countries, hepatitis A is most commonly seen
among travellers to endemic countries, injecting drug users
(IDUs), men who have sex with men (MSM) and household or
sexual contacts of known cases. Sporadic food and waterborne
outbreaks or outbreaks in crèches also occur. Hepatitis A in
children is often asymptomatic or mild and usually resolves
within a couple of weeks. Clinical severity tends to increase
with age and adults can experience severe illness lasting
several months. Symptoms include sudden onset of fever,
fatigue, loss of appetite, nausea and abdominal pain. Jaundice
usually occurs within a few days of onset of symptoms.1,2 
A safe and effective vaccine is available for hepatitis A. In
Ireland, vaccination is recommended for individuals in high-
risk groups such as travellers to high endemicity countries,
patients with chronic liver disease, individuals at occupational
risk, close contacts of infected persons, individuals with
haemophilia and recipients of plasma-derived clotting factors.3
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Materials and Methods
Hepatitis A is a notifiable disease under the Infectious
Diseases Regulations 1981. Aggregate data on notifications
are available from 1982 and disaggregate data are available
since mid-2000. An amendment to the regulations
implemented on 1st January 2004 (S.I. 707 of 2003)
introduced case definitions for hepatitis A (Box 1).
Results
Hepatitis A incidence remained low, with 47 cases notified to
the HPSC during 2004. This corresponds to an age-
standardised incidence rate (ASIR) of 1.1 per 100,000
population and represents an increase of 88% compared to
the number of notifications received in 2003 (n=25) (figure
1). Thirty-six cases were reported as confirmed, five were
reported as possible and the case classification was not
reported for six cases. The ERHA notified 64% of all cases
(n=30), corresponding to an ASIR of 2.1 cases per 100,000
population (figure 2). Fifty-five percent of cases of hepatitis A
notified in 2004 were female (n=26). Adults aged between 25
and 44 years (n=20) and children aged between 0 and 4 years
(n=9) were most affected. The overall median age for
hepatitis A notifications was 28 years (figure 3).
Discussion
Hepatitis A incidence remained low in Ireland in 2004.
However cyclic recurrences of hepatitis A can occur in
developed countries and the annual incidence of hepatitis A
has varied considerably since 1989 (figure 1). Many hepatitis A
cases occur in the context of family or local community
outbreaks and two family outbreaks and one outbreak in a
crèche were reported to the HPSC in 2004. The source of
these infections was not identified but it was known that they
were not travel-related.
Outside of Ireland, a large foodborne outbreak of hepatitis A
was reported in European tourists who had stayed in a
particular hotel in Egypt in the summer of 2004. Over 300
people were affected and the outbreak was ultimately linked
to the consumption of fruit juice.4 Outbreaks among MSM
were reported in Norway, Copenhagen and London and an
outbreak was reported among a homeless and drug user
community in Rotterdam.5,6,7,8 No outbreaks in either MSM or
IDUs in Ireland were reported to the HPSC in 2004.
Although risk factor information is collected in the context of
outbreaks there is currently no enhanced surveillance system
for hepatitis A in Ireland. More detailed information would
contribute to the prevention and control of hepatitis A and
the efficient detection of outbreaks.
Viral Hepatitis – Type B
Introduction
Hepatitis B virus (HBV) is transmitted by contact with blood
or body fluids of an infected person and is 50 to 100 times
more infectious than HIV. Only 10% of children and 30-50%
of adults develop clinical symptoms during the acute phase of
hepatitis B infection and if the virus is cleared at this stage,
the infection may never be recognised.1,9
The course and clinical symptoms of hepatitis B infection
depend on the patient’s age and immune status. Between
one and ten percent of those infected as older children or
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Figure 1. Number of cases of hepatitis A notified 1989-2004
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adults, and 90% of infants infected at birth, develop chronic
hepatitis B infection. More than 350 million people worldwide
are chronically infected with HBV. In Sub-Saharan Africa,
South-East Asia and parts of China over 8% of the population
have chronic HBV infections, most of which were contracted
at birth or through child-to-child contact in household
settings. Chronic infection is associated with an increased risk
of developing cirrhosis and/or hepatocellular carcinoma, and
premature death from chronic liver disease occurs in 15-25%
of chronically infected people.1,9 The prevalence of HBV
infection in Ireland is low (<1%)10, however infection is more
prevalent in certain high-risk populations such as IDUs11,12,
prisoners13 and immigrants from high endemicity countries.
Hepatitis B is a vaccine-preventable disease and in 1992 the
WHO recommended that hepatitis B vaccine be included in
routine immunisation programmes in all countries by 1997.9
In Ireland, vaccination is currently recommended for
individuals in high risk groups such as babies born to mothers
with acute or chronic hepatitis B infections, patients with
chronic renal failure or haemophilia, individuals at
occupational risk, close contacts of infected persons, IDUs,
prisoners, homeless people, heterosexuals with multiple
partners and MSM.3 
Materials and Methods
Hepatitis B is a notifiable disease under the Infectious
Diseases Regulations 1981. An amendment to the regulations
implemented on 1st January 2004 (S.I. 707 of 2003)
introduced case definitions and differentiated between
notifications of acute hepatitis B and chronic hepatitis B for
the first time (Box 2). In addition, laboratory directors are now
required to report cases of notifiable diseases identified in
their laboratories.
Results
The increase in hepatitis B notifications seen in recent years
continued in 2004, with 797 cases notified. This represents a
46% increase compared to 2003 (figure 4). The national age-
standardised notification rate was 20 per 100,000 population,
with the highest rates reported by the ERHA (ASIR:
33/100,000 population) (figure 5). Case classification was
reported for 582 cases, with 569 cases reported as confirmed
and 13 cases reported as probable.
Seventy-seven percent of notifications (n=611) contained
information on acute/chronic status. Where status was known,
91% of cases were reported as chronic (n=553) and 9% were
reported as acute (n=58).
The age and sex breakdown for acute and chronic cases
differed substantially and is presented separately in figures 6a
and 6b. Seventy-six percent of acute cases notified in 2004
were male (n=44), 22% were female and the sex of one case
was unknown. The majority of cases (67%) were aged
between 20 and 44 years. However, there were six acute
hepatitis B notifications for males over the age of 65 years. In
contrast to the acute cases, the percentage of male (54%)
and female (46%) chronic cases was similar. Eighty-four
percent of chronic cases were aged between 20 and 44 years.
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Figure 3: Age- and sex-specific incidence rates of hepatitis A per 100,000 population, 2004
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Risk factor information and region of birth also differed
significantly between acute and chronic cases. Risk factor
information was available for 30 of the 58 acute cases and
the main risk factor for acute cases in Ireland in 2004 was
sexual exposure. Where risk information was provided, 43%
(n=13) of cases were MSM and a further 17% (n=5) were
associated with possible sexual exposure. Other risk factors
reported include household contact (n=2), injecting drug use
(n=2), travel/living abroad (n=2) and being a baby of a
hepatitis B surface antigen-positive mother (n=2). Of the six
acute cases over the age of 65, one had multiple risk factors
including sexual exposure but no risk factors were identified
for the other five cases. Where region of birth was known for
acute cases (n=25), 88% were born in Ireland.
Limited risk information was available for chronic cases, but
where information was available, 120 out of 128 cases were
identified as either asylum seekers or as having been born in a
country where hepatitis B is endemic. Where region of birth
was identified (n=48), 56% of chronic cases were born in Sub-
Saharan Africa, 19% were born in Eastern Europe, 8.3% were
born in East Asia and the Pacific and 6.3% were born in South
and South-East Asia. Only 4.2% of chronic cases, where region
of birth was known, were born in Western Europe. Where the
reason for testing was reported (n=97), 80% (n=80) of
chronic cases were identified through asylum seeker screening
and 8% (n=8) were identified through antenatal screening.
Discussion
Hepatitis B data have improved significantly with the
introduction of case definitions, laboratory reporting and
differentiation between acute and chronic hepatitis B. Some
enhanced surveillance data were also received for over 50% of
acute cases and over 20% of chronic cases. These data clearly
illustrate the differences in the epidemiology of acute and
chronic hepatitis B in Ireland.
Although Ireland is considered a low endemicity country,
hepatitis B notifications have increased substantially in recent
years. This is partly due to changes in immigration patterns to
Ireland. The number of asylum seeker applications increased
from 1,179 in 1996 to a peak of 11,634 in 2002, and
decreased to 4,766 in 2004. Large numbers of work permits
have also been issued in recent years.14 Many of these
immigrants come from countries of intermediate- or high-
endemicity for hepatitis B. It is also likely that case
identification and notification have improved with the
introduction of laboratory reporting and screening
programmes such as voluntary health screening for asylum
seekers and some antenatal screening in maternity hospitals.
Where the reason for testing was reported, the majority of
chronic cases were identified through asylum seeker
screening.
Limited information is available on the actual risk factors for
cases with chronic infections but it is likely that a large
proportion of infections were acquired at birth or in early
childhood where individuals were born in countries where
hepatitis B is endemic. A large proportion of acute cases were
in the 20-34 year age group and where risk exposure
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Figure 5. Age-standardised incidence rates of hepatitis B per 100,000 population by health board, 2002-2004
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Figure 6a. Number of acute cases of hepatitis B notified in 2004 by age and sex
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information was known, most infection’s had been acquired
sexually.
Good quality surveillance data are essential in order to follow
trends, inform vaccination policy and plan public health
initiatives and service provision for the prevention and control
of hepatitis B. Given the serious nature of HBV infection,
particularly when acquired in infancy, and the potential for
prevention with a safe and effective vaccine, the planned
introduction in 2005 of a programme of universal antenatal
screening is to be welcomed.
Viral Hepatitis-Type C
Introduction
The hepatitis C virus (HCV) was first identified in 1989. Prior
to this, hepatitis C was usually labelled non-A non-B hepatitis.
HCV is transmitted primarily via exposure to contaminated
blood or blood products. The main causes of infection are
sharing infected needles or other drug paraphernalia, and the
receipt of unscreened blood or blood products. Occupational
exposure to infected blood and mother-to-baby and sexual
transmission also occur but are less common. In developed
countries, it is estimated that 90% of people with chronic
hepatitis C are current or former injecting drug users or have
received unscreened blood or blood products. The WHO
estimates that about 170 million people worldwide are
infected with hepatitis C, with prevalence ranging from 1% in
Europe to 4.6% in the Eastern Mediterranean and 5.3% in
Africa. 1,15
Over 90% of cases are asymptomatic in the acute phase of
the disease but between 50 and 80% progress to chronic
infection. Of those chronically infected about 10-20%
develop cirrhosis and between 1 and 5% develop
hepatocellular carcinoma over a period of 20-30 years. There
is currently no vaccine available for hepatitis C. 1,15
Materials and Methods
Hepatitis C became a notifiable disease under the Infectious
Diseases Regulations amendment introduced on the 1 January
2004 (S.I. 707 of 2003). Previously hepatitis C could be
notified under the category “viral hepatitis, type unspecified”,
but was not a notifiable disease in its own right. Since the
HPSC started collecting disaggregate data in mid-2000, many
of the notifications of viral hepatitis type unspecified have
included information on the causative agent and most of
these were hepatitis C. The case definitions for hepatitis C can
be seen in Box 3.
Results
2004 was the first year that hepatitis C was notifiable in
Ireland and 1,154 cases were notified, compared to 85 cases
of viral hepatitis, type unspecified in 2003 (figure 7). This
corresponds to an ASIR of  29/100,000 population. Over 80%
(82.7%) of cases were notified by the ERHA, corresponding to
an ASIR of 62/100,000 population (figure 8). There was a large
disparity between the sexes: 61% of cases were male
(n=706), 37% were female (n=426) and sex was reported as
unknown for 2% (n=22). Young adults were most affected,
with over 83% of male cases (n=586) and over 80% of
female cases (n=355) aged between 20 and 44 years. The age
and sex-specific incidence rates can be seen in figure 9.
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Figure 6b. Number of chronic cases of hepatitis B notified in 2004 by age and sex
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Discussion
Prior to 2004, there was very little routine information
available to describe the epidemiology of hepatitis C in
Ireland. The 2004 data indicate that the incidence of hepatitis
C is higher than that of hepatitis B (29.5 compared to
20/100,000 population) and that the geographic distribution
is skewed towards the ERHA. There is currently no enhanced
surveillance system for hepatitis C in Ireland. However,
previous studies in Irish settings indicate that the hepatitis C
epidemic in Ireland is mainly occurring in injecting drug users
and is strongly associated with sharing syringes or other drug
paraphernalia.11,12, 13 A cross-sectional study of blood-borne
infections in clients attending addiction treatment centres in
the ERHA, found that 66% had antibodies to the hepatitis C
virus, and a national study of individuals entering prisons
found that 72% of injecting drug users had antibodies to the
hepatitis C virus.12,13 Enhanced surveillance is essential for the
identification of risk factors and for planning public health
strategies for hepatitis C prevention and future health service
provision.
National Hepatitis C Database
A national database of people infected with hepatitis C
through the administration of blood or blood products has
been set up by HPSC in association with the eight designated
hepatology units. This project was recommended by the
Consultative Council on Hepatitis C16 and is supported
financially by the Department of Health and Children.
The objectives of the database are:
1. To follow the natural history of infection in this group of
people
2. To evaluate the impact of various host factors on the
progression of the disease 
3. To evaluate the outcomes of treatment
4. To monitor the uptake of services
5. To provide information for the planning and evaluation of
health services.
6. To serve as a resource for future research into hepatitis C
Any person who has contracted hepatitis C infection through
the administration of blood or blood products within the
State is eligible to be included in the database. It is estimated
that about 1,600 persons have been infected with hepatitis C
in this way. These include women infected through anti-D
immune globulin, persons with haemophilia, recipients of
blood transfusion and persons who received treatment for
renal disease.
Data collection commenced at the end of 2004 and is based
on data contained in the medical records of patients who
have attended any of the eight designated hepatology units. It
is estimated that baseline data collection will take 9 to 12
months to complete. Follow-up information will be collected
annually thereafter. Only patients who have given written
consent are included in the database. The database does not
contain names or addresses. Ethical approval for the database
has been received from the ethics committees of the eight
hospitals. Patient support groups are represented on the
Steering Committee, which oversees the project.
An annual report will be prepared. There will be an annual call
for research based on the data contained in the database. This
process will be overseen by the Steering Committee.
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Figure 8. Age-standardised incidence rates of hepatitis type unspecified per 100,000 population 2002-2003, and hepatitis C per 100,000 population 2004, by health board
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Box 1. Case definition for Hepatitis A17
Hepatitis A (acute) 
Clinical description
In symptomatic cases, clinical picture compatible with hepatitis, i.e.
discrete onset of symptoms and/ or jaundice or elevated serum
aminotransferase levels. Asymptomatic cases are common.
Laboratory criteria for diagnosis
One of the following:
IgM-class to hepatitis A virus (anti-HAV) positive
Detection of antigen in stool
Detection of nucleic acid in serum
Case classification
Possible: A case that meets the clinical case definition but has
no epidemiological link
Probable: A case that meets the clinical case definition and has
an epidemiological link
Confirmed: A case that meets the clinical case definition and is
laboratory confirmed
Box 2. Case definition for Hepatitis B17
Hepatitis B (acute and chronic) 
Clinical description
In symptomatic cases, clinical picture compatible with
hepatitis, i.e. discrete onset of symptoms and/ or jaundice
or elevated serum aminotransferase levels. Asymptomatic
cases are common.
Hepatitis B (acute) 
Laboratory criteria for diagnosis
One of the following:
IgM antibody to hepatitis B core antigen (anti-HBc)
positive
Detection of hepatitis B virus (HBV) nucleic acid in serum
Case classification
Possible: N/A
Probable: A symptomatic case that is HBsAg positive
and has a clinical picture compatible with an
acute hepatitis
Confirmed: A case that is laboratory confirmed
Hepatitis B (chronic)
Laboratory criteria for diagnosis
One of the following:
Hepatitis B surface antigen (HBsAg) positive and antibody
to hepatitis B core antigen (anti-HBc) positive and IGM
antibody to hepatitis B core antigen negative
Persistence for more than 6 months of either HBsAg or
HBV nucleic acid in serum
Case classification
Possible: N/A
Probable: N/A
Confirmed: A case that is laboratory confirmed
Box 3. Case definition for Hepatitis C17
Hepatitis C 
Clinical description
In symptomatic cases, clinical picture compatible with
hepatitis, i.e. discrete onset of symptoms and/ or jaundice or
elevated serum aminotransferase levels. Asymptomatic cases
are common.
Laboratory criteria for diagnosis
One of the following:
Detection of hepatitis C virus (HCV) specific antibodies 
Detection of HCV nucleic acid from clinical samples
Case classification
Possible: N/A
Probable: N/A
Confirmed: A case that is laboratory confirmed.
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Key Points
• Meningococcal disease became a notifiable disease in its
own right on 1st January 2004
• Incidence of meningococcal disease declined in 2004
compared with previous years
• In 2004, 199 cases of meningococcal disease were
notified
• Only five serogroup C cases occurred in 2004, which was
identical to 2003. This was a 96% reduction compared
with pre MenC vaccine era
• There were 10 meningococcal disease related deaths in
2004
Introduction
In the late 1990s, Ireland had one of the highest incidence
rates of meningococcal disease in Europe with >14 cases per
100,000 total population being notified per annum. This was
equivalent to over 500 cases per year. Approximately 80% of
these cases were laboratory confirmed. Serogroup C disease
accounted for 30% of laboratory confirmed cases, with
infants, children under five years of age and young adults
mostly affected. In October 2000, the MenC conjugate
vaccine was introduced in Ireland to the infant schedule at 2,
4 and 6 months. A catch-up campaign targeting those under
23 years of age was also run at the time. Since then the
incidence of serogroup C disease had substantially declined in
Ireland, with very few cases now occurring each year. The
overall incidence of meningococcal disease has also been on
the decline in recent years, from the high of 14.8 cases per
100,000 in 1999, to 8.4 cases per 100,000 in 2001, to 6.1
cases per 100,000 in 2003.
Materials & Methods
Meningococcal disease became a notifiable disease in its own
right on the 1st January 2004 with the implementation of the
Infectious Disease (Amendment) (No. 3) Regulations 2003 (SI
No. 707 of 2003).1 Prior to this, it was notifiable under the
category bacterial meningitis (including meningococcal
septicaemia). Most forms of bacterial meningitis are now
notifiable under the specific disease pathogen name as listed
in the legislation. For bacterial meningitis pathogens not
listed, these forms of meningitis are notifiable under the
disease bacterial meningitis (not otherwise specified).
The case definitions used are described in the NDSC Case
Definitions for Notifiable Diseases booklet.2
Meningococcal Disease in Ireland,
2004
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An enhanced surveillance system has been in operation in
Ireland since 1997 for bacterial meningitis, which also includes
meningococcal septicaemia. Cases are notified daily to HPSC
since 1999. When a clinician or diagnostic laboratory reports
any case of meningococcal disease/bacterial meningitis, the
medical officer notified of the case completes part one of the
enhanced surveillance form on the day of notification. This
form is then faxed to local Department of Public Health and
to HPSC. Part two of the form is completed once final
laboratory and epidemiological data becomes available.
At HPSC, meningococcal disease notifications in 2004 were
entered on an MS Access database. The Irish Meningococcal
and Meningitis Reference Laboratory (IMMRL) maintains an
active national surveillance system for laboratory confirmed
cases of meningococcal disease. Throughout 2004, the HPSC
meningococcal disease database was reconciled monthly with
the IMMRL database and a few times a year with the
Departments of Public Health databases.
In February 2005, HPSC commenced using the Computerised
Infectious Disease Reporting (CIDR) system for handling the
majority of the notifiable infectious disease notifications,
which included meningococcal disease. At this time
meningococcal disease notifications since 1999 (including all
the enhanced information available) held at HPSC were
migrated from the MS Access system to CIDR. Final data
cleaning and validation checks on the 2004 notifications were
performed in conjunction with the Departments of Public
Health and IMMRL following year-end. Any updates to these
data were made directly to the events on the CIDR system.
For the purposes of this report, data analysis was performed
using both Business Object Reporting in CIDR and MS Excel.
Incidence rates were calculated using population data taken
from 2002 Census of Population as the denominator.
The direct method of age standardisation was used to control
for the confounding effect of age so that incidence rates
between health boards can be compared. The Irish population
was used as the standard population.
Results
Total meningococcal disease notifications
In 2004, 199 cases of meningococcal disease were notified in
Ireland (5.1/100,000 total population). This was a 16%
decrease from 2003 when 237 cases were notified
(6.1/100,000) (figure 1). The incidence of meningococcal
disease in Ireland has steadily declined since 1999, when it
was almost treble the incidence rate it is now (figure 1). One
hundred and seventy one (86%) of the meningococcal disease
notifications were classified as definite, three as presumed and
25 as possible. Eighty eight percent of these notifications
(175/199) were laboratory confirmed. Detection of N.
meningitidis in normally sterile sites by PCR alone was the
technique most commonly used in the diagnosis of the
laboratory confirmed cases (59%, 103/175 cases). This was
followed by culture and PCR (n=63) and culture alone (n=5).
For three cases that were laboratory confirmed, N.
meningitidis was cultured from non-sterile sites while for
another case confirmation was based on microscopy results.
Meningococcal disease by age and gender
As in previous years, the incidence of meningococcal disease
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Figure 1.  Crude incidence rate of meningococcal disease in Ireland, 1999-2004
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in 2004 remained highest in infants and young children. The
age specific incidence rate was 90 per 100,000 in infants <1
year of age, 36 per 100,000 in children aged 1-4 years,
followed by incidences of 6.7 and 6.1 per 100,000 for the 15-
19 and 5-9 year old age groups, respectively. The male:female
ratio for meningococcal disease was 1.05:1.0.
Meningococcal disease by serogroup
The incidence of both serogroup B and serogroup C disease
has been on the decline. In 2004, 163 serogroup B cases
(4.2/100,000) were notified, compared to 206 cases
(5.3/100,000) in 2003 (figure 1). Serogroup B now accounts
for 82% of the meningococcal disease notifications, while
serogroup C accounts for just 3% of these (figure 2).
Serogroup C disease therefore continued to remain low in
2004, with just five cases notified (0.1/100,000). This was
identical to the number notified in 2003. The age range of the
five cases in 2004 was 16-80 years. Two of these cases were
in the age group eligable for MenC vaccination but were
unvaccinated. The remaining three cases were in older adults
and therefore would not have received the MenC vaccine. The
pronounced decline in serogroup C cases was seen soon after
the MenC conjugate vaccine was introduced in Ireland in
October 2000 and this decline has continued over the last
four-year period (figure 2 and figure 3). The incidence of
serogroup C meningococcal disease declined by 96% in 2004
when compared with that in 2000.
The incidence of non-B/non-C serogroups of Neisseria
meningitidis has not changed in recent years and their
incidence remains low (figure 2). Therefore, in 2004, in
addition to the 163 serogroup B and five serogroup C cases
notified there were two serogroup Y, one serogroup W135 and
one non-groupable case. No organism was detected for the
remaining 27 cases of meningococcal disease.
Meningococcal disease by Health Board
Following direct age standardisation of the meningococcal
disease data to control for the confounding effect of age
across health boards the highest incidence rate occurred in
NWHB (7.7/100,000; 95% CI 4.0-11.4/100,000) while the
lowest rate was in WHB (3.2/100,000; 95% CI 1.4-
5.1/100,000). However, none of these rates were regarded as
significantly different from the national rate (5.1/100,000;
95% CI  4.4-5.8 /100,000) since their confidence intervals
overlapped. The crude incidence rates and age standardised
incidence rates by health board are presented in figure 4.
Meningococcal disease deaths
There were 10 meningococcal disease deaths in 2004, which
is a case fatality rate (CFR) of 5%. Seven were due to
serogroup B, one serogroup C and no organism was detected
for the two remaining deaths, both of these were classified as
possible meningococcal disease cases. The serogroup B deaths
were all in children under five years of age, while the
serogroup C related death was in an elderly adult. In 2003,
there were 12 meningococcal disease deaths, 11 due to
serogroup B and one to serogroup C. There have been no
serogroup C deaths in those <25 years of age since 2001,
when two deaths occurred. In 2000, there were 11 serogroup
C related deaths in this age group (figure 3).
Imported cases of meningococcal disease
Four cases of meningococcal disease were imported in 2004,
three serogroup B (ERHA, SEHB, WHB) and one serogroup Y
(MWHB). All imported cases were in individuals aged <20
years. The cases were imported from Portugal, Latvia, Spain
and England. There were no deaths amongst these cases. For
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Figure 3.  Serogroup C cases and deaths in under and over 25 year olds, 1999-2004
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the purposes of this report imported cases have been included
at all stages of the analysis.
Other forms of bacterial meningitis
Meningococcal disease accounts for the vast majority of
bacterial meningitis cases notified in Ireland. However, other
forms do occur and in 2004 the breakdown was as follows: 37
cases of bacterial meningitis (not otherwise specified), 22
cases of Streptococcus pneumoniae meningitis, six TB
meningitis (provisional figure), four Haemophilus influenzae
type b (Hib) meningitis and one case of meningitis due to
Listeria monocytogenes. There are separate chapters in this
report that cover invasive H. influenzae disease, invasive
Streptococcus pneumoniae infection and tuberculosis in more
detail.
Regarding the 37 bacterial meningitis (not otherwise
specified) cases, notified in 2004, eight were classified as
confirmed (6 group B streptococci, 1 Escherichia coli and 1
Pseudomonas aeruginosa), six as probable and 23 as possible.
There was one death reported due to bacterial meningitis 
(not otherwise specified) in 2004, this was the confirmed 
E. coli case.
Discussion
Although meningococcal disease continues to be the most
common form of bacterial meningitis notified in Ireland, the
incidence of this disease has been declining in recent years. It
has fallen from over 14 cases per 100,000 total population in
1999 to 5 per 100,000 in 2004. The introduction of the
MenC conjugate vaccine in October 2000 had a major impact
in this decline. Serogroup C disease now only accounts for
3% of the notifications compared to 30% in 1999 and
morbidity and mortality due to this form of the disease have
declined substantially. The epidemiology of non-B/non-C
serogroups of meningococcal disease has not changed over
this period and their incidence continues to be low. The
incidence of serogroup B disease has also been on the decline
over the last number of years, suggesting that Ireland is
emerging from the hyper-endemic period experienced at the
end of the last decade. Serogroup B disease is now by far the
most predominant serogroup occurring and accounts for 93%
of the laboratory confirmed cases. The highest incidence rates
are occurring in young children. In 2004, 69% of all serogroup
B cases occurred in children <5 years of age, while all (100%,
n=7) of serogroup B related deaths occurred in this age group.
Despite a decline in the incidence of serogroup B disease, the
burden of illness due to this serogroup is still substantial in
Ireland. The development of a suitable and effective MenB
vaccine targeting a broad spectrum of serosubtypes would be
very much welcomed.
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Key Points
• In 2004, the incidence rate of human salmonellosis
decreased (10.6/105) compared to 2003 (11.5/105)( from
analysis of the clinical notification data)
• The highest rate was observed in children under 5 years
of age
• After S. Enteritidis (n=172) and S. Typhimurium (n=125),
the next most common serotypes were S. Bredeney
(n=11), and S. Virchow (n=10)
• 18% of cases were reported to be associated with travel
outside of Ireland in 2004
Background
Salmonella is a ubiquitous gram-negative bacteria that is a
common cause of foodborne illness in Ireland and worldwide.
At present, over 2,460 serotypes of Salmonella have been
identified. Two serotypes, however, S. enterica serotype
Enteritidis and S. enterica serotype Typhimurium have
accounted for the majority of cases of human salmonellosis in
recent years.
Salmonellosis presents clinically as an acute enterocolitis, with
sudden onset of headache, abdominal pain, diarrhoea, nausea
and occasionally vomiting. Fever is almost always present.
Dehydration, especially amongst vulnerable populations such
as infants, the immunocompromised and the elderly, may be
severe. S. Typhi and S. Paratyphi can cause enteric fever, a
severe systemic life threatening condition, but this is very rare
in Ireland and mainly travel-associated.
Salmonella is a zoonoses and a wide range of domestic and
wild animals, as well as humans can act as the reservoir for
this pathogen. Prevention, surveillance and control of
Salmonella infections is of major public health importance.
Methods
The National Salmonella Reference Laboratory (NSRL) was
established in 2000 in the Department of Medical
Microbiology, University College Hospital, Galway. This
laboratory accepts S. enterica isolates from all clinical and
food laboratories for serotyping, phage typing and
antimicrobial sensitivity testing.
This report reviews data available from the National
Salmonella in Ireland, 2004
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Salmonella Reference Laboratory (NSRL) and weekly events of
salmonellosis extracted from the CIDR system for the year
2004. These data enable us to provide an overview of the
epidemiology and burden of disease caused by Salmonella
infections in Ireland today.
Results
Demographic information
There were 419 clinical isolates of S. enterica referred to NSRL
in 2004. The male: female ratio was 1.2:1. The age groups
and sex of those affected are shown in  Table 1. The highest
number of cases was seen in children under five years of age.
When age-specific incidence rates were calculated (Figure 1),
the burden of illness in this age group was even more evident.
Seasonality
Analysis of the number of salmonellosis events notified to
HPSC by week in 2004, revealed a rise in cases in late August/
early September. A seasonal peak is typically seen each year
at this time.
Serotyping, phage typing and antibiotic susceptibility
results from NSRL
Serotyping
The breakdown of Salmonella serotypes by health board is
shown in Table 2. It should be noted however that for the
NSRL data, health board location refers to the location of the
clinical laboratory that the isolate was originally sent to, and
may not always correspond with the geographic location of
the case.
As has been the trend in recent years, the predominant
serotype causing human illness in 2004 was S. Enteritidis
(n=172), followed by S. Typhimurium (n=125).
Table 3 depicts the changing shift in the more common
serotypes in the past number of years. In 2004, after S.
Enteritidis and S. Typhimurium, the next most commonly
isolated serotypes were S. Bredeney (n=11), S. Virchow
(n=10), S. Kottbus (8) and S. Kentucky (7). There were just
five cases of S. Typhi detected, which was a decrease on 2003
when there were nine cases reported.
Phage typing
The predominant phage types of S. Typhimurium and S.
Enteritidis are summarised in Tables 4 and 5. The commonest
phage type of S. Typhimurium reported in 2004 was DT104
(38%), followed by DT104b (18%). This trend was the reverse
seen in 2003 when DT104b was the most commonly
detected type.
An interesting trend was noted with S. Enteritidis phage
typing, with PT1 becoming the predominant phage type of
this serovar for the first time since 1998, replacing PT4 as the
previously most common phage type detected.
Travel-association
75 out of 419 isolates (18%) reported to NSRL in 2004 were
found to be associated with travel outside of Ireland. The
most commonly reported countries were Spain (n=26),
Greece (n=5), Thailand (n=4), and India (n=3).
Antimicrobial resistance
The antimicrobial susceptibility patterns of the most
Table 1. Analysis of clinical isolates of S. enterica (n=419) referred to NSRL,
(2004) by age-group and gender.
Age group (years)  No. of isolates (%)  Male  Female  Unknown
0-4 81 (19) 40 35 6
5-9 30 (7) 11 17 2
10-14 15 (4) 4 11 0
15-19 19 (5) 8 11 0
20-24 42 (10) 19 22 1
25-34 72 (17) 30 37 5
35-44 46 (11) 18 28 0
45-54 39 (9) 17 22 0
55-64 36 (9) 14 21 1
65+ 30 (7) 20 10 0
Unknown 9 (2) 5 3 1
Total 419 186 217 16
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 Figure 1. Age-specific incidence rate of human salmonellosis in Ireland, 2004.
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Table 2.  Serotypes of Salmonella enterica by health board, 2004.
Serotype  ERHA MHB MWHB NEHB NWHB SEHB SHB WHB Total
Adelaide 0 0 0 0 1 1 0 0 2
Agona 0 0 0 0 0 1 0 1 2
Albany 2 0 0 0 0 0 0 0 2
Anatum 0 0 0 1 0 0 0 0 1
Berkeley 0 0 0 0 0 0 1 0 1
Bredeney 10 0 0 0 0 0 0 1 11
Chester 0 0 0 0 0 1 0 1 2
Corvallis 1 0 0 0 0 0 0 0 1
Derby 0 0 0 0 1 1 0 0 2
Dublin 1 0 1 0 1 0 1 0 4
Enteritidis 80 21 4 11 6 15 24 11 172
Goldcoast 0 0 0 0 0 0 1 0 1
Hadar 1 0 0 0 1 1 0 1 4
Haifa 1 0 0 0 0 1 0 0 2
Havana 4 1 0 0 0 0 0 0 5
Heidelberg 1 0 0 0 0 0 0 0 1
Hvittingfoss 1 0 0 0 0 0 0 0 1
Indiana 0 0 0 0 0 1 0 0 1
Infantis 0 0 0 0 0 1 0 0 1
Kentucky 5 0 0 0 1 0 1 0 7
Kottbus 1 4 0 1 0 0 0 2 8
Mbandaka 0 1 0 0 0 0 1 0 2
Montevideo 1 0 0 0 0 0 0 1 2
Muenster 1 0 0 0 0 0 0 0 1
Newport 2 0 1 0 1 0 1 1 6
Othmarschen 1 0 0 0 0 0 0 0 1
Panama 1 0 0 0 1 0 0 0 2
Paratyphi A 1 0 0 0 0 1 1 0 3
Poona 0 0 0 0 0 0 0 1 1
Potsdam 1 0 0 0 0 0 0 0 1
Reading 1 0 0 0 0 0 0 0 1
Richmond 0 0 0 0 1 0 0 0 1
Rissen 0 0 0 0 0 1 0 0 1
Rubislaw 0 0 1 0 0 0 0 0 1
Saintpaul 3 0 0 0 0 0 0 0 3
Senftenberg 1 0 0 0 0 0 0 0 1
Shangani 1 0 0 0 0 0 0 0 1
Stanley 0 0 1 0 0 1 0 1 3
Thompson 0 0 0 0 1 0 2 1 4
Typhi 3 0 0 0 1 0 0 1 5
Typhimurium 27 24 9 12 10 15 23 5 125
Virchow 3 0 1 0 0 5 0 1 10
Weltvreden 0 0 0 1 1 0 1 0 3
Wien 0 0 0 0 0 0 0 1 1
Zanzibar 0 0 0 0 0 0 0 1 1
Unknown 3 0 0 0 1 0 2 1 7
Total 158 51 18 26 28 46 59 32 418*
CIR 11.3 22.6 5.3 7.5 12.6 10.9 10.2 8.4 10.7
CIR: Crude incidence rate per 100,000 population
* 1 case of S. Enteritidis was known to be resident in UK
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 Figure 2. Number of salmonellosis notifications by week, 2004 (data from CIDR).
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commonly isolated serotypes in 2004 are presented in 
Table 6. High levels of resistence among S.Typhimurium
isolates, particularly DT104 isolates, was again noted in 2004.
Clinical notification data
Salmonellosis is a notifiable disease. Medical practitioners
have a statutory obligation to report all suspected cases.
There were 415 cases notified to HPSC through the weekly
notification system in 2004, giving a crude incidence rate of
10.6 per 100,000 population (see figure 3).
Outbreaks
In 2004, there were eight outbreaks of S. enterica notified to
HPSC; one general, six family outbreaks, and one small cluster
was reported as travel-associated. The general outbreak
involving ten persons, occurred in a restaurant, and was
caused by S. Typhimurium DT49. The food implicated
epidemiologically in this outbreak was tiramisu dessert.
Discussion 
Salmonella enterica continues to be an extremely significant
cause of gastroenteritis in Ireland, despite a decrease in the
rate of infections due to salmonellosis in 2004 (10.6/105)
compared to 2003 (11.5/105). The highest incidence was
reported in the Midland health board region. Higher rates
were seen for the year 2004 in Northern Ireland1 (26.3),
England and Wales2 (24.0) and Scotland3 (22.5).
Similar trends regarding the epidemiology of this pathogen
were noted in 2004 as in previous years. Males and females
were equally affected. All age-groups were seen to be
affected but the highest incidence was noted in children less
than five years of age. It is likely that more specimens are
submitted for testing from this age-group, so this should be
borne in mind when interpreting these data.
National roll-out of the CIDR system commenced in 2005
and is continuing on a health board region by region phased
approach. Once all regions are ‘live’ on the system, all data
relating to human cases of salmonellosis in Ireland will be
stored in the CIDR repository. This will prove invaluable as for
the first time, a single dataset of clinical, epidemiological and
laboratory data can be analysed for each individual case of
illness.
The typing of all human Salmonella cases by the NSRL
continues to be an extremely powerful discriminatory tool
particularly for cluster/ outbreak detection and especially for
the two most common serotypes S. Enteritidis and 
S. Typhimurium. NSRL currently employs serotyping, phage
typing, antimicrobial sensitivity testing, and pulsed field gel
electrophoresis (PFGE) methodologies. Early identification of
clusters/ outbreaks of salmonellosis continue to be first
detected by the reference laboratory in this way. In addition,
rapid typing methods allow NSRL to identify if isolates
diagnosed in Ireland are part of a larger, possibly international
outbreak, and hence we can alert our international colleagues
through the Enter-net network.
In 2004, an increase was noted in the number of cases of
illness of salmonellosis reported as being associated with
travel outside of Ireland, compared to 2003. It should be
noted that undoubtedly the true burden of travel-associated
cases is even higher. Every year, an increasing number of
Table 5. Phage types of S. Enteritidis 
in human isolates (2004) 
Phage type No. of isolates (%)
PT1 48 (28)
PT4 43 (25)
PT21 18 (10)
PT6a 11 (6)
PT14b 11 (6) 
PT8 10 (6)
PT6 10 (6)
PT24var 4 (2)
PT4b 3 (2)
Other 13 (7)
No type 2 (1)
Total 173
Table 3. Serotypes of S. enterica referred to NSRL (1998-2004) (%). 
Serotype 1998  1999  2000  2001 2002  2003 2004
S. Enteritidis 60 (8) 155 (33) 239 (36) 248 (46) 165 (40)  205 (42) 173(41)
S. Typhimurium 578 (80) 200 (42) 286 (43) 165 (30) 140 (34)  135 (28) 125 (30)
S. Bredeney 15 (2) 55 (12) 24 (4) 11 (2)   2 (0.5)       3 (1) 11 (3)
S. Kentucky 14 (2) 12 (3) 15 (3) 4 (1)   1 (0.2)     10 (2) 7 (1) 
All others 54 (7) 52 (11) 101 (15) 115 (21) 108 (26)  133 (27) 103 (25)
Total 721 474 665 543  416  486 419
    Table 4. Phage types of S. Typhimurium in human isolates (2004) 
Phage type No. of isolates (%)
DT104 48 (38)
DT104b 23 (18)
DT49 10 (8)
DT1 4 (3)
DT104c 4 (3) 
DT120 3 (2)
DT193a 3 (2)
DT208 3 (2)
U310 3 (2)
Other 15 (12)
No type 9 (7)
Total 125
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more ‘unusual’ serotypes are being detected and it is quite
probable that many of these are acquired abroad. In addition
a significant number of travel-associated typhoid cases are
reported each year. It is important that travellers are made
aware of the measures that can be taken to reduce the risk of
developing food-/ water-borne illness whilst abroad and
especially that typhoid vaccination is given when travelling to
endemic countries.
Finally, analysis of the 2004 AMR data (antimicrobial
resistance) of the various Salmonella serotypes again
demonstrated high levels of resistance among S. Typhimurium
isolates, particularly DT104 isolates.4 A recently published
review outlines that during the period 1992-2001, the
incidence of MDR (multi-drug resistant) S. Typhimurium and
DT104 increased on a continuous basis globally, although the
problem affected primarily Europe and North America. The
study highlighted that MDR S. Typhimurium constitute an
increasing public health problem in many parts of the world,
not alone Ireland, and emphasised the importance of
surveillance and control programs.
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Figure 3.  Crude rate of Salmonellosis in Ireland per 100,000 population 1982-2004.
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Table 6. Antimicrobial susceptibilities of human Salmonella enterica serotypes 
isolated in Ireland in 2004.
        % Resistance
Serotype (Number)   Amp  Chl  Strep  Sulph  Tet  Trim  Nal
Enteritidis (173) 10 0.5 2 2 6 2 33
Typhimurium (125) 68 62 64 71 71 10 7
Bredeney (11) 18 0 0 0 0 0 0
Virchow (10) 20 0 10 20 20 20 50
Kentucky (7) 28 0 14 28 28 0 14
Typhi (5) 20 20 20 20 20 20 20
Hadar (4) 25 0 100 0 75 0 50
Amp = Ampicillin, Chl = Chloramphenicol, Strep = Streptomycin, Sulph = Sulphonamide,
Tet = Tetracycline, Trim = Trimethoprim, Nal = Naladixic acid
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Ireland was one of 22 European Countries participating in the
European Sero-Epidemiology Network 2 (ESEN2) (figure 1).
This project has now come to a close and the data are being
analysed.
The aim of the project was to co-ordinate and harmonise the
serological surveillance of immunity to communicable disease
across Europe. The ESEN2 network focused on eight vaccine
preventable diseases in particular: measles, mumps, rubella,
pertussis, diphtheria, varicella zoster, hepatitis A and hepatitis
B. By standardising both laboratory and epidemiological
methodology, international comparisons can be made to
evaluate the effectiveness of different immunisation
programmes and to coordinate vaccine policy to ensure
adequate levels of immunity exist throughout Europe.
In collaboration with the NDSC and the NVRL, laboratories
from six health boards / authorities completed the collection
of more than 2000 samples for the ESEN2 study in 2003.
Testing of these samples began in 2003 and was completed in
2004. Testing for the measles, mumps, rubella, varicella zoster,
hepatitis A and hepatitis B work-packages was carried out at
the National Virus Reference Laboratory, Dublin. Testing for
the diphtheria and pertussis work-packages was carried out at
the Communicable Disease Surveillance Centre, Colindale,
London.
Key information on the history and development of
vaccination programmes and historic data on disease
incidence in the ESEN2 participating countries was collected
as part of the project. This information was central to the
interpretation of the  results generated from this study.
ESEN2 data - used for developing immunisation policy
Valuable information on the level of immunity in the Irish
population to these serious preventable diseases has been
provided by this project. This information has already proved
useful for identifying age groups within the population that
are most susceptible to these diseases and is being used to
develop immunisation policy in Ireland.
During 2004, a mumps outbreak occurred in Irish colleges,
mainly affecting students in their late teens or early twenties.
Using the ESEN2 data the mumps outbreak control team
were able to identify those age groups most susceptible to
mumps infection, and make appropriate recommendations for
targeting MMR vaccine towards those most at risk of
infection.
These data have also been used to review vaccination policy
in the areas of other vaccine preventable diseases such as
measles, rubella and hepatitis B.
Additional work is ongoing in HPSC to analyse the sero-
immunity to the other diseases  (pertussis, diphtheria,
varicella zoster, hepatitis A) and review vaccination policy in
view of these findings.
HPSC is working with ESEN2 partners (national and
international) to prepare this information for publication and
dissemination to a wider audience in the near future.
European Sero-Epidemiology
Network 2 (ESEN 2)
Figure 1. Countries participating in ESEN2: Belgium, Bulgaria, Cyprus, Czech Republic, 
Finland, Germany, Greece, Hungary, Ireland, Israel (not shown), Italy, Latvia, Lithuania,
Luxembourg, Netherlands, Malta, Romania, Slovakia, Slovenia, Spain, Sweden, United 
Kingdom
HPSC Annual Report 200462
Campylobacteriosis in Ireland,
2004
Key Points
• Campylobacter remains the commonest cause of
gastroenteritis of bacterial aetiology in Ireland
• In 2004, there were 1711 cases of campylobacteriosis
notified (CIR 43.7/105) which is the highest number of
cases reported since 1999 (2085 cases)
• The highest burden of illness was in children under 5
years of age
• In 2004, the highest incidence rate was reported from
the Western health board region (63.1/ 105)
Background
Campylobacteriosis is the commonest reported bacterial
cause of infectious intestinal disease in Ireland. Two species
account for the majority of infections: C. jejuni and C. coli.
Illness is characterised by severe diarrhoea and abdominal
pain. Symptoms may subside after a number of days or may
persist for weeks. Rarely, more severe sequelae may develop
such as reactive arthritis, Reiter’s syndrome, or HUS and
approximately 1 in every 1000 cases leads to a severe
neurological disorder called Guillain-Barré Syndrome (GBS).
Undercooked meat especially poultry is often associated
with illness, as is unpasteurised milk and untreated water.
The majority of infections, however, remain largely
unexplained by recognised risk factors for disease.
Methods
Human campylobacter infection became a statutorily
notifiable disease for the first time on 1.1.2004 under the
Amendment to the Infectious Diseases Regulations.1
Data for this report were extracted and analysed from the
CIDR system.
Results
Incidence
In total, 1711 notifications of human campylobacteriosis
were notified in 2004 in Ireland. This gives a crude incidence
rate (CIR) of 43.7 cases per 100,000 population (table 1).
This compared with a CIR of 39.9 cases per 100,000 in 2003.
The annual number of cases by year since 1999 is shown in
Figure 1.
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Age standardised rates were calculated to allow comparisons 
to be made between health board regions without the
confounding effects of age (Figure 2). In 2004, the highest
incidence was reported from the Western health board
region followed by the Midland health board. The lowest
rate was reported from the Mid-Western region.
Seasonal distribution
Analysis of the data by week of notification is shown in
Figure 3. A peak in cases is evident in week 24 and again in
week 38.
Age
When the distribution of cases for each age group is
examined, it is evident that by far the highest burden of
illness is seen in children less than five years (Figure 4). This
was also noted in previous years and is a well-reported
feature of the illness worldwide.
Gender distribution
The variance in gender distribution that has been noted
since 1999 was again evident from analysis of the data in
2004, with males accounting for 54.1% of cases and females
45.5% (0.5% unknown) (see Table 2). This is clearly evident
in figure 5 when the data are adjusted for age and sex. In
almost all age-groups there is a predominance of male
cases.
Outbreak data
There was one small family outbreak of campylobacteriosis
involving two persons notified in 2004. The mode of
transmission was suspected to be foodborne.
Discussion
In 2004, human campylobacter infections became statutorily
notifiable for the first time under the Amendment to the
Infectious Diseases Regulations.1 Therefore in 2004, the data
on campylobacteriosis was collated directly from the
notifiable disease data on CIDR and not as part of the
Zoonoses Directive data collection (as had been the
situation since 1999).
Analysis of the 2004 data reveals that campylobacteriosis
still remains the most common cause of bacterial
gastroenteric infection in Ireland (with over four times the
number of salmonellosis cases reported in 2004).
The crude incidence rate (CIR) of campylobacteriosis
increased in Ireland in 2004 (43.7 cases/100,000 persons)
compared to 2003 (39.9/100,000). This was in fact the
highest rate reported in Ireland since the year 1999. In
most regions, an increase was seen in 2004, especially in the
NWHB region.
For the same period, a slightly higher rate was noted for
Northern Ireland2 (49.6/100,000), but similar to 2003, much
higher rates were observed for England and Wales3
Table 1: Number of cases and CIR per 100,000 population of human campylobacteriosis in 
Ireland by health board, 2004
Health Board No. of cases CIR - (incl. 95% C.I.)
ERHA 591 42.2 [38.8 - 45.6]
MHB 134 59.5 [49.4 - 69.6]
MWHB 107 31.5 [25.5 - 37.5]
NEHB 113 32.8 [26.8 - 38.8]
NWHB 92 41.5 [33.0 - 50.0]
SEHB 194 45.8 [39.4 - 52.2]
SHB 240 41.4 [36.2 - 46.6]
WHB 240 63.1 [55.1 - 71.1]
Total 1711 43.7 [41.6 - 45.8]
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Figure 1.  Annual number of cases of campylobacteriosis in Ireland, 1999-2004 
(2004 data from CIDR)
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Table 2. Gender distribution of campylobacter cases by health board region, 2004.
 Female Male  Unknown Total
ERHA 279 311 1 591
MHB 71 63 0 134
MWHB 45 62 0 107
NEHB 42 70 1 113
NWHB 42 49 1 92
SEHB 84 110 0 194
SHB 110 128 2 240
WHB 105 133 2 240
Total 778 926 7 1711
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Figure 2: Age standardised incidence rates (ASIR) of human campylobacteriosis 
in Ireland, compared to crude incidence rates (CIR) in each health board, 2004.
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(79.5/100,000) and Scotland4 (86.0/100,000) (provisional
data).
As has been noted consistently since 1999, some interesting
epidemiologic features of this pathogen have emerged in
recent years. In particular, the higher incidence rate in
young  children and the bias towards male cases in almost
all age-groups.
To try to address some of these questions, the first Irish
case-control study was conducted in 2004 aiming to
examine the risk factors that exist for campylobacter
infection in the Irish population and help to unravel the
aetiology of this disease in Ireland. The study took place on
an all-island basis in the ERHA region in the ROI and in all
four Health and Social Services Boards (HSSB) in NI. The
study was completed in 2005. Preliminary findings from the
study reveal that eating chicken, and lettuce, and eating out
in restaurants/ takeaways are major risk factors for
campylobacteriosis in Ireland, North and South.5
An important conference entitled “Campylobacter
Surveillance and Research in Ireland – The Way Ahead?” was
held in UCD in June 2005. This conference and
accompanying workshop, involving international experts, was
convened to highlight current knowledge gaps and views on
the best way forward for research on Campylobacter in
Ireland. It is hoped that the findings, due to be published
shortly, will prioritise future strategies for Campylobacter
prevention, control and  surveillance and help to elucidate
some of the complexities of this zoonotic agent.
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Figure 3: Total cases of campylobacteriosis events by week, 2004 (data from CIDR)
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Figure 4:  Age specific incidence rates for campylobacteriosis in Ireland, 2004 
(data from CIDR)
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Figure 5: Age-gender adjusted incidence of campylobacteriosis according to age-group 
in 2004.
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The Epidemiology of
Verocytotoxigenic
E. coli O157 in Ireland, 2004
Introduction
Verotoxigenic E. coli (VTEC) are so-called because of their
ability to produce one or both of two verotoxins (VT1 and
VT2). They are an important cause of gastroenteric illness in
Ireland with between 42 and 88 cases of VTEC O157 reported
annually between 1999 and 2004.1 Their relative significance
lies not in their numbers but in the severity of illness they can
cause, and in the requirement for prompt public health action
to prevent further transmission. They cause a wide range of
symptoms, from mild diarrhoea to haemorrhagic colitis with
severe abdominal pain and bloody diarrhoea. Illness is usually
self-limiting and resolves after about eight days. A proportion
of patients however (approx. 9% of symptomatic Irish cases)
develop haemolytic uraemic syndrome (HUS), a life-
threatening complication.
E. coli O157 was the first E. coli serogroup to be associated
with this distinctive illness but several other verotoxin-
producing E. coli serogroups have been reported, including
O26, O111, O103 and O145. The primary reservoir is believed
to be cattle, although VTEC have been isolated from a variety
of healthy animal carriers including sheep, horses, goats and
wild birds, and while this organism was first recognized as a
foodborne pathogen (the ‘burger bug’), it is now known that it
can also be transmitted through contaminated water, the
environment and by direct contact with animal carriers.
Person-to-person spread is an important mode of
transmission in households, child-care facilities and
institutions.
Key points:
• In 2004, there were 61 confirmed human VTEC
infections, a decrease of 36% on the number reported
for 2003
• Nine VTEC infections (15%) were caused by non-O157
VTEC, including two cases of HUS
• As in previous years, the highest number of VTEC cases
was reported in late summer
• Untreated private wells were believed to be the source
of infection in a number of outbreaks in 2004 
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Methods
Since 1999 HPSC, in co-operation with Directors of Public
Health in each health board region, have operated an
epidemiological surveillance system for VTEC O157; the data
reported under this system has formed the basis of the HPSC
annual reports on E. coli O157 for the last 5 years. Details on
how this system operates, and the case definition used, have
been outlined in previous reports. 1
In 2004, changes to the infectious disease legislation resulted
in all VTEC becoming notifiable (S.I. 707 of 2003), and this
annual report is the first that aims to describe disease caused
in Ireland by VTEC of all serogroups. Enhanced information
was supplied as in the previous years by health board
personnel, and in addition, typing data was provided by the
HSE-SWA Public Health Laboratory at Cherry Orchard
Hospital which offers specialist diagnostic and typing services
for VTEC.
Data from the enhanced surveillance system in 2003 was also
compared with data from the HSE-SWA PHL database
retrospectively. A composite list of cases from 2003 showed
that 88 cases of VTEC O157 and 7 cases of VTEC O26
occurred. The data quoted in this report for 2003 has been
updated to reflect the combined data.
Results
Sixty-one confirmed cases of VTEC were notified to HPSC
during 2004, an incidence rate of 1.6 per 100,000. This
compares with 95 cases reported in 2003 (2.4/100,000), a
reduction of 36% (Figure 1 and Table 1). Among these 61
cases were 52 cases of VTEC O157 (1.3/100,000), four VTEC
O26, two VTEC O111, and one each of VTEC O145, O146 and
O Ungroupable.
Regional distribution
Regional variation was noted in the numbers of cases reported
(Table 2), with the highest incidence rates this year in the
North-Eastern and Western Health Boards, however the
number of cases per region is small, and differences unlikely
to be significant.
Age-sex distribution
The highest incidence was recorded in young children (Figure
2), which is consistent with previous years. This was
particularly pronounced among male cases.
It was also notable that all non-O157 VTEC infections
reported were in persons less than 15 years or over 65 years
(Figure 3).
Clinical Features
Information on symptoms was available for 56 cases, of
whom 47 (84%) were reported as symptomatic. Reported
symptoms included: bloody diarrhoea in 25 cases (53%), and
HUS in four cases (8.5%). All four cases of HUS occurred in
children under 10 years of age. Significantly, two of these
HUS cases were caused by non-O157 VTEC.
Table 1. Number and crude incidence rates (CIR) VTEC and VTEC O157 infection, Ireland 
1999-2004
Year No. of VTEC   CIR VTEC O157*       No of all VTEC   CIR VTEC* 
 O157 cases    (95% CI)  cases‡   (95% CI) 
1999 51  1.4 (1.0-1.8) N/A   N/A
2000 37(42)§  0.9 (0.6-1.3) N/A   N/A
2001 50 (52)§  1.3 (0.9-1.6) N/A   N/A
2002 68 (70)§  1.7 (1.3-2.2) N/A   N/A
2003† 88   2.2 (1.8-2.7) 95   2.4 (1.9-2.9)
2004 52  1.3 (1.0-1.7) 61   1.6 (1.2-2.0)
* Data from 1996 census was used to calculate the rate in 1999 while the 2002     
   census were used to calculate rates from 2000-2004, rates exclude non-residents.  
† Composite data from 2003 –see methods section.
N/A= Not available
‡ Includes serogroup O157
§  Brackets include non-resident case           
Table 2. Number, crude incidence rate (CIR) and age-standardised incidence rate
with 95% confidence intervals of confirmed cases of VTEC by health board of res
Ireland, 2004
Health  No. of cases  No. of cases  CIR VTEC  ASIR VTE
Board all VTEC VTEC O157  (95% CI) per 100,000 (95% CI) per 1
ERHA 12 11 0.9  (0.4-1.4) 0.9  (0.4-1.
MHB 2 2 0.9  (-0.3-2.1) 0.9 (-0.4-2
MWHB 6 4 1.8  (0.4-3.2) 1.8  (0.4-3.
NEHB 11 10 3.2  (1.3-5.1) 3.1  (1.3-5.
NWHB 3 2 1.4  (-0.2-2.9) 1.3  (-0.2-2
SEHB 6 5 1.4  (0.3-2.5) 1.4  (0.3-2.
SHB 11 8 1.9 (0.8-3.0) 1.9  (0.8-3.
WHB 10 10 2.6 (1.0-4.2) 2.6 (1.0-4.2
Total 61 52 1.6  (1.2-2.0) 
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Seasonality of VTEC cases
The largest number of cases in 2004 occurred in the third
quarter (46%), very similar to the trend observed in previous
years (Figure 4), although the peak in the number of cases
was not as pronounced. Specifically, all non-O157 cases were
reported in quarter 2 and 3.
Travel-association
Seven cases were travel-associated. The countries visited
within 14 days of onset of illness were Spain (2), UK (2), Italy
(1), Malaysia (1) and Turkey (1), reflecting to some extent the
frequency of travel by Irish people to these destinations.
Phage Typing Results
Table 3 shows the phage types of the VTEC O157 strains
isolated in 2004. As in previous years, PT32 was the
commonest phage type reported, accounting for 58% of the
VTEC O157 reported.
Verotoxin profiles of VTEC strains isolated in Ireland 2004
In 2004, 71% of VTEC O157 strains carried the genes for VT2
while a further 25% carried the genes for both VT1 and VT2
(Table 4). In contrast, 56% of non O157 VTEC isolates carried
the genes for VT1 only, 11% for VT2 only and 22% VT1 and
VT2. It is notable that strains for all HUS cases (both non-
O157 and O157) carried the genes for VT2.
Outbreaks
In 2004, eight clusters/outbreaks of two or more cases were
reported. Microbiological and /or epidemiological evidence
was obtained linking human cases in a number of these
outbreaks with water and/or livestock.
The NEHB reported a general cross-health board outbreak of
VTEC O157 linked to a sports club. Four confirmed cases were
reported, three of whom were admitted to hospital. Drinking
water used at the venue, and supplied from an untreated
private well, was found positive for the outbreak strain.
Epidemiological evidence was also obtained linking infection
with water consumption at the venue. In total, 900 people
were potentially exposed. During the investigation further
non-outbreak VTEC strains were identified in environmental
samples, emphasizing the potential public health risk from
environmental contamination.
Two additional family clusters in the NEHB were also reported
as waterborne. Definitive microbiological evidence was
obtained linking water from a private well to 2 confirmed
cases in one of these outbreaks.2 For the second, water from a
private well was found positive for E. coli and coliforms but no
VTEC were isolated.
A third family cluster (WHB) was reported as being
transmitted either by water or by animal contact. In this
instance, both water from a small group water scheme used
by the family, and samples taken subsequently from sheep on
the family farm, tested positive for VTEC O157 that were
indistinguishable from those isolated from the human cases.
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While the precise route of transmission is unclear, the group
water scheme had experienced problems over a protracted
period of time, and was observed to be poorly maintained,
with the schemes chlorinator non functional and the water
source unprotected.
For the 4 remaining family/household clusters, two were
suspected to be due to contact with livestock on family
farms, one to person-to-person transmission and for the
remaining cluster the mode of transmission was reported as
unknown.
Discussion
Significant changes were made in 2004 in the reporting of
cases of VTEC. Illness caused by enterohaemorrhagic E. coli
(EHEC) became a notifiable disease on January 1st 2004. For
the first time also in this report, typing data from the HSE-
SWA PHL has been linked with the epidemiological data from
the HPSC providing a composite picture of the epidemiology
of VTEC in Ireland. As a result, data reported here is more
comprehensive for both O157 and non-O157 infections.
Sixty-one VTEC cases were reported in 2004, a rate of 1.6 per
100000. When only VTEC O157 are considered, the rate was
1.3, considerably lower than was reported for Ireland for the
last two years. This compares with provisional VTEC O157
incidence rates of 1.1/100,000 in Northern Ireland (CDSC NI
personal communication), 4.1/100,000 in Scotland3 and 1.3 in
England and Wales (HPA Colindale, personal communication)
in 2004.
Of particular interest are the nine (15%) VTEC infections
reported in 2004 that were caused by non-O157 E. coli
strains. All nine were reported in quarters 2 and 3, which is in
keeping with the seasonal distribution noted both historically
and this year for VTEC O157 in Ireland. Although the case
numbers were small, non-O157 VTEC cases were reported
from 6 of the 8 health board regions, indicating that they
were widely distributed throughout the country. All non-O157
VTEC infections reported were in children less than 15 years
or adults over 65 years. In fact, non-O157 serogroups
comprised 30% of VTEC cases reported in children less than 5
years. In addition, 2 of the four VTEC-associated HUS cases
reported in 2004 were caused by non-O157 VTEC. While
these latter two observations presumably reflect a greater
degree of screening for non-O157 VTEC in these higher risk
groups, it is evident that non-O157 VTEC were an important
cause of VTEC infections in Ireland in 2004. It is also notable
that while in the past, VTEC O26 was the primary non-O157
VTEC reported in Ireland, the range of serogroups reported in
2004 was much greater.
A variety of sources and transmission routes have been
demonstrated worldwide for VTEC, including food, water,
environmental and direct animal contact as well as person-to-
person transmission. In 2004 in Ireland, two outbreaks, one
general and one family were linked epidemiologically and/or
microbiologically with drinking water from private wells,
demonstrating the potential of this type of water supply in
the transmission of VTEC infection. A private well was also
suspected as the route of transmission for a further family
Table 3 Phage Types of VTEC O157 isolates referred to the HSE SWA Public Health 
Laboratory, Cherry Orchard Hospital in 2004
Phage type Number (%)
PT32 30 (58%)
PT8 5 (10%)
PT14 5 (10%)
RDNC 3 (6%)
PT21/28 2 (4%)
PT1 1 (2%)
PT31 1 (2%)
PT34 1 (2%)
PT51 1 (2%)
N/K 3 (6%)
Total 52 (100%)
N/K= Not known
Table 4. Verotoxin typing results for the VTEC isolates referred to the HSE SWA Public 
Health Laboratory, Cherry Orchard Hospital in 2004 
 VT1 only VT2 only VT1 and VT2 N/K Total
O157 0 37 13 2 52
O26 2 0 1 0 3
O111 1 0 1 0 2
O145 0 1 0 0 1
O146 1 0 0 0 1
O Ungroupable 1 1 0 0 2
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Figure 4. Confirmed VTEC cases by quarter of onset of symptoms, Ireland, 2001-2004
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cluster. The general outbreak illustrates the danger that even
a small private water supply can pose if it provides water to a
large number of people in a short period of time, exposing
them to infection if the water is contaminated.
No other sources or transmission routes were definitively
identified for any of the other VTEC outbreaks reported in
2004 although person-to-person transmission and/or animal
contact were suspected in a number of family/household
clusters. In several case control studies internationally, contact
with farm animals and farming environments has been shown
to be a strong risk factor for VTEC infection among sporadic
cases.4 As a result of zoonotic disease outbreaks relating to
farm animal contact in public settings in the US, the US
National Association of State Public Health Veterinarians
published a ‘Compendium of Measures To Prevent Disease
Associated with Animals in Public Settings, 2005’ which
outlines recommendations for public health officials,
veterinarians, animal venue operators, animal exhibitors,
visitors to animal venues and exhibits, and others concerned
with disease-control and with minimizing risks associated
with animals in public settings.5
The HPSC established a sub-committee to develop guidance
for health professionals regarding human cases of VTEC
infection. A report by this sub-committee is due to be
published shortly and will provide guidance for clinicians, and
laboratory, infection control and public health professionals,
for the diagnosis, treatment and care of those suffering from
VTEC infection, and advice for the prevention of transmission
of infection.
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Invasive Haemophilus influenzae
in Ireland, 2004
Introduction
Haemophilus influenzae can cause serious invasive disease
especially in young children. Many strains of H. influenzae are
surrounded by an outer polysaccharide capsule. Of the six
antigenically distinct capsular types (a-f), H. influenzae type b
(Hib) is the predominant cause of such serious infections as
meningitis, septicaemia and epiglottitis in children. Other
capsular serotypes, notably types e and f and non-capsulated
strains can also cause serious infections.
A conjugate vaccine against Hib disease has been available in
Ireland since October 1992, when it was introduced to the
routine childhood immunisation schedule at 2, 4 and 6
months. A catch-up campaign targeting under five year olds
was also undertaken the time. The Hib immunisation
programme has had a striking impact in reducing the rate of
Hib disease. After the vaccine was introduced the number of
cases fell by 90%, from an incidence of 2.8 per 100,000 total
population in the late 1980’s to 0.26 per 100,000 total
population by 2002. Hib disease however, has not
disappeared completely and a small number of cases continue
to occur, sometimes even in fully vaccinated children.
Materials and Methods
A case of invasive H. influenzae disease is defined as the
isolation/detection of the organism or its nucleic acid from a
normally sterile site. A detailed description of the case
definition is provided in the HPSC Case Definitions booklet.1
Prior to the 1st January 2004 data on invasive H. influenzae
were collected from a number of sources including bacterial
Key Points
• 38 cases of invasive H. influenzae disease were notified
in 2004
• 18 of the cases were due to H. Influenzae type b (Hib)
disease
• 9 Hib cases occurred in children < 15 years of age
• 67% of the children who had Hib disease in 2004 had
been fully vaccinated (TVFs). This is an increase in Hib
vaccine failures compared to previous years.
• A national Hib Booster Catch-up Campaign was
launched in November 2005 for children 12-47 months
of age to protect them against Hib infection
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meningitis notifications, data obtained from the laboratories
and updates from the HPA Haemophilus Reference Unit in
UK. On the 1st January 2004 invasive H. influenzae disease
became notifiable in Ireland, with clinicians and laboratories
legally obliged to notify. An enhanced surveillance system is
in place whereby demographic, clinical, microbiological and
epidemiological information are provided by Departments of
Public Health to HPSC. Notifications in 2004 were reconciled
regularly with updates from HPA Haemophilus Reference Unit
in UK.
H. influenzae data prior to 2004 are on a MS Access database.
H. influenzae notifications from 2004 were inputted to the
Computerised Infectious Disease Reporting (CIDR) system and
analysis was performed using Business Object Reporting in
CIDR and MS Excel. Incidence rates were calculated using
population data taken from 2002 Census of Population as
denominator.
Results
Invasive Haemophilus influenzae disease
In 2004, 38 cases of invasive H. influenzae disease were
notified (0.97/100,000 total population). H. influenzae type b
(Hib) accounted for 47% of these notifications (n=18) and
non-capsular strains for 24% (n=9) (figure 1).
An increase in H. influenzae cases was seen in 2004 (n=38)
compared with 2002 and 2003 when 21 and 22 cases were
reported, respectively (figure 2). The reason for this increase
can largely be attributed to the rise in the number of non-
type b cases reported, from eight in 2003 to 20 in 2004. The
vast majority of these occurred in adults (80%, n=16; Table 1).
In 2003 five of the eight non-type b cases were in adults. The
total number of invasive H. influenzae cases in adults almost
trebled in 2004, rising from nine in 2003 to 25 in 2004.
The age distribution of cases by serotype is presented in Table
1 and the age specific incidence rates for Hib and all forms of
invasive H. influenzae are also presented. The age specific
incidence rate was highest in the 1-4 year olds (4.0/100,000,
n=9). These cases were predominantly due to type b strains.
Hib accounted for eight of these nine notifications
(3.6/100,000). The elderly (aged 65 years or older) had the
next highest age incidence rates for H. influenzae
(2.3/100,000, n=10), but Hib contributed to only 0.9 per
100,000 of the cases (n=4).
There were 3 deaths reported due to invasive H. influenzae in
2004, one death was in a child and two were in adults. All
deaths were due to non-capsular strains. However, the
outcome was not reported for 18/38 H. influenzae
notifications and therefore, an accurate case fatality rate
cannot be calculated.
Haemophilus influenzae type b
Eighteen Hib cases were notified in 2004 (0.5/100,000 total
population). This was an increase from 14 cases in 2003
(0.4/100,000 total population). A rise in adult Hib cases
accounted for this increase, as these comprised of 50% of the
Hib notifications (figure 3). Nine Hib cases occurred in
children <15 years of age in 2004 compared to 10 cases in
2003. The nine Hib cases in children in 2004, actually
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Figure 2.  Invasive H. influenzae cases in Ireland, 1996-2004
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Figure 1.  Invasive Haemophilus influenzae disease notifications in 2004 by serotype
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Table 1.  Invasive Haemophilus influenzae cases notified in 2004, by age group and serotype
Serotype <1 1-4 5-9 10-14 15-19 20-44 45-64 >65 Total  
Type b 1 8 0 0 0 4 1 4 18
Type f 0 0 1 0 0 1 1 0 3
Non-capsular (NC) 0 1 2 0 0 2 2 2 9
Other 0 0 0 0 0 1 3 4 8
All H. influenzae 1 9 3 0 0 8 7 10 38
ASIR of type b (Hib) 1.8 3.6 0.0 0.0 0.0 0.3 0.1 0.9 0.5
ASIR of all H. influenzae 1.8 4.0 1.1 0.0 0.0 0.7 0.8 2.3 1.0
ASIR, age specific incidence rate per 100,000
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occurred in the under 4 year old age group age range 1 month
– 3 years, while the nine adult Hib cases ranged in age from
25-93 years (table 1).
The clinical presentation of Hib disease in the children was
meningitis and/or septicaemia for seven of the nine cases, one
case of osteomyelitis was reported and the clinical diagnosis
was not reported for one case. In adults the disease
presented as septicaemia (n=3), pneumonia (n=2), epiglottitis
(n=1) and clinical diagnosis not reported (n=3). No Hib
deaths were reported in 2004, but two children had
permanent adverse neurological sequelae.
Hib vaccine failures
A true vaccine failure (TVF) is defined as the occurrence of a
laboratory confirmed case of Hib disease in a person who had
been fully vaccinated, while an apparent vaccine failure (AVF)
is the occurrence of Hib disease in a person who was
incompletely vaccinated (i.e. had commenced but had not
completed the Hib immunisation schedule). Six of the nine
children (67%) who had Hib disease in 2004 had been fully
vaccinated (TVFs) compared to three in 2003 and four in
2002 (figure 3). Five of the six vaccine failures occurred
between August and December of 2004.
The TVFs occurred in children ranging in age from 17 to 45
months. The failures arose between 10 and 39 months
following the third dose Hib vaccine in these children. In
2004 there was one AVF in a 2 year old child, two AVFs
occurred in 2003.
Discussion
The number of cases of invasive H. influenzae disease reported
in 2004 increased when compared with previous years. The
increase can largely be attributed to a rise in the number of
adult cases notified, in particular non type b cases, but an
increase in adult Hib cases was also seen. The reasons for this
increase may be due to a number of factors (i) perhaps there
was a true rise in adult H. influenzae cases (ii) a reflection of
improved reporting of the disease in adults as a result of H.
influenzae being made a notifiable disease from 1st January
2004 (iii) a combination of the two previous reasons.
However, this upsurge in adult cases has not been seen to
date in 2005 even though it is still a notifiable disease, which
would more support the hypothesis that there was a true
increase in adult cases in 2004.
The number of H. influenzae cases notified in children under
15 years of age remained unchanged in 2004 compared with
2003, with 13 cases reported in both years. The number of
Hib cases in this age group declined by one in 2004, from ten
to nine cases. However, an increase in the number of Hib
vaccine failures was seen in 2004, increasing from three in
2003 to six in 2004. Prior to 2004, the number of TVFs never
exceeded four in any one year. There was just one TVF over
the first seven and half months of 2004, while the other five
occurred in the space of four and half months. The fact that
five vaccine failures had occurred over such a short period of
time was a cause for concern. The situation was closely
monitored over the first half of 2005; eight cases of Hib
disease occurred, all in fully vaccinated children. As a result of
this upward trend in Hib disease and the fact cases were
predominantly in vaccinated children, the National
Year
N
um
be
r o
f c
as
es
Figure 3.  Number of Haemophilus influenzae type b (Hib) cases in under and over 15 year
olds 1996-2004 and the number of true vaccine failures (TVF)
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Immunisation Advisory Committee recommended that an
additional booster dose was required for children >1 year. A
Hib catch-up campaign is to be launched in November 2005
offering an additional dose of Hib vaccine to children under 4
years of age (12-47 months) in order to further protect these
children against Hib infection.
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Epidemiology of Influenza in
Ireland, 2004/2005 Season
Key Points
• During the 2004/2005 season, influenza activity peaked
in January 2005
• Influenza A (H3N2) was the predominant circulating
subtype 
• The most significant global event during the 2004/2005
season was the continuing spread of poultry outbreaks
of avian influenza A (H5N1) in Asia
Introduction
The 2004/2005-influenza season was the fifth year of influenza
surveillance using computerised sentinel general practices in
Ireland. The HPSC is working in collaboration with the NVRL
and the ICGP on this surveillance project.
Influenza activity was mild in Ireland for most of the
2004/2005 season, with a short peak of activity in January
2005. Influenza A (H3N2) and A (H1N1) co-circulated for the
first part of the season, followed by circulation of influenza B
for the last 12 weeks of the season. Influenza activity mainly
affected 15 to 64 year olds, unlike the 2003/2004 season,
which mainly affected 0 to 4 year olds.
The most significant global event during the 2004/2005-
influenza season was the continuing spread of poultry
outbreaks of avian influenza A (H5N1) in South East Asia,
associated with sporadic cases and clusters of human infection
and a significant proportion of human deaths. 1, 2
Materials and Methods
Clinical data
Thirty-six general practices were recruited to report
electronically, on a weekly basis, the number of patients with
influenza-like illness (ILI). ILI is defined as the sudden onset of
symptoms with a temperature of 38°C or more, with two or
more of the following: headache, sore throat, dry cough and
myalgia. Cases were those attending for the first time with
these symptoms. In total, the 36 sentinel general practices,
comprising 68 general practitioners, represent 2.9% of the
national population. Practices were located in all HSE health
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areas with the number of sentinel practices in each HSE
health area largely based on the population of the HSE health
area.
Virological data
Sentinel GPs were requested to send a combined nasal and
throat swab on at least one patient per week where a clinical
diagnosis of ILI was made. Swabs were sent to the NVRL for
testing for influenza and respiratory syncytial virus (RSV)
using immunofluorescence and PCR techniques and results
were reported to HPSC. The NVRL also reported the results
of respiratory specimens (mainly paediatric), referred mainly
from hospitals, on a weekly basis.
Other indicators of influenza activity
The Departments of Public Health sent an influenza activity
index (no report, no activity, sporadic-, localised-, regional- or
widespread activity) every week, to HPSC. The activity index
is analogous to that used by the WHO global influenza
surveillance system and the European Influenza Surveillance
Scheme (EISS). 3, 4 The index is based on sentinel GP ILI
consultation rates, laboratory-confirmed cases of influenza,
sentinel hospital admissions data and/or sentinel school
absenteeism levels. One sentinel hospital was located in each
HSE health area, reporting total hospital admissions, accident
and emergency admissions and respiratory admissions data
on a weekly basis. Sentinel primary and secondary schools
reported absenteeism data on a weekly basis, and were
located in each health area in close proximity to the sentinel
GPs.
The Departments of Public Health also notified HPSC on a
weekly basis of all cases of influenza and all influenza/ILI
outbreaks (following the amendments to the infectious
disease regulations (SI No. 707 of 2003)). An enhanced
dataset on all hospitalised influenza cases aged between 0
and 14 years of age was also reported to HPSC from the
Departments of Public Health.
From January 2005, HPSC was also notified of all registered
deaths on a weekly basis from the General Registrar’s Office,
including influenza and pneumonia deaths.
Weekly report and EISS
HPSC produced a weekly influenza report, which was posted
on the HPSC website www.hpsc.ie each Thursday. Results of
clinical and virological data were reported, along with a map
of influenza activity and a summary of influenza activity
worldwide. HPSC also reported the clinical and virological
dataset to the EISS every Thursday.
Results 
It should be noted that hospital admissions data and enhanced
surveillance data for the 2004/2005 season are provisional.
Clinical data
Influenza activity in Ireland peaked later in the 2004/2005
season, compared to the 2003/2004 season. Activity was mild
for most of the 2004/2005 influenza season, with a sharp
peak during week one 2005, peaking at 89.0 per 100,000
population (figure 1). This was the highest peak rate since the
2000/2001 season when rates peaked at 121.0 per 100,000
during week eight. During the peak in ILI consultation rates,
Season
Figure 1. ILI rate per 100,000 population and the number of positive influenza specimens detected by the NVRL during the 2000/2001, 2001/2002, 2002/2003, 2003/2004 
and 2004/2005 seasons
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the majority of cases reported were aged between 15 to 64
years (figure 2). A total of 585 ILI cases were reported by
sentinel GPs during the 2004/2005 season compared to 625
during the 2003/2004 season.
Virological data
The NVRL tested 370 sentinel specimens for influenza virus
during the 2004/2005 season. One hundred and forty-two
(38.4%) sentinel specimens were positive for influenza: 103
influenza A (62 A H3N2, 36 A H1N1 and 5 A unsubtyped) and
39 influenza B (figure 1). The predominant influenza virus
subtype identified was influenza A (H3N2), accounting for
43.7% of positive specimens. The majority of positive
influenza sentinel cases were in the 15 to 64 year age group
(83.8%). Of the 370 sentinel specimens tested, six (1.6%)
were positive for RSV. Five of the six RSV positive sentinel
specimens were aged between 0 and 9 years and one was
aged over 65 years of age.
The NVRL also tested 1526 non-sentinel respiratory
specimens, mainly from hospitals. Of the 1526 specimens
tested, 52 (3.4%) were positive for influenza A, eight (0.5%)
for influenza B and 349 (22.9%) were positive for RSV. The
majority (86.1%) of non-sentinel respiratory specimens were
aged between 0 and 4 years of age.
Vaccination status and antigenic characterisation
Of the 142 positive influenza virus detections from sentinel
specimens, 107 (75.3%) were unvaccinated, four (2.8%) were
vaccinated and vaccination status was unknown in 31 (21.8%)
cases. Of the four cases that were vaccinated, influenza A
(H3N2) was detected in two cases, influenza A (H1N1) in one
case and influenza B in one case.
Three influenza specimens were sequenced at the NVRL and
phylogenetic analysis was undertaken at the WHO laboratory
(Mill Hill) in London. One influenza A (H1N1) isolate was
antigenically characterised as A/New Caledonia/20/99-like,
which was included in the 2004/2005 vaccine. One influenza
A (H3N2) isolate was found to be closest in antigenic
character to the reference viruses A/Shantou/1219/04 and
A/Oslo/807/04. A/Shantou/1219/04-like strains have been
found to be closely related to the newer reference strain
A/California/7/04 (H3N2). The A/California/7/04 (H3N2)-like
isolates have reduced titres to the A/Fujian/411/02-like
antisera (included in the 2004/2005 vaccine), but the H3N2
component of the 2004/2005 vaccine was expected to
provide some protection against this new variant. One
influenza B isolate was antigenically characterised as being
closely related to B/Jiangsu/10/2003. B/Jiangsu/10/2003 was
included in the 2004/2005 vaccine (as a B/Shanghai/361/
2002-like virus).
Regional influenza activity 
Influenza A and B were detected in all HSE-health areas
during the 2004/2005 season. Influenza A was the
predominant influenza type detected in all areas, except for
HSE-MA, where influenza A and B co-circulated in equal
numbers. Influenza activity peaked during week one 2005,
with HSE-ER and HSE-SEA both reporting regional influenza
activity (figure 3). Overall, influenza activity was most intense
in HSE-ER and HSE-SEA during the 2004/2005 season.
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Figure 2. Age-specific GP consultation rate for ILI per 100,000 population by week for the 2004/2005-influenza season
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Figure 3. Map of influenza activity by HSE-health area during the 2004/2005 season peak 
of influenza activity, week 1 2005.
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Outbreaks 
Three influenza outbreaks were reported to HPSC during the
2004/2005 season. A school outbreak of ILI in a sentinel
school occurred during week 48 in HSE-MWA. A total of 32
pupils were reported ill. There were no hospitalisations.
Influenza A (unsubtyped) was isolated from two cases. An
outbreak of influenza A (H3N2) in a long-stay care facility for
the elderly was reported by HSE-ER during week three. Thirty-
seven patients and 19 staff members were affected,
corresponding to an attack rate of 33.4%. A school outbreak
of ILI occurred during week 16 in HSE-MA. A total of 32 out
of 35 pupils (91.4%) were reported ill. Seven throat swabs
were taken and influenza B was isolated from five of these.
All patients made a full recovery.
Sentinel hospitals & sentinel schools
Hospital respiratory admissions peaked or were at elevated
levels in the two weeks preceding and/or during the peak of
influenza activity (week 1 2005), in HSE-ER, -NEA, -SEA, –SA
and -WA. The percentage of respiratory admissions over total
admissions in six sentinel hospitals compared to ILI
consultation rates are shown in figure 4. Total hospital
admissions and/or total accident and emergency admissions
were also at elevated levels either prior to or during the peak
of clinical influenza activity in HSE-MWA, HSE-NEA, HSE-
NWA, HSE-SEA, and HSE-WA.
As the peak in clinical influenza activity occurred over the
Christmas holiday period, schools were closed and sentinel
school absenteeism levels could not be used as an indicator of
influenza activity in the weeks preceding the peak in influenza
activity.
Enhanced influenza surveillance
A total of 13 cases aged between 0 and 14 years were
reported through the enhanced influenza surveillance system
during the 2004/2005 season. All 13 cases were notified from
HSE-ER. All cases were hospitalised and were positive for
influenza A. Five cases were aged less than one year, seven
were aged between 1 and 2 years and one case was 13 years
of age. One case was vaccinated, four were not vaccinated
and the vaccination status was unknown for eight cases. The
number of days in hospital ranged from one to 62 days. Two
cases were in at risk categories for influenza, one of whom
was not vaccinated and the vaccination status was unknown
for the second case.
Mortality data
Two deaths attributed to influenza were reported to HPSC
during the 2004/2005 season. Both deaths were registered
during week one 2005, one in a child in the 5 to 14 age group
with an underlying chronic medical condition who died in
early December 2004 and the second in an adult aged over
64 years who died in early January 2005.
Influenza notifications data
Influenza notifications for 2004 are discussed in a separate
chapter on infectious disease notifications within this annual
report.
Influenza activity worldwide
In the United Kingdom, low levels of influenza activity were
experienced throughout the 2004/2005 season, peaking late
in the season (January to March). Virological activity also
remained at low levels, with influenza A/Wellington/1/2004
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(H3N2)-like viruses identified as the dominant circulating
strain. 5
Influenza activity in other European countries also started
later than in the 2003/2004 season, with spatial analysis
indicating both a west to east and south to north spread of
influenza across Europe. Based on subtyping data of all
influenza virus detections reported to EISS up to week 16
2005, 47% were A (unsubtyped), 32% were A(H3), 5% were
A(H1) and 17% were B. A total of 4083 viruses (29% of all
isolates) have been antigenically and/or genetically
characterised: 1263 A/California/7/2004 (H3N2)-like viruses,
1226 A/Wellington/1/2004 (H3N2)-like viruses, 112
A/Fujian/411/2002 (H3N2)-like viruses, two
A/Panama/2007/99 (H3N2)-like viruses, 765 A/New
Caledonia/20/99 (H1N1)-like viruses, 401 B/Jiangsu/10/2003-
like viruses and 314 B/Hong Kong/330/2001-like viruses. 3
In Canada and the US, influenza activity also started later
than the 2003/2004 season, with clinical activity peaking in
February 2005. Influenza A (H3N2) was the predominant
subtype identified, with the majority of strains identified as
A/Fujian/411/2002 (H3N2)-like and A/California/7/2004
(H3N2)-like viruses. 6, 7 
The most significant global influenza event during the
2004/2005 season was the continuing poultry outbreaks of
avian influenza A (H5N1) in Asia. Avian influenza (H5N1)
outbreaks spread rapidly and widely across Asia and resulted
in mass poultry culls, and were associated with cases/clusters
of human infections and a number of human deaths. 1, 2
The WHO announced its recommendations for the
composition of the influenza vaccine for the northern
hemisphere for 2005/2006 on February 10th 2005. The
members of the WHO Collaborating Centres on Influenza
recommended that influenza vaccines contain the following
strains: A/New Caledonia/20/99(H1N1)-like virus,
A/California/7/2004(H3N2)-like virus and B/Shanghai/361/
2002-like virus. 8
Discussion
Influenza activity peaked late in Ireland during the
2004/2005-influenza season with influenza A (H3N2) being
the predominant circulating virus, occurring mostly in 15 to
64 year olds. Influenza activity also started later in most of
Europe, Canada and the US, with lower levels of activity
reported than the previous season. 3, 5, 6, 7
Surveillance of hospital admissions data and school
absenteeism data plays a significant role in the early
detection of influenza epidemics. 9 This was demonstrated
during the 2004/2005 season, with increased levels of
admissions reported from sentinel hospitals detected prior to
the peak in influenza activity. The value of collating school
absenteeism data as an indicator of influenza activity was also
highlighted with the detection of an ILI outbreak in a sentinel
school.
The small number of influenza associated deaths reported to
HPSC for the 2004/2005 season is not unexpected. Excess
deaths due to influenza are often not registered as influenza
deaths. The overall impact of influenza on mortality is
estimated to be greater than registered influenza mortality.
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Monitoring influenza and pneumonia deaths is one method of
identifying these influenza-non-attributed deaths, and from
this estimating the mortality burden caused by influenza each
season. 10
Avian outbreaks of influenza A (H5N1) have posed a
significant threat to human health since 2003. In a number of
outbreaks in Asia, the virus has jumped from infected chickens
or ducks directly to humans. These direct human infections
have produced severe and sometimes fatal outcomes. The risk
of virus transmission to humans from infected poultry will
continue as long as outbreaks are occurring in poultry. Of
greatest concern is the risk that continuing transmission of
the virus to humans will give avian and influenza viruses an
opportunity to exchange genes (reassortment), thereby
acquiring the ability to transmit easily from human-to-human
and thus triggering a pandemic.1, 2
In July 2005, avian outbreaks of influenza A (H5N1) spread
westwards to Russian bird populations, posing an ever-greater
threat of pandemic in Europe. EU Member States are
strengthening their preparedness for a potential human
influenza pandemic.11 As a result of the threat posed to
human health, a number of additional measures have been
put in place in Ireland to improve surveillance of ILI/influenza.
Work is in progress to increase the number of sentinel GPs,
thereby improving geographical and population
representation. Sentinel GPs are also currently monitoring ILI
on a year round basis. In addition, influenza and all
ILI/influenza outbreaks became notifiable in Ireland on January
1st 2004. Good reporting of such events is critical to early
detection of influenza activity. An enhanced influenza
surveillance system was set up to detect all hospitalised
influenza cases aged between 0 and 14 years of age, in
response to the circulation of the Fujian strain of influenza,
particularly amongst younger age groups, during the
2003/2004 season. Other activities that are in progress to
improve the surveillance of influenza include, weekly
surveillance of influenza and pneumonia registered deaths,
monthly surveillance of influenza vaccine uptake data in those
aged 65 years and older, an evaluation of sentinel hospital
admissions and school absenteeism data, and the construction
of baseline and epidemic threshold levels for influenza activity
in Ireland. This information will in turn inform continuing
progress on the Irish national influenza pandemic
preparedness plan.
Further information on influenza is available on the HPSC
website http://www.ndsc.ie/DiseaseTopicsA-Z/InfluenzaFlu/
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Corporate Services
Corporate Services provides HPSC with a quality support
service that promotes, advises, communicates and assists
work across the organisation.
Extensive work was undertaken during 2004 in preparation for
the streamlining of the centre into the new Health Service
Executive in January 2005. This involved ongoing consultation
and communication with the Board, staff and staff
representatives. A submission was also prepared for inclusion
in the HSE National Service Plan 2005.
As an organisation, HPSC continues its commitment to
working in a culture of openness, transparency and
accountability, and to the continual improvement and
attainment of the highest standards. Our commitment to
excellence is demonstrated by our progress in introducing the
quality management system ISO 9001:2000. Work on this
project commenced in late 2004 and continues in 2005. In
addition, an internal audit system was introduced in 2004,
following the approval of an audit plan by the Board.
Human Resources
Progress continued in 2004 towards making the centre an
employer of choice, including improved access to educational,
training and development initiatives and the expansion of
flexible working policies.
Specialist expertise was enhanced during 2004 with the
appointment of a Consultant Microbiologist as part of a joint
post with The Children's University Hospital, Temple Street.
Communications
During 2004, the communications office continued to provide
ongoing support to all divisions across the organisation. This
included providing key public health messages and
information to the media and the public and ensuring the
production of quality publications and reports for the public
and allied health care professionals. Key publications in 2004
included:
• National Guidelines On The Management Of Outbreaks Of
Norovirus Infection In Healthcare Settings
• Preventing Foodborne Disease: A Focus on the Infected Food
Handler
• Report of the Waterborne Cryptosporidiosis Subcommittee
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Surveillance of Infectious Disease
Outbreaks in Ireland, 2003
Key points
• 109 infectious disease outbreaks, of which 102 were
gastroenteric/infectious intestinal disease (IID)
outbreaks were reported in 2003
• The IID outbreaks were responsible for at least 2113
cases of illness
• Noroviruses were the most common cause of IID
outbreaks
• The majority of outbreaks occurred in healthcare
settings
Introduction
The aim of outbreak investigations is to identify the source of
the outbreak, institute control measures and prevent
additional cases. The data obtained during outbreak
investigations can be used to determine possible ways of
preventing future outbreaks.
The primary objective of the national outbreak surveillance
system is to gain information on the epidemiology of all
outbreaks of infectious disease in Ireland.
More specific objectives of the system include measuring the
burden of illness caused by outbreaks, identifying high-risk
groups in the population and estimating the workload
involved in the management of outbreaks. The information
gathered can be used to inform public health professionals on
the causes and factors contributing to outbreaks, to target
prevention strategies and to monitor the effectiveness of
prevention programmes.
Outbreak definition
An outbreak of infection or foodborne illness may be
defined as two or more linked cases of the same illness or
the situation where the observed number of cases exceeds
the expected number, or a single case of disease caused by
a significant pathogen. Outbreaks may be confined to
some of the members of one family or may be more
widespread and involve cases either locally, nationally or
internationally.
Methods 
Since July 2001, public health professionals have been
requested to report all investigated infectious disease
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outbreaks to HPSC using a preliminary notification form (by
fax or email). A follow-up investigation form and/or final
report is then forwarded by the lead investigator at the end of
the investigation. The data collected include information on
the source of reporting of the outbreak, the extent of the
outbreak, mode of transmission, location, pathogen involved,
laboratory investigation, morbidity and mortality data,
suspected vehicle and factors contributing to the outbreak.
These data are stored and analysed in a Microsoft Access
database in HPSC.
Results
During 2003, 109 outbreaks of infectious disease were
reported to HPSC, of which 102 were gastrointestinal/
infectious intestinal disease (IID) outbreaks. The IID outbreaks
were responsible for at least 2113 people becoming ill. The
regional distribution of all outbreaks of infectious disease, and
those specifically IID are detailed in Table 1. The majority of
outbreaks were reported from the ERHA region (n=42),
although the highest outbreak rates were in the South-
Eastern and Southern health board regions. The lowest rate
was reported from the WHB.
Causative Pathogen
Tables 2 and 3 outline the breakdown of IID and non-IID
outbreaks by pathogen respectively. In 2003, as has been the
trend since the year 2000, the IID outbreaks have been
dominated by norovirus or suspect viral outbreaks, comprising
74% of all IID outbreaks in 2003 (Figure 1). The overall
numbers of IID outbreaks decreased in comparison with 2002,
but was still an increase on all other previous years (Figure 2).
The only other confirmed viral cause of IID outbreaks in 2003
was rotavirus, causing an outbreak in a crèche in the Eastern
region. After norovirus, the next most commonly reported
outbreaks were Salmonella enterica and E. coli O157.
There were eight outbreaks of S. enterica reported in 2003,
three general and five household outbreaks. The general
outbreaks were all reported to be foodborne, and all 
occurred in restaurant/cafes. There was one general outbreak
of S. Hadar (11 ill), one of S. Rissen (11 ill) 
and one outbreak of S. Typhimurium (6 ill). There 
were four household outbreaks of S. Enteritidis and one of 
S. Kentucky.
Two general outbreaks of VTEC E. coli O157 occurred during
the summer months of 2003. Both occurred in hotel
restaurants in the Eastern region. Five confirmed and twelve
probable cases were reported in one outbreak, with seven
cases hospitalised. An intensive investigation took place, but
no food or water items were identified as the source of the
outbreak. In the second general outbreak of VTEC, three
confirmed cases were identified. One of the cases developed
haemolytic uraemic syndrome (HUS) and two cases were
hospitalised. No source was identified. Five family outbreaks
of VTEC were reported to the outbreak surveillance system in
2003. In addition, the HPSC Enhanced Surveillance system for
E. coli O157 identified a further eight family clusters1, as a
result of sporadic case investigation, but only those outbreaks
notified through the national outbreak surveillance system are
analysed in this report.
There were two outbreaks of Campylobacter spp reported in
2003, one occurred in a residential institution (19 ill) and the
Table 1.  All outbreaks of ID, number of IID outbreaks and total numbers ill in IID outbreaks 
reported by health board (2003).
Health Board No. Outbreaks Outbreak rate per  No. of IID    No. ill in IID
  100,000 pop outbreaks outbreaks
ERHA 42 3.0 39 1103
MHB 3 1.3 2 70
MWHB 6 1.8 6 85
NEHB 6 1.7 6 151
NWHB 6 2.7 6 60
SEHB 19 4.5 16 204
SHB 26 4.5 26 412
WHB 1 0.3 1 28
Total 109 2.8 102 2113
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Figure 1. IID outbreaks by pathogen, 2003.
Campylobacter spp Staph. aureus
Clostridium difficile Salmonella spp
E. coli O157 Rotavirus
Norovirus/suspect viral Not Known
81%74%
7%
6%
1%
1%
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8%
Table 2.  Pathogens associated with IID outbreaks notified in 2003.
Pathogen Number of outbreaks Number ill
Suspect viral  39 576
Norovirus 37 1168
S. enterica 8 44
E. coli O157 7 188
Campylobacter spp 2 25
Clostridium difficile 1 5
Rotavirus 1 12
Staph. aureus 1 4
Not Known 6 91
Total 102 2113
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other in a hospital (6 ill). The sources were not identified in
either of these outbreaks.
There were seven non-IID outbreaks reported in 2003 (Table
3) namely, Influenza A (3), Measles (1), Tuberculosis (2) and
MRSA (1).
Mode of Transmission
In the majority of outbreaks of IID reported in 2003, the
principal mode of transmission was reported as person-to-
person (Table 4). The majority of these outbreaks were due to
norovirus/ suspect viral, similar to the trend in 2002.
There were six outbreaks where the primary mode of
transmission was described as foodborne. Four of these were
due to Salmonella enterica, one was S. aureus and one was
suspect norovirus. No waterborne outbreaks were reported in
2003.
Location
Similar to the trend reported in 2002, the commonest
location in which outbreaks occurred in 2003 was health-care
settings (Table 5). 64% of all reported outbreaks occurred in
these settings. The greatest number of people ill was also
associated with outbreaks in the health-care sector, with
almost 1000 people known to be ill as a result of hospital
outbreaks alone.
A significant number of suspect foodborne outbreaks also
occurred in private homes and in eating establishments,
emphasising the need for reinforcing good hygiene and food
safety practices in these settings.
Seasonal distribution
When the IID outbreaks in 2003 are analysed by month of
onset of illness of first case, it is seen that the majority of
outbreaks occurred in the month of February (Figure 4). This
is explained by the large number of outbreaks of norovirus
that occurred at this time of the year. A smaller peak was
noted in September when the majority of S. enterica and E.
coli outbreaks occurred.
Discussion
Analysis of the outbreak data for 2003 shows a decrease in
the overall number of outbreaks reported nationally compared
to 2002. There were 102 outbreaks of IID reported nationally
in 2003, compared to 188 in 2002. The overall number of
outbreaks for 2003 however is still higher than that reported
from 1998 to 2001.
The trend in recent years of a predominance of norovirus
outbreaks seen since 2001, has continued in 2003 with the
highest proportion of IID outbreaks being either confirmed as
norovirus or suspect viral. This trend has also been noted
across much of Europe.1 Interestingly, the numbers ill in these
outbreaks seems to be much lower than in 2002. There were
over 7650 people ill due to norovirus outbreaks in 2002. In
2003, however, that figure had decreased to 1744. It is likely
that with the institution of early control measures, these
outbreaks were being contained at a much earlier stage and
hence there was a marked reduction in person-to-person
spread of the virus. It is also likely that short-term immunity
had developed to the new norovirus sub-type that was first
seen in Ireland in 2002 (GII-4).2 The national norovirus
outbreak guidelines developed by the Viral Gastroenteritis
Table 3.  Non–IID outbreaks notified in 2003
Disease Number of outbreaks Number ill
Influenza A 3 302
Measles 1 95
Tuberculosis 2 32
MRSA 1 12
Total 7 441
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Figure 2. Number of outbreaks by year and by pathogen, 1998-2003 (Data prior to July 2001
provided by FSAI)
0
160
120
80
40
100
60
140
20
19991998 2000 2001 2002 2003
All other pathogens
HPSC Annual Report 2004 87
sub-committee of HPSC appear to be in wide use and serve
to assist in the management of these outbreaks particularly in
healthcare settings.
Similar to 2002, all of the Salmonella enterica outbreaks
reported in 2003 were small in size. Two very significant
general outbreaks of E. coli O157 occurred in 2003. Both
were associated with hotel restaurants in the Eastern part of
the country. In one outbreak, over 130 possible cases were
identified during the intensive investigation, and the final
outcome was five confirmed and twelve probable cases, with
seven cases hospitalised. Despite the thorough investigation,
no food or water items were identified as a source of the
outbreak. Similarly despite an intensive investigation of the
second VTEC O157 outbreak, no source was identified.
For the first time, data on non-IID outbreaks were reported to
the national outbreak surveillance system in 2003. With the
introduction of the new ID legislation, all outbreaks and
unusual clusters of illness became statutorily notifiable on 1st
January 2004, so it is hoped that more complete reporting of
all outbreaks will occur in the coming years.
In addition, with the advent of the CIDR system in 2004, real
time data on outbreaks should become available to all users
nationally as they go-live on the system. This will enable key
epidemiological, microbiological and environmental data
relating to the outbreak to be shared and assist in the
management and control of the outbreak.
Outbreak investigations remain one of the most important
components of public health in terms of learning more about
the epidemiology of infectious diseases and their transmission
routes. The lessons learnt from outbreak investigations should
always be documented, so that information on the causes and
factors contributing to outbreaks can be used to inform future
prevention strategies.
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Table 4. IID Outbreaks by location and numbers ill, 2003.
Location Number of Outbreaks  Number ill
Animal Contact 1 3
Foodborne 6 45
Person-to-person 62 1646
P-P/Airborne 11 197
P-P/Foodborne 1 16
Other 1 6
Unknown 20 200
Total 102 2113
Table 5. IID Outbreaks by location, 2003. 
Location Number of Outbreaks  
Hospital 34
Residential Institution 31
Private House 12
Hotel 8
Restaurant/ Café 5
Crèche 4
Other 3
Tour Bus 2
Guest House/ B&B 1
School 1
Travel Related  1
Total 102
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Surveillance of Infectious Disease
Outbreaks in Ireland, 2004
Key points
• 187 infectious disease outbreaks, of which 169 were
gastroenteric/infectious intestinal disease (IID)
outbreaks were notified in 2004, which was an increase
on 2003
• The IID outbreaks were responsible for at least 4008
cases of illness
• Viral gastroenteritis caused by norovirus (NV) continues
to the most common cause of IID outbreaks (81% of IID
outbreaks confirmed/suspected NV)
• The majority of IID outbreaks (69%) were reported to
have occurred in healthcare settings.
Introduction
Outbreak investigations aim to identify the source of the
outbreak, institute control measures and prevent additional
cases. The information gathered during outbreak
investigations can be used to determine possible ways of
preventing future outbreaks.
The principal objective of the national outbreak surveillance
system is to gain information on the epidemiology of all
outbreaks of infectious disease in Ireland.
More specific objectives include measuring the burden of
illness caused by outbreaks, identifying high-risk groups in the
population and estimating the workload involved in the
management of outbreaks. The information gathered can be
used to inform public health professionals on the causes and
factors contributing to outbreaks, to target prevention
strategies and to monitor the effectiveness of prevention
programmes.
Outbreak definition
An outbreak of infection or foodborne illness may be
defined as two or more linked cases of the same illness or
the situation where the observed number of cases exceeds
the expected number, or a single case of disease caused by
a significant pathogen. Outbreaks may be confined to
some of the members of one family or may be more
widespread and involve cases either locally, nationally or
internationally.
Methods 
Since 1st January 2004, outbreaks or “unusual clusters of
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changing patterns of illness” became notifiable under the
Amendment to the Infectious Diseases Regulations.1 (see
outbreak definition in box). Since that date, medical
practitioners and clinical directors of diagnostic laboratories
are required to notify to the medical officer of health any
unusual clusters or changing patterns of illness, and individual
cases thereof, that may be of public health concern.
In addition since 1st January 2004, all outbreak data are being
entered into the CIDR system database (either directly by the
HSE-region, if that region has gone live onto CIDR) or
indirectly by staff in HPSC.
Results
During 2004, 187 outbreaks of infectious disease were
reported to HPSC, of which 169 were gastrointestinal/
infectious intestinal disease (IID) outbreaks. The IID outbreaks
were responsible for at least 4008 people becoming ill, and
there were 115 reported hospitalisations. The regional
distribution of all outbreaks of infectious disease, and those
specifically IID are detailed in Table 1. The highest number of
outbreaks was reported from the ERHA region (n=67),
although the highest outbreak rates were in the SHB and
NEHB (both 6.9/100,000). The lowest rate was reported from
the Western health board region (1.8/100,000).
Causative Pathogen
The breakdown of IID and non-IID outbreaks by pathogen are
outlined in Tables 2 and 3 respectively. In 2004, as has been
the trend since the year 2000, the IID outbreaks have been
dominated by norovirus/ suspect viral outbreaks, comprising
81% of all IID outbreaks in 2004 (Figure 1). The overall 
numbers of IID outbreaks reported, increased compared with
2003.
After norovirus, the next most commonly reported outbreaks
were EHEC and Salmonella enterica.
There were ten outbreaks of EHEC reported in 2004, one
general and nine family outbreaks. The general outbreak
involved a significant investigation and occurred at a sports
event in June 2004. Four cases were confirmed as E. coli
(VTEC) O157 (VT1 and VT 2 positive) infection. Three cases
were hospitalised. Cases ranged in age from twelve to forty-
nine years. Epidemiological, environmental and
microbiological investigations implicated the consumption of
water from the sports club as the cause of the outbreak.
Consumption of this water was prohibited as soon as it was
confirmed as a possible source of infection and this action
effectively ended the outbreak.
Interestingly, a microbiological and/or epidemiological link
with waterborne transmission was also found for a number of
the family outbreaks/clusters of VTEC in 2004. In addition,
contact with animals was also suspected for a number of the
waterborne outbreaks.
There were eight outbreaks of S. enterica reported, one
general, six family outbreaks, and one small outbreak was
deemed to be travel-associated. The general outbreak was
caused by S. Typhimurium and occurred in a restaurant in the
WHB region. Ten persons became ill, and the food implicated
in the outbreak epidemiologically, was tiramisu dessert. The
restaurant was closed during the investigation and
subsequently no additional cases were identified.
There were five outbreaks of cryptosporidiosis reported in
Table 1.  All outbreaks of ID, number of IID outbreaks and total numbers ill in IID outbreaks 
reported by health board (2004).
Health Board No. Outbreaks Outbreak rate per  No. ill in all No. of IID 
  100,000 pop outbreaks outbreaks
ERHA 67 4.8 1949 61
MHB 9 4.0 218 9
MWHB 8 2.4 290 8
NEHB 21 6.1 315 19
NWHB 12 5.4 336 8
SEHB 23 5.4 390 21
SHB 40 6.9 569 36
WHB 7 1.8 85 7
Total 187 4.8 4152 169
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Figure 1. Number of outbreaks by year and by pathogen, 1998-2004
(Data prior to July 2001 provided by FSAI)
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Table 2.  Pathogens associated with IID outbreaks notified in 2004.
Disease Number of outbreaks Number ill
Noroviral Infection 78 2838
Suspect norovirus 59 1038
Enterohaemorrhagic Escherichia coli 10 17
Salmonellosis 8 30
Cryptosporidiosis 5 25
Shigellosis 2 15
Campylobacter infection 1 2
Giardiasis 1 2
Rotavirus 1 5
C. difficile 1 11
Unknown 3 25
Total 169 4008
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2004, four general and one family outbreak. All the general
outbreaks were reported as waterborne. Two outbreaks of
shigellosis were notified, one general and one family outbreak.
The general outbreak occurred in a crèche and eleven children
were reported ill.
Eighteen outbreaks of non-IID/gastroenteric diseases were
notified in 2004, which is the highest numbers reported since
we initiated surveillance of all infectious disease outbreaks.
Table 3 outlines the pathogens implicated and numbers ill.
Further details on the non-IID outbreaks are available in the
individual disease chapters. It is hoped that surveillance data
on these outbreaks will improve in the coming years.
Mode of Transmission
Similar to previous years, the principal mode of transmission
was reported to be person-to-person spread in the majority of
outbreaks of IID reported in 2004 (Table 4). Most of these
outbreaks were due to norovirus/ suspect viral.
There were twelve outbreaks where the primary mode of
transmission was described as foodborne, and six outbreaks
were deemed to be waterborne in 2004, compared to 2003
when there no reports of waterborne outbreaks. There was
also an increase in the number of outbreaks reported to be
due to contact with livestock compared with 2003.
Location
Similar to the trend which first emerged in 2002, the
commonest location in which outbreaks occurred in 2004 was
healthcare settings (Table 5). 69% of all reported outbreaks
occurred in these settings. The greatest number of people ill
was also associated with outbreaks in the health-care sector.
Seasonal distribution
When the IID outbreaks in 2004 are analysed by month of
onset of illness of first case, it is seen that the majority of
outbreaks occurred in the winter months of November and
December. This is not surprising as the majority of outbreaks
of norovirus occur during the winter season.
Discussion
In 2004, all outbreaks of infectious diseases became notifiable
for the first time, under the new Infectious Diseases
Legislation.1 There was an increase in the overall number of
outbreaks reported nationally in 2004, with 169 outbreaks of
IID notified, compared to 102 in 2003. In addition, the
highest number of non-IID outbreaks since the surveillance
system commenced was notified in 2004 (n=18).
The 2004 outbreak data continues the trend in recent years of
a predominance of outbreaks of viral gastroenteritis,
principally caused by norovirus (81% of IID outbreaks
confirmed/suspected NV). Detailed molecular detection and
typing of norovirus isolates was introduced by the National
Virus Reference Laboratory (NVRL) in 2003, which has
enabled us to study in much greater detail the molecular
epidemiology of strains causing outbreaks in Ireland.
A one-year North-South study funded by FSPB, coordinated
jointly between HPSC and NVRL in the ROI, commenced in
2004. The aim of this study was to merge epidemiological
and virological data on norovirus outbreaks on the island of
Ireland by genotyping and obtaining sequence date from one
sample of every outbreak detected North and South for a
one-year period. The study is due to be completed in October
Table 3.  Non–IID outbreaks notified in 2004
Disease Number of outbreaks Number ill
Hepatitis A (acute) 3 8
Measles 2 7
Mumps 2 16
Hepatitis B (acute and chronic) 1 3
Leptospirosis 1 5
Vancomycin Resistant Enterococci 1 n/a
Meningococcal disease 1 3
Tuberculosis 1 3
Chickenpox 1 3
MRSA 1 4
Respiratory suspected viral 1 65
Suspected Rubella/Parvovirus 1 11
Suspected Scabies 1 5
Not identified 1 11
Total 18 144
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 Figure 2.  Seasonal distribution of IID outbreaks, 2004.
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2005 and will be published shortly thereafter. Some
interesting trends have emerged from preliminary analysis of
the data such as the emergence of the GII-4 (2004 variant)
so-called “Jam” strain in the winter season of 2004.2
This strain was originally detected from an outbreak of NV at
an international scout Jamboree held in the Netherlands in
the summer of 20043, and then went on to cause a global
increase in this variant. In 2004, Ireland also joined the
European network ‘Divine-net’, which is an extension of the
previous network entitled “Foodborne Viruses in Europe”.4 This
network aims to merge epidemiological and virological data
on outbreaks of viral gastroenteritis, including norovirus,
across Europe.
Water was seen to be an important mode of transmission
from analysis of the 2004 data, with a general cross-health
board outbreak of VTEC O157, as well as a number of smaller
family outbreaks confirmed/suspected to be waterborne. In
addition, four small general outbreaks of cryptosporidiosis
were considered to be waterborne. With the potential for a
substantial number of people to be exposed in such
outbreaks, the message must be reinforced that untreated
water supplies, particularly from private wells, may pose a
significant risk to public health.
Outbreak data has been entered into the CIDR system since
the beginning of 2004, therefore real time data on outbreaks
is available to all CIDR users nationally as they go-live on the
system. It is hoped that as national roll-out on CIDR is
achieved, enhanced surveillance data on all outbreaks of
infectious disease will be even more timely and complete as
users enter their own outbreak data.
This will enable epidemiological, microbiological and
environmental data relating to the outbreak to be shared
locally and nationally, and should greatly assist in the
management and control of outbreaks, as well as allowing
analysis of the national data to inform future public health
policies.
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Table 4.  Principal mode of transmission reported in outbreaks of IID (2004).
Primary Mode of Transmission  Number of IID Outbreaks
Person to person 136
Foodborne 12
Waterborne 6
Animal contact 3
Not Specified 12
Total 169
Table 5. IID Outbreaks by location, 2004. 
Location Number of Outbreaks  
Hospital 68
Residential institution 49
Private house 17
Hotel 12
Not Specified 7
Other 6
School 4
Restaurant / Cafe 3
Crèche 1
Public house 1
Travel related 1 
Total 169
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Antimicrobial Resistance 
in Ireland, 2004
Key Points
In 2004,
• 1323 invasive isolates of Staphylococcus aureus were
reported. The proportion of isolates that was meticillin-
resistant S. aureus (MRSA) was 41.8%, which remains one
of the highest in countries reporting to EARSS
• 400 invasive isolates of Streptococcus pneumoniae were
reported. The proportion that was penicillin-non-
susceptible S. pneumoniae (PNSP) was 10.3%, which is
moderately high compared to most other European
countries. Of the 41 PNSP isolates identified, seven were
found to be high-level resistant [minimum inhibitory
concentration (MIC), >2 mg/L] and 28 were determined to
have intermediate levels of resistance (MIC, 0.12-1.0
mg/L). No MICs were available for six isolates. The
proportion of S. pneumoniae that was erythromycin-
resistant was 14.2%
• 1256 invasive isolates of Escherichia coli were reported.
The proportions of isolates that were resistant to third-
generation cephalosporins (3GCs), fluoroquinolones and
aminoglycosides were 2.4%, 12.5% and 5.7%,
respectively. Multi-drug resistance (MDR) was reported in
5.6% of all Irish isolates. Resistance to fluoroquinolones
and gentamicin is increasing but the rise in 3GC
resistance observed in many European countries has not
yet been seen in Ireland
• 242 invasive isolates of Enterococcus faecalis were
reported. The proportion of isolates that were
vancomycin-resistant was 1.3%. Although this figure is
low, it is still slightly higher than observed in most other
European countries (<1%)
• 187 invasive isolates of Enterococcus faecium were
reported. The proportion of isolates that were
vancomycin-resistant was 23.2%, which is one of the
highest in Europe
Introduction
The European Antimicrobial Resistance Surveillance System
(EARSS) was established in 1998 and is funded by DG SANCO
of the European Commission. It is an international network of
national surveillance systems, encompassing approximately
800 laboratories serving 1300 hospitals in 28 countries, which
aims to collect comparable and reliable antimicrobial resistance
data on invasive infections of Staphylococcus aureus,
Streptococcus pneumoniae, Escherichia coli, and Enterococcus
faecium/faecalis for public health action.1
EARSS in Ireland started in 1999 with the surveillance of 
S. aureus and S. pneumoniae and expanded in 2002 to include
three further pathogens, E. coli and the enterococci, E. faecalis
and E. faecium. Thirteen additional laboratories joined the
program in 2004 bringing the total number of participating
laboratories to 41. Based on acute public hospital activity data
obtained from Department of Health and Children (DoHC), the
estimated population coverage of EARSS in 2004 was
approximately 98%, which represents an increase from 90%
coverage in 2003. In 2003, EARSS coverage in other European
countries ranged from 16% in the UK and 19% in Spain to
100% in smaller countries such as Estonia, Norway and
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Slovenia (coverage in Belgium, France, Germany, Greece and
Italy was not available).1
Protocol
Data are collected on the first invasive isolate per patient per
quarter of S. aureus and the enterococci (from blood only)
and S. pneumoniae and E. coli [from blood and cerebrospinal
fluid (CSF)]. Laboratories report routinely generated
qualitative disc diffusion data on:
• oxacillin/meticillin (Note: revised spelling in accordance with
new International Pharmacopoeia guidelines) /cefoxitin for
S. aureus
• oxacillin/penicillin and erythromycin for S. pneumoniae
• ampicillin, cefotaxime/ceftriaxone and/or ceftazidime
(3GCs), ciprofloxacin or ofloxacin (fluoroquinolones) and
gentamicin or tobramycin (aminoglycosides) for E. coli.
Laboratories are also asked to specifically test for the
presence of extended-spectrum beta-lactamases (ESBLs)
• ampicillin, high-level gentamicin (HLG) and vancomycin for
enterococci
All MRSA isolates are submitted to the National MRSA
Reference laboratory (NMRSARL) at St James’s Hospital,
where MICs are determined for oxacillin and vancomycin.
Laboratories are requested to submit data on MICs or Etests®
performed in-house for penicillin and cefotaxime or
ceftriaxone on all PNSP isolates.
Epi Info 6 software (CDC, Atlanta, USA and WHO, Geneva,
Switzerland) was used to determine the 95% confidence
intervals (CIs) for medians and to perform Chi-squared tests,
x2, and Chi-squared tests for trend, x2trend.
Rates of MRSA bacteraemia per 1,000 bed days were
calculated using the total number of patient bed days used
from the Acute Public Hospital Activity Data provided by the
DOHC for those hospitals that participated in EARSS over the
relevant time period. Data from all private hospitals, even if
participating in EARSS, were not included in these calculations
as activity data were not available for these hospitals.
No. of MRSA bacteraemias reported to EARSS
Total No. of bed days used over the 
surveillance period
Crude rates of invasive pneumococcal disease (IPD) per
100,000 population were calculated based on the estimated
population coverage of hospitals participating in EARSS over
the relevant time period and the total population of
3,917,203 in the Republic of Ireland as determined in the
2002 census.
Results
Staphylococcus aureus
In 2004, 1323 reports of S. aureus isolates from bacteraemia
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Figure 1.  Trends for S. aureus by time period: by year for 1999-2004 and by quarter 
for 2004 (Q1-Q4) – total numbers of S. aureus/MRSA and percentage MRSA with 
95% confidence intervals.  Changes in the numbers of laboratories participating 
in the surveillance system by year-end are indicated above the chart
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Figure 2. Age and sex distribution of MRSA cases reported to EARSS in 2004. 
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were received from 38 laboratories, of which 553 (41.8%)
were resistant to meticillin (see table 1). By comparison, the
proportion of S. aureus isolates that were meticillin-resistant
in 2003 was 42.1%. In 2004, there was a peak in Q2 when the
proportion of MRSA was 43.4% compared with the other
three quarters of the year when the proportion ranged from
39.9-42.2% (see figure1). A similar pattern was seen in 2003.
The median age of patients with S. aureus bacteraemia was
64 years (95% CI, 62-66 years). The difference in median
ages of patients with meticillin-sensitive S. aureus (MSSA) [57
years (95% CI, 55-59 years)] and MRSA bacteraemia [72 years
(95% CI, 70-73 years)] was considered to be significant as the
CIs did not overlap. The probability of acquiring MRSA
bacteraemia as opposed to MSSA bacteraemia in patients
aged 65 years or more was approximately twice greater than
in patients under 65 years (RR, 1.9; 95% confidence interval,
1.7 to 2.1; x2=93.2, P<0.0001). There were significantly more
isolates from males than from females for both MSSA (61%
versus 39%; z-test=6.0, P<0.0001) and MRSA (62% versus
38%; z-test=5.7, P<0.0001). The age and sex distribution of
MRSA cases reported in 2004 is shown in figure 2.
The national MRSA rate, based on the EARSS case definition
(first isolate of S. aureus per patient per quarter: an MRSA
isolate is not reported if it is isolated subsequent to an MSSA
isolate within the same quarter), was 0.14 per 1000 bed days
in 2003 and 0.15 in 2004. By comparison, the rate in England
for the period April 2003 to March 2004 was 0.17 per 1000
bed days while the rate in Scotland was 0.15 per 1000 bed
days between July 2002 and June 2003.2,3 The rates in
England and Scotland are broadly similar to that found in
Ireland but are calculated using a different case definition (an
episode of MRSA bacteraemia is counted every 14 days). In
Scotland, the system of data collection has recently been
changed by combining data from two separate surveillance
systems (from Scottish Centre for Infection and
Environmental Health’s MRSA Reporting System and EARSS)
to ensure more complete and accurate reporting on MRSA
bacteraemia and this will result in slightly higher reported
rates.4
Ireland has one of the highest proportions of MRSA in Europe
(see figure 3). Between 1999 and 2002, the proportion of
MRSA increased from 39% to 43%, however, this trend was
borderline approaching significance (x2trend=3.14; P=0.08).
Since 2002, the proportion has stabilised and even decreased
slightly. Other countries reporting high proportions of MRSA
in 2004 include the UK, France, Spain, Portugal, Italy and
Greece, although the proportions in Ireland and the UK seem
to have levelled off in recent years. The lowest proportions
are still observed in the Netherlands and the Nordic countries.
Between 2000 and 2003, EARSS reported that the
Netherlands, Belgium, Germany and Portugal have seen
significant increases in the proportion of MRSA. Increases
were also observed in the Nordic countries but at a lower
level. This trend is worrying according to EARSS as “a low
threshold for losing control may exist but is not well
defined”.1 A recent report by the Scandinavian Society for
Antimicrobial Chemotherapy also indicates that the level of
MRSA, from both colonized and infected individuals, is
increasing throughout the Nordic countries.5
Figure 3.  Map illustrating the distribution of MRSA in EARSS countries in 2004.
No data
<1%
1-5%
5-10%
10-25%
25-50%
>50%
Time period
N
um
be
r o
f i
so
la
te
s
Figure 4.  Trends for S. pneumoniae by time period: by year for 1999-2004 and by 
quarter for 2004 (Q1-Q4) – total numbers of S. pneumoniae/PNSP and percentage 
PNSP with 95% confidence intervals.  Changes in the numbers of laboratories 
participating in the surveillance system by year-end are indicated above the chart
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Streptococcus pneumoniae
In 2004, 400 reports of S. pneumoniae isolates from
bacteraemia/meningitis were received from 28 laboratories
(see table 1). The majority of isolates (n=395) were from
blood but five were from CSF. Forty-one isolates (10.3%)
were PNSP. By comparison, the proportion of S. pneumoniae
isolates that were penicillin-non-susceptible in 2003 was
11.8%.
As in previous years, a seasonal variation was seen in the
numbers of S. pneumoniae isolates reported with a trough in
Q3, reflecting the quieter summer period (see figure 4).
Of the 41 PNSP isolates reported, MIC data for penicillin and
cefotaxime were available for 35 and 29 isolates, respectively.
Seven isolates were found to be high-level penicillin resistant
(MIC,>=2 mg/L) and the remaining 28 isolates of the 35
tested were determined to have intermediate levels of
resistance (MIC, 0.12–1.0 mg/L). No MICs were available for
six PNSP isolates. One isolate from blood was intermediately
resistant to cefotaxime according to Clinical Laboratory
Standards Institute (CLSI, formerly NCCLS) non-meningitis
breakpoints (MIC, 2 mg/L) in addition to being high-level
resistant to penicillin (MIC, 2 mg/L). Another isolate from CSF
was also intermediately resistant to cefotaxime (see below).
The remaining 27 isolates of the 29 tested were susceptible
to cefotaxime (MIC,<=1 mg/L).
One additional isolate was reported to be oxacillin-resistant
on screening by disc diffusion but was subsequently found to
be penicillin-susceptible on MIC testing (MIC, 0.064 mg/L).
This highlights the importance of MIC testing on all isolates
that appear to be non-susceptible on the initial screening test.
Data on susceptibility to erythromycin were available for 388
isolates. Fifty-five (14.2%) were reported to be resistant. By
comparison, 11.6% of isolates in 2003 were erythromycin-
resistant.
Twelve isolates were resistant to erythromycin in addition to
being non-susceptible to penicillin, of which 10 were
intermediate and one was high-level resistant (HLR). No MICs
were available for the remaining isolate.
The median age of patients with invasive S. pneumoniae
infection was 58 years (95% CI, 53-61 years). The difference
in the median ages of patients with PNSP [66 years (95% CI,
51-66 years)] and penicillin-susceptible S. pneumoniae (PSP)
[57 years (95% CI, 44-75 years)] was not considered to be
significant as the CIs overlapped. There were approximately
equal numbers of S. pneumoniae isolates from males and
females (51.5% and 48.5%, respectively; z-test=0.61, P=0.55).
Of the five CSF isolates reported in 2004, one (from a six-
month old child) was intermediately resistant to both
penicillin (MIC, 0.75 mg/L) and cefotaxime (MIC, 0.75 mg/L,
interpreted using CLSI meningitis breakpoints). The other four
isolates (one from a six-month old child and three from
adults aged 32, 64 and 77 years, respectively) were
susceptible to penicillin.
The crude incidence of IPD in Ireland was estimated to be
10.4 per 100,000 population, which is the same as reported in
2003. The corresponding figures for 1999, 2000, 2001 and
2002 were 8.2, 7.8, 8.1 and 8.8 per 100,000 population,
respectively. By comparison, the rates of invasive
Figure 5.  Map illustrating the distribution of PNSP in EARSS countries in 2004.
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Figure 6.  Trends for E. coli by quarter for 2004 – total numbers of E. coli and percentage 
resistance to 3GCs, ciprofloxacin/ofloxacin (CIP/OFX) and gentamicin (GEN). 
Number of participating laboratories is indicated for each quarter
% 3GC-R % CIP/OFX-RTotal E. coli
Q1
2002
Q2
2002
Q3
2002
Q4
2002
Q1
2003
Q2
2003
Q3
2003
Q4
2003
0
50
100
150
200
250
300
%
 R
es
is
ta
nc
e
0
4
6
8
10
14
12
16
% GEN-R
18 2119 2419 24 26 27 
Q1
2004
Q2
2004
Q3
2004
Q4
2004
32 36 40 40
350
400
2
HPSC Annual Report 200496
pneumococcal disease reported in England and Wales in 1999
and 2000 were 8.6 and 8.9 per 100,000 population,
respectively.6,7 In Scotland, the overall incidence of IPD
between 1999 and 2001 was found to be 11 per 100,000.8 In
2004, the crude incidence rates of IPD in Ireland in children
less than 5 years and adults aged 65 years and older were
24.1 and 37.6 per 100,000 population, respectively. These
figures compare with projected rates of 21.0 and 37.9 per
100,000 population, respectively, in the US in 2004, with an
overall projected national rate 12.6 per 100,000 population.9
The proportion of PNSP in Ireland has decreased significantly
over the six years of surveillance of this pathogen (see figure
4): from 19% in 1999 to just over 10% in 2004 (x2trend=5.81;
P=0.02). The proportions of both PNSP and erythromycin-
resistant S. pneumoniae in Ireland are at moderate levels
compared to other countries reporting to EARSS (see figure
5). The highest proportions of both are observed in Spain and
Slovakia.
Escherichia coli
In 2004, 1256 reports of E. coli isolates from
bacteraemia/meningitis were received from 37 laboratories
(see table 1). The majority of isolates (n=1252) were from
blood but four were from CSF.
The proportions of isolates reported to be resistant to
ampicillin, 3GCs, fluoroquinolones and gentamicin were
65.0%, 2.4%, 12.5% and 5.7%, respectively, compared with
61.9%, 2.4%, 9.5% and 3.9%, respectively, reported in 2003.
The total numbers of E. coli isolates and proportion of
resistance reported by quarter for 3GCs, fluoroquinolones and
gentamicin are shown in figure 6.
Sixty-six isolates were identified as MDR [defined as
resistance to three or more of the mandatory antibiotics
(ampicillin, 3GCs, fluoroquinolones and gentamicin)]:
• ten isolates were resistant to ampicillin, 3GCs,
fluoroquinolones and gentamicin. Five of these were ESBL-
positive
• forty-four were resistant to ampicillin, fluoroquinolones and
gentamicin
• twelve were resistant to ampicillin, 3GCs and
fluoroquinolones. Six of these were ESBL-positive
MDR isolates accounted for 5.6% of all E. coli isolates tested
against all four mandatory antibiotic groups in 2004
compared with 3.6% (34 isolates) in 2003 and 2.4% (17
isolates) in 2002. The increase in MDR E. coli was found to be
significant (x2trend= 12.53; P<0.001).
In total, 861 (69%) of the 1256 isolates were examined for
the presence of ESBLs (compared with 58% in 2003). ESBLs
were detected in 11 (1.3%) of these (compared with 1.9% in
2003).
The median age of patients with invasive E. coli infection was
71 years (95% CI, 70-72 years). The difference in the median
ages of patients with MDR [67 years (95% CI, 63-72 years)]
and non-MDR strains [71 years (95% CI, 70-73 years)] was
not considered to be significant as their CIs overlapped.
Figure 7. Map illustrating the distribution of resistance to fluoroquinolones among E. coli in
EARSS countries in 2004 
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Figure 8. Map illustrating the distribution of resistance to aminoglycosides among 
E. coli in EARSS countries in 2004 
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Overall, there were more isolates from females than from
males (58% versus 42%; z-test=-5.9, P<0.0001). However,
there were more MDR isolates from males than from females
but this was not statistically significant (56% versus 44%; z-
test=0.99, P=0.32).
The four CSF isolates, from patients aged 1, 46, 60 and 86
years, respectively, were resistant to ampicillin but susceptible
to 3GCs, fluoroquinolones and gentamicin.
Between 2001 and 2003, an increasing trend in resistance to
3GCs and fluoroquinolones in E. coli was observed in seven
and 15 European countries, respectively.1 Ireland has seen an
increase in the proportions of resistance to fluoroquinolones
(x2trend=26.06; P<0.0001) and gentamicin (x2trend=10.11;
P=0.001) over the 3 years of surveillance of this pathogen
(see figures 7 and 8). The increase in gentamicin resistance is
unlike the trend reported elsewhere in Europe. The apparent
increase and spread of 3GC resistance in other countries
coincides with numerous reports of a particular class of ESBL
(CTX-M) in E. coli. This increase in 3GC resistance has not yet
been seen in Ireland. The lowest proportions of resistance
were observed in the Scandinavian countries while the highest
proportions were seen in Southern and Eastern Europe.
Enterococcus faecalis
In 2004, 242 reports of E. faecalis isolates from bacteraemia
were received from 26 laboratories (see table 1).
The total numbers of E. faecalis isolates and proportion of
resistance reported by quarter for ampicillin, HLG and
vancomycin are shown in figure 9.
Two isolates (0.8%) were reported to be ampicillin-resistant
(compared to 5% in 2003). Ampicillin resistance in E. faecalis
is unusual and further investigation of these isolates is
warranted to confirm their identity as it is generally
acknowledged that speciation of enterococci can be
problematic.
Ninety-two isolates (42%) of the 218 tested were reported to
be HLG resistant, of which 44 were confirmed by MIC
determination. By comparison, 34% of isolates were reported
to be HLG resistant in 2003.
Three isolates (1.3%) were reported to be vancomycin
resistant (not confirmed by MIC). Two of these were also
resistant to teicoplanin (teicoplanin was not reported on the
third isolate). By comparison, 1.4% of isolates were
vancomycin-resistant in 2003.
No isolates were resistant to all three indicator antibiotics
(ampicillin, HLG and vancomycin).
The median age of patients with E. faecalis bacteraemia was
66 years (95% CI, 62-69 years). There were more isolates
from males than from females (61% versus 38%, respectively;
z-test=3.66, P<0.001).
Although the proportion of vancomycin-resistant E. faecalis
(VREfa) in Ireland is low, it is still higher than that reported in
most other countries reporting to EARSS (see figure 10).
From 2002 to 2003, the proportion of VREfa decreased from
2.4% to 1.4% but was not significant (Yates’ corrected
x2=0.11, P=0.79). Resistance to HLG among E. faecalis is
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Figure 9.  Trends for E. faecalis by quarter for 2004 – total numbers of E. faecalis and 
percentage resistance to ampicillin (AMP), high-level gentamicin (HLG) and vancomycin 
(VAN).  Number of participating laboratories is indicated for each quarter
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Figure 10. Map illustrating the distribution of resistance to glycopeptides among E. faecalis 
in EARSS countries in 2004.
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Figure 13.  Trends for E. faecium by quarter for 2004– total numbers of E. faecium and 
percentage resistance to ampicillin (AMP), high-level gentamicin (HLG) and 
vancomycin (VAN).  Number of participating laboratories is indicated for each quarter
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Figure 12. Map illustrating the distribution of resistance to glycopeptides among E. faecieum
in EARSS countries in 2004
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common throughout Europe. There was no obvious trend in
HLG resistance in Ireland between 2002 and 2004.
Enterococcus faecium
In 2004, 187 reports of E. faecium isolates from bacteraemia
were received from 21 laboratories (see table 1).
The total numbers of E. faecium isolates and proportion of
resistance reported by quarter for ampicillin, high-level
gentamicin and vancomycin are shown in figure 11.
The proportions of isolates reported to be resistant to
ampicillin, HLG and vancomycin were 96%, 58% and 23%,
respectively, compared with 91%, 55% and 19%, respectively,
in 2003. Globally, most E. faecium are ampicillin-resistant.
Thirty-three of the 43 isolates reported as resistant to
vancomycin were additionally tested for susceptibility to
teicoplanin: 24 were resistant, four were intermediately-
resistant and five were susceptible. One isolate was reported
as intermediately-resistant to teicoplanin (with no result for
vancomycin).
Thirty-three isolates were resistant to ampicillin, HLG (13
confirmed by MICs) and vancomycin (17 confirmed by MICs).
Such MDR isolates accounted for 18% of all E. faecium
reported in 2004 compared with 17% in 2003.
The median age of patients with E. faecium bacteraemia was
63 years (95% CI, 59-66 years). The differences in the median
ages of patients with vancomycin-resistant [59 years (95% CI,
51-65 years)] versus vancomycin-susceptible E. faecium [64
years (95% CI, 60-67 years)] and MDR [59 years (95% CI, 47-
70 years)] and non-MDR strains [64 years (95% CI, 60-67
years)] were not considered to be significant as their CIs
overlapped. There were more isolates from males than from
females (57% versus 42%, respectively; z-test =2.08, P=0.04).
Ireland had one of the highest proportions of vancomycin-
resistant E. faecium (VREfm) in Europe in 2004 (see figure 12).
The majority of countries reported proportions of <5% for
vancomycin resistance. Of countries reporting to EARSS, only
Portugal had a higher proportion of VREfm. The proportion of
VREfm increased from 11% in 2002 to 23% in 2004
(x2trend=5.01; P=0.03). This increase is of borderline
significance and is supported by the overlapping confidence
intervals. Ireland also had one of the highest proportions of
resistance to HLG. Between 2002 and 2003, there was a
significant increase in the proportion of HLG resistance from
17% to 55% (x2=13.6; P<0.001). Between 2003 and 2004,
there was a slight increase from 55% to 58% but this was not
significant (x2=0.25; P=0.61).
Additional Information
The quarterly EARSS Newsletters and other useful reports and
documents produced by HPSC can be accessed on the HPSC
website at: http://www.hpsc.ie/A-Z/Microbiology
AntimicrobialResistance/EuropeanAntimicrobialResistanceSurv
eillanceSystemEARSS/MainBody,1137,en.html
Antimicrobial resistance data, including the most up-to-date
maps (in full colour) showing the distributions of resistance,
for all five pathogens surveyed in the 28 countries
participating in this surveillance system can be obtained from
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the interactive database available on the EARSS website at:
http://www.earss.rivm.nl/PAGINA/interwebsite/home_earss.ht
ml
The impact of the first five years of EARSS in Ireland, which
was instrumental in the development of a national
antimicrobial resistance surveillance programme, is discussed
in a recent report.10
Enhanced Surveillance of EARSS Pathogens
As well as resistance data, as collected under the EARSS
protocol, collection of additional information, both clinical and
demographic, was identified as vital in understanding the
factors affecting the acquisition of bloodstream infections in
Ireland. This in turn could offer input into future infection
control measures both nationally and in those hospitals that
participate in the surveillance scheme. Comprehensive
enhanced data were collected on EARSS pathogens causing
bloodstream infections in Ireland for the first time in 2004.
Hospitals voluntarily contributing to the enhanced survey
were asked to supply a completed questionnaire for each
isolate from blood culture on a quarterly basis. The fields
included were patient age/sex, admission and specimen dates,
inter-hospital transfers, clinical significance, risk factors,
primary source and secondary foci. Clinical and scientific staff
at the microbiology departments of contributing institutions
completed the forms after obtaining the data from a variety
of hospital systems.
Seven laboratories contributed to the enhanced surveillance
on 985 records that were matched to the resistance data on
the EARSS dataset. The resistance profiles of these isolates
were found to be representative of equivalent blood culture
isolate data for all the EARSS participating hospitals for 2004.
The breakdown of the number of records for each 
organism was as follows: S. aureus 426 (MRSA 193, 45%),
S. pneumoniae 90 (PNSP 13, 14%), E. coli 311, E. faecalis 81
(VRE 1, 1%) and E. faecium 77 (VRE 21, 27%).
Contributing hospitals specified if the infection was hospital
or community acquired. S.aureus bacteraemia was hospital-
acquired in 64% of known cases (MRSA 81% and MSSA
61%). Similarly, S. pneumoniae was noted as hospital-
acquired in 10%, E. coli in 47% and enterococci in 82%.
During the feedback of data some contributing hospitals
indicated that a number of episodes were incubating at the
time of admission as a result of inter-hospital transfer and in
cases where the infections may have been acquired through
care received in long-term care facilities and other healthcare
settings. The data collection protocol will be modified to
include healthcare-associated category for subsequent years.
Table 1.  Summary of EARSS data by pathogen over the period 1999-2004 (with total 
numbers of isolates reported and proportion (%) resistance to the key antibiotics).
 1999 2000 2001 2002 2003 2004
Max. no. of labs  12 19 20 23 28 41
by year end 
S. aureus     
No. of isolates 510 639 815 1042 1140 1323
Meticillin 38.8% 39.0% 41.3% 42.7% 42.1% 41.8%
S. pneumoniae    
No. of isolates 157 201 245 278 364 400
Penicillin 19.1% 12.9% 12.2% 11.5% 11.8% 10.3%
Erythromycin* 13.4% 12.0% 12.6% 12.7% 11.6% 14.2%
     
E. coli     
No. of isolates 741 991 1256
3GC*   3.0% 2.4% 2.4%
Ciprofloxacin* 5.4% 9.5% 12.5%
Gentamicin* 2.7% 3.9% 5.7%
     
E. faecalis     
No. of isolates 168 218 242
Vancomycin* 2.4% 1.4% 1.3%
HLG*  39.2% 34.1% 42.2%
     
E. faecium     
No. of isolates 85 135 187
Vancomycin* 11.1% 19.4% 23.2%
HLG*  16.7% 54.7% 57.8%
* Not all isolates tested; 3GC, 3rd Generation Cephalosporin (e.g. cefotaxime, ceftriaxone, 
ceftazidime); HLG, High-Level Gentamicin
HPSC Annual Report 2004100
The age distribution analysis showed that the burden of
infection for all of the pathogens is on the very young and
especially the old. The probability of isolating MRSA as
opposed to MSSA in blood cultures from patients of age 65 or
over (59%) is nearly twice that in younger patients (33%,
P<0.001, RR=1.79). This probably reflects a combination of
greater exposure to healthcare, increased likelihood of serious
underlying medical conditions and waning immunity among
older persons.
Among primary sources of S. aureus bacteraemia, central
venous catheter (CVC) usage was by far the most commonly
noted (47% of known sources), followed by respiratory tract
(11%) and skin/soft tissue (18%) infections. The proportion
of isolates that were MRSA among these three main sources
of S. aureus bacteraemia was widely different: CVC 48%
(which is close to the overall level of 45% MRSA in the study),
respiratory tract 61% (which is higher although without
reaching statistical significance at P=0.08) and skin/soft tissue
infections 29% (which is significantly lower than the overall
level with P=0.005). These differences probably reflects the
fact that MRSA infection is most likely to occur in patients
who have a prolonged hospital stay or have significant
underlying medical conditions. Respiratory tract was usually
the primary source for S. pneumoniae bacteraemia (97% of
known sources). Urinary tract with or without catheter (61%)
and intra-abdominal/gastro-intestinal tract (27%) were
commonly the sources for E. coli bacteraemia, and intra-
abdominal/gastro-intestinal tract (36%) was a common
source of enterococcal bloodstream infections along with CVC
usage (also 36%).
One or more known risk factors were noted for each infection.
Major factors affecting S. aureus bloodstream infections, with
varied proportions of MRSA, were: haemodialysis (52%,
P=0.09), recent surgery (49%, P=0.4) and treatment in
intensive care unit (58%, P=0.02). Malignancies and
immunosuppression were collectively by far the most
common risk factors associated with the acquisition of EARSS
pathogens. For E. coli and enterococci, stay in intensive care
unit and recent surgery were frequently recorded.
Secondary foci were largely non-identifiable however
bone/joints and the cardiovascular system (endocarditis) for S.
aureus were noted in nine of the cases.
In conclusion, the study of factors affecting acquisition of
infections caused by EARSS pathogens has shown that
surveillance could explain some aspects of the dynamics of
the rates of bacteraemia, which are a reflection of hospitals
regularly treating patients with certain case-mix profiles. In
the upcoming year data on outcomes (death or discharge)
will also be collected and analysis of these along with length
of stay should shed more light on the impact of EARSS
pathogens.
The Future
From 1st July 2005, EARSS is expanding to include two
additional pathogens, Klebsiella pneumoniae and
Pseudomonas aeruginosa. All Irish laboratories wishing to
participate are invited to contribute data from 1st October
2005 (corresponding with the start of Quarter 4).
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Infectious Disease Notifications,
2004
Key Points
• An amendment to the Infectious Diseases Regulations
that came into effect on the 1st January 2004
• introduced a revised and extended list of notifiable
diseases
• legally obliges clinicians and diagnostic laboratories
to notify infectious diseases
• introduced case definitions for the first time in
Ireland
• Infectious disease notifications in 2004 increased by
62% compared to 2003 
• Hepatitis C and noroviral infection notifications mainly
accounted for this increase 
• A mumps outbreak commenced towards the end of
2004, this also contributed to the increase in total
notifications 
Introduction
The Health Act, 1947 entitles the Minister for Health and
Children to specify by regulation diseases that are infectious,
covered by legislation and that require notification to a
medical officer of health. The infectious diseases notifiable in
Ireland are regulated in the 1981 Infectious Diseases
Regulations, which were revised in 1985, 1988, 1996 and
2003. An amendment (S.I. No. 707 of 2003) to these
regulations that came into effect on 1st January 2004 brought
in important changes in the infectious diseases legislation in
Ireland.1 In summary, these amended regulations: (1)
specified a revised and expanded list of notifiable diseases (2)
introduced a requirement, for the first time, for clinical
directors of diagnostic laboratories to notify infectious
diseases (3) introduced the use of case definitions for
infectious diseases for the first time in Ireland and (4)
specified that unusual clusters or changing patterns of illness
that may be of public health concern must be reported.
Under the legislation, as soon as a medical practitioner
becomes aware of or suspects that a person is suffering from
or is a carrier of an infectious disease specified in the
regulations, or as soon as a clinical director of a diagnostic
laboratory identifies an infectious disease specified in the
regulations, he/she is required to provide a written or
electronic notification to a Medical Officer of Health. For a
subset of diseases that have serious public health
implications, medical practitioners/laboratory directors are
required to give immediate preliminary notification (e.g. by
phone) to the medical officer.1
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The health boards forward these notification data to HPSC on
a weekly basis, where a weekly infectious disease report on
national data is produced. National surveillance allows
infectious disease trends to be monitored, provides
information about the need for, and impact of, infectious
disease prevention and control programmes, guides infectious
disease policy development and allows Ireland to meet
international reporting requirements such as providing
infectious disease data to EU disease specific networks and
the World Health Organisation (WHO).
This review summarises the 2004 weekly infectious disease
notification data.
Materials and Methods
Medical officers in the health boards provide case based data
to the Director of HPSC by the Wednesday of each week, on
infectious diseases notified to them during the previous week,
using an agreed dataset.2 Case classifications are assigned to
notifications as per the Case Definitions for Notifiable
Diseases.3
Infectious disease notifications received during 2004 were
inputted on a Microsoft Access database. In February 2005
HPSC commenced using the Computerised Infectious Disease
Reporting (CIDR) system. Historical notifiable infectious
disease data since 1988 were migrated from the Microsoft
Access system to CIDR. Extensive data cleaning and
validation of 2004 infectious diseases data was undertaken
with the Departments of Public Health. Any revisions and
updates to 2004 data were made on the CIDR system. The
figures presented in this report are based on data from the
CIDR system as of the 30th September 2005.
Data analysis was performed using Business Objects and
Microsoft Excel. Incidence rates were calculated using
population data taken from the 2002 census.
Notifiable infectious diseases in 2004, excluding three of the
European Antimicrobial Resistance Surveillance System
(EARSS) diseases (enterococcal bacteraemia, Escherichia coli
infection (invasive) and Staphylococcus aureus bacteraemia),
sexually transmitted infections (STIs) and tuberculosis (TB) are
presented in this chapter. Reports on the EARSS, STI and TB
data are included as separate chapters within this document.
A report on infectious disease outbreaks is also included
elsewhere in this document.
Results
Notifiable infectious diseases
There were 9452 infectious disease notifications reported
during 2004, representing a 62% increase in notifications
compared to 2003. In the years prior to the changes in the
infectious diseases legislation the number of notifications had
not fluctuated greatly; from 2001 to 2003 the number of
notifications ranged between 5000 and 6000 annually (figure
1). Hepatitis C and noroviral infection notifications mainly
accounted for the increase in total notifications in 2004.
Case classification was assigned for 81% of the notifications in
2004. Seventy-two percent were classified as confirmed, five
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Figure 1.  Number of infectious disease notifications received, 2001 – 2004  
(Please note the EARSS, STI and TB data are not included in these figures).
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Figure 2.  Infectious disease notifications received, in 2004 by case classification
(Please note the EARSS, STI and TB data are not included in these figures).
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Table 1. Number of notifiable infectious diseases by health board in 2004  
Inectious disease ERHA MHB MWHB NEHB NWHB SEHB SHB WHB Total  
         2004 
Acute anterior poliomyelitis 0 0 0 0 0 0 0 0 0 
Acute infectious gastroenteritis 618 161 93 116 59 320 450 100 1917 
Anthrax 0 0 0 0 0 0 0 0 0 
Bacillus cereus food-borne infection/intoxication 0 0 0 0 0 0 0 0 0 
Bacterial meningitis (not otherwise specified) 16 3 4 2 3 4 1 4 37 
Botulism 0 0 0 0 0 0 0 0 0 
Brucellosis 0 1 57 1 0 0 1 0 60† 
Campylobacter infection 591 134 107 113 92 194 240 240 1711 
Cholera 0 0 0 0 0 0 0 0 0 
Clostridium perfringens (type A) food-borne disease 2 0 0 0 0 1 2 0 5 
Creutzfeldt Jakob disease ** ** ** ** ** ** ** ** 4 
Creutzfeldt Jakob disease (new variant) 0 0 0 0 0 0 0 0 0 
Cryptosporidiosis 23 62 45 30 41 80 74 77 432 
Diphtheria 0 0 0 0 0 0 0 0 0 
Echinococcosis 0 0 0 0 0 0 0 0 0 
Enterohaemorrhagic Escherichia coli 12 2 6 11 9 6 11 10 67 
Giardiasis 25 3 4 2 1 3 9 6 53 
Haemophilus influenzae disease (invasive) 16 3 3 1 1 5 7 2 38 
Hepatitis A (acute) 30 2 2 3 0 1 5 4 47 
Hepatitis B (acute and chronic) 507 19 60 38 5 56 57 55 797 
Hepatitis C 954 21 33 22 5 30 45 44 1154 
Influenza 14 2 42 2 6 6 6 2 80 
Legionellosis ** ** ** ** ** ** ** ** 4 
Leptospirosis 6 1 1 2 1 2 1 1 15 
Listeriosis 5 1 2 0 0 1 0 2 11 
Malaria 12 3 1 2 0 5 2 2 27 
Measles 223 10 10 17 22 9 26 13 330 
Meningococcal disease 62 10 16 20 17 28 34 12 199 
Mumps 96 111 12 13 112 9 16 55 424 
Noroviral infection 568 29 235 36 72 45 79 64 1128 
Paratyphoid ** ** ** ** ** ** ** ** 4 
Pertussis 37 0 22 1 4 5 14 10 93 
Plague 0 0 0 0 0 0 0 0 0 
Q fever 1 1 4 0 0 0 0 1 7 
Rabies 0 0 0 0 0 0 0 0 0 
Rubella 24 4 1 4 4 5 3 4 49 
Salmonellosis 162 48 21 30 18 43 56 37 415 
Severe Acute Respiratory Syndrome (SARS) 0 0 0 0 0 0 0 0 0 
Shigellosis 23 0 2 2 2 18 8 2 57 
Smallpox 0 0 0 0 0 0 0 0 0 
Staphylococcal food poisoning ** ** ** ** ** ** ** ** 3 
Streptococcus group A infection (invasive) 25 0 1 1 0 7 1 0 35 
Streptococcus pneumoniae infection (invasive) 72 3 14 25 3 42 9 6 174 
Tetanus ** ** ** ** ** ** ** ** 1 
Toxoplasmosis 20 3 2 0 3 2 0 3 33 
Trichinosis 0 0 0 0 0 0 0 0 0 
Tularemia 0 0 0 0 0 0 0 0 0 
Typhoid 3 0 0 0 1 0 2 1 7 
Typhus 0 0 0 0 0 0 0 0 0 
Viral encephalitis 2 1 0 0 2 0 0 0 5 
Viral haemorrhagic fevers 0 0 0 0 0 0 0 0 0 
Viral meningitis 9 3 3 1 3 1 2 1 23 
Yellow fever 0 0 0 0 0 0 0 0 0 
Yersiniosis 3 0 0 0 0 0 2 1 6 
NN - Not specified as a notifiable disease prior to 2004         
† See section on brucellosis
*Prior to 2004 meningococcal disease was not specified as a notifiable disease.  In 2003 there were 74 non-meningococcal and 237 meningococcal notifications under t
category bacterial meningitis (including meningococcal septicaemia)         
**Data not reported to health board level when total figures for Ireland less than five cases         
‡ Of the 11 Typhoid and Paratyphoid notifications in 2003, four were paratyphoid and seven were typhoid notifications  Please note the EARSS, STI and TB data are n
report.  Data on these diseases can be found in separate chapters in this document         
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Table 2. Number of notifiable infectious diseases by age group (years) in 2004  
Infectious disease    0-4 5-9 10-14 15-19 20-24  25-34  35-44  45-54  55-64  65+  Unknown  Total
Acute infectious gastroenteritis 1756 27 11 9 10 21 22 12 8 16 25 1917
Bacterial meningitis (not otherwise specified) 17 1 1 4 0 5 2 4 1 1 1 37
Brucellosis 0 1 0 1 3 2 16 19 9 9 0 60
Campylobacter infection 492 110 60 72 142 286 164 126 102 144 13 1711
Clostridium perfringens (type A) food-borne disease 2 0 1 0 0 0 0 0 0 2 0 5
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 1 1 2 0 4
Cryptosporidiosis 259 69 21 11 10 20 17 6 1 14 4 432
Enterohaemorrhagic Escherichia coli 22 6 4 4 2 2 8 6 3 7 3 67
Giardiasis 10 5 2 1 5 9 8 6 5 1 1 53
Haemophilus influenzae disease (invasive) 10 3 0 0 0 5 3 4 3 10 0 38
Hepatitis A (acute) 9 1 4 1 4 9 11 3 1 1 3 47
Hepatitis B (acute and chronic) 6 3 4 52 144 377 134 39 16 12 10 797
Hepatitis C 6 1 3 15 168 519 273 108 33 14 14 1154
Influenza 21 7 5 4 1 5 6 7 9 15 0 80
Legionellosis 0 0 0 0 0 0 0 1 1 2 0 4
Leptospirosis 0 0 0 2 2 4 1 5 1 0 0 15
Listeriosis 0 0 0 0 0 2 2 1 2 3 1 11
Malaria 4 4 1 0 0 6 5 4 2 1 0 27
Measles 252 49 12 3 5 4 1 2 0 0 2 330
Meningococcal disease 129 16 9 21 11 5 2 2 2 2 0 199
Mumps 22 8 23 116 130 45 16 7 4 2 51 424
Noroviral infection 95 7 5 7 5 39 35 45 90 765 35 1128
Paratyphoid 0 0 0 1 1 2 0 0 0 0 0 4
Pertussis 65 10 10 2 0 1 1 1 1 0 2 93
Q fever 2 0 0 0 1 0 3 0 0 1 0 7
Rubella 38 4 3 0 0 2 0 0 0 0 2 49
Salmonellosis 82 31 17 24 40 67 45 42 34 32 1 415
Shigellosis 10 6 1 0 5 9 8 8 7 3 0 57
Staphylococcal food poisoning 2 0 1 0 0 0 0 0 0 0 0 3
Streptococcus group A infection (invasive) 4 3 0 1 1 7 3 0 3 13 0 35
Streptococcus pneumoniae infection (invasive) 40 5 4 0 1 5 23 13 24 57 2 174
Tetanus 0 0 0 0 0 0 0 1 0 0 0 1
Toxoplasmosis 0 1 0 5 3 11 8 3 0 1 1 33
Typhoid 1 2 0 1 0 2 1 0 0 0 0 7
Viral encephalitis 1 1 2 0 0 0 0 0 0 0 1 5
Viral meningitis 8 3 4 1 1 2 1 2 0 0 1 23
Yersiniosis 3 0 1 0 0 1 0 0 0 1 0 6
Total 3368 384 209 358 695 1474 819 478 363 1131 173 9452
Please note the EARSS, STI and TB data are not included in this report.  Data on these diseases can be found in separate chapters in this document     
   
percent as probable, four percent as possible, while 19% had no
case classification assigned (figure 2).
The breakdown of infectious diseases notified in 2004 by
health board, age group, sex and case classification are
presented in tables 1 - 4. Please note that notifiable diseases
with no cases in 2004 are not presented in tables 2 - 4.
No cases of acute anterior poliomyelitis, anthrax, Bacillus
cereus food-borne infection/intoxication, botulism, cholera,
nvCJD, diphtheria, echinococcosis, plague, rabies, SARS,
smallpox, trichinosis, tularemia, typhus, viral haemorrhagic
fevers or yellow fever were notified during 2004.
Acute infectious gastroenteritis
During 2004, 1917 cases (48.9/100,000) of acute infectious
gastroenteritis were notified. The majority were due to
rotavirus (1611, 84%) while the remainder were unspecified
gastroenteritis cases (306, 16%). Ninety-two percent of the
notifications were in the age group 0-4 years.
Acute infectious gastroenteritis was first specified as a
notifiable infectious disease in 2004; only cases of rotavirus
and gastroenteritis unspecified are notifiable under this
disease category while cases of giardia, cryptosporidiosis and
norovirus are specified as separate notifiable diseases. Prior to
2004 cases of gastroenteritis were only notifiable under the
disease category gastroenteritis (when contracted by children
under two years of age). In 2003, 1835 cases of
gastroenteritis were notified, these notifications included
cases of rotavirus and gastroenteritis unspecified as well as
cases of adenovirus, cryptosporidiosis, giardia and norovirus in
those less than two years of age. In total during 2004 there
were 1694 notifications of acute infectious gastroenteritis,
cryptosporidiosis, giardiasis and norovirus in this age group.
Bacterial meningitis (not otherwise specified)
During 2004, 37 bacterial meningitis (not otherwise specified)
cases were notified. Enhanced surveillance of bacterial
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meningitis (including meningococcal septicaemia)
commenced in Ireland in 1997. Data obtained through this
enhanced surveillance system, during 2004, are presented in
the meningococcal disease chapter within this document.
Brucellosis
During 2004, 60 cases of brucellosis were notified. Case
classification was provided for 59 of the 60 brucellosis
notifications; two were classified as confirmed cases while 57
were classified as probable cases. The number of notifications
in 2004 appears to be a significant increase on the previous
ten years, but it is important to bear in mind that cases are
now being notified by laboratories that would previously have
gone unreported and the notifications classified as probable
may be a reflection of past infection rather than acute
infection as laboratory reports were based on an isolated high
titre result. Fifty-two of the cases in 2004 were male (87%)
while eight were female (13%). The cases ranged in aged
from 7 years to 77 years with over half in the age group 35-
54 years.
Campylobacter infection
During 2004, there were 1711 notifications (43.7/100,000) of
campylobacter infection. Prior to 2004 cases of
campylobacter were only notifiable under the disease
category food poisoning (bacterial other than salmonella). Of
the 1623 food poisoning notifications in 2003 Campylobacter
species was reported as the causative organism for 1440
(89%). A comprehensive report on campylobacteriosis is
presented as a separate chapter elsewhere within this
document.
Clostridium perfringens (type A) food-borne disease
Five cases of Clostridium perfringens (type A) food-borne
disease were notified during 2004. The cases ranged in age
from <1 year to 80 years. Four of the five cases were female.
Clostridium perfringens (type A) food-borne disease was first
specified as a notifiable infectious disease in 2004. Prior to
2004 cases of Clostridium perfringens (type A) were only
notifiable under the disease category food poisoning (bacterial
other than salmonella). In 2003 no cases of Clostridium
perfringens (type A) were reported under this category.
Creutzfeldt Jakob disease 
In 2004, four cases of classical Creutzfeldt Jakob disease (CJD)
were notified while in 2003 two cases were notified. All four
cases in 2004 occurred in females and were aged greater than
45 years.
Cryptosporidiosis 
Cyrptosporidiosis was first specified as a notifiable infectious
disease in 2004. There were 432 notifications of
cryptosporidiosis in 2004 with 60% of these notifications
occurring in children less than five years of age. Prior to 2004
cryptosporidiosis was only notifiable under the disease
category gastroenteritis (when contracted by children under
two years of age). In 2003, under this category 106 cases of
cryptosporidiosis were reported. This is similar to 2004 when
133 cryptosporidiosis notifications were aged less than two
years. A comprehensive report on cryptosporidiosis is
presented as a separate chapter within this document.
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Table 3. Number of notifiable infectious diseases by sex in 2004
Infectious disease    Male Female  Unknown  Total
Acute infectious gastroenteritis 1012 882 23 1917
Bacterial meningitis (not otherwise specified) 17 20 0 37
Brucellosis 52 8 0 60
Campylobacter infection 926 778 7 1711
Clostridium perfringens (type A) food-borne disease 1 4 0 5
Creutzfeldt Jakob disease 0 4 0 4
Cryptosporidiosis 224 207 1 432
Enterohaemorrhagic Escherichia coli 37 29 1 67
Giardiasis 25 27 1 53
Haemophilus influenzae disease (invasive) 20 18 0 38
Hepatitis A (acute) 20 26 1 47
Hepatitis B (acute and chronic) 403 362 32 797
Hepatitis C 706 426 22 1154
Influenza 37 42 1 80
Legionellosis 3 1 0 4
Leptospirosis 14 1 0 15
Listeriosis 5 6 0 11
Malaria 14 12 1 27
Measles 159 167 4 330
Meningococcal disease 102 97 0 199
Mumps 230 192 2 424
Noroviral infection 481 647 0 1128
Paratyphoid 3 1 0 4
Pertussis 42 51 0 93
Q fever 3 4 0 7
Rubella 27 22 0 49
Salmonellosis 194 218 3 415
Shigellosis 32 25 0 57
Staphylococcal food poisoning 0 3 0 3
Streptococcus group A infection (invasive) 19 16 0 35
Streptococcus pneumoniae infection (invasive) 90 84 0 174
Tetanus 1 0 0 1
Toxoplasmosis 12 21 0 33
Typhoid 4 3 0 7
Viral encephalitis 3 2 0 5
Viral meningitis 19 4 0 23
Yersiniosis 2 4 0 6
Total 4939 4414 99 9452
Please note the EARSS, STI and TB data are not included in this report.  Data on these diseases can be found in separate chapters in this document   
 
Enterohaemorrhagic Escherichia coli
Enterohaemorrhagic Escherichia coli (EHEC) was specified as a
notifiable infectious disease in Ireland for the first time in
2004. Sixty-seven cases of EHEC were notified during 2004.
A comprehensive report on EHEC is presented as a separate
chapter elsewhere in this document.
Giardiasis
Fifty-three cases of giardiasis were notified in 2004 in Ireland,
giving a notification rate of 1.4 per 100,000 total population.
Age was reported for 52 cases, these ranged in age from 1
year to 77 years (mean age, 28 years; median age, 30 years).
Twenty-seven of the cases were female, 25 were male while
gender was unreported for one case.
Giardiasis was first specified as a notifiable infectious disease
in Ireland in 2004. Prior to 2004, giardiasis was only notifiable
under the disease category gastroenteritis (when contracted
by children under two years of age). In 2003, two cases of
giardiasis were reported under this category. This compares to
five giardiasis notifications in 2004 in children less than two
years.
Haemophilus influenzae disease (invasive)
During 2004 there were 38 notifications of Haemophilus
influenzae disease (invasive). Haemophilus influenzae disease
(invasive) was specified as an infectious disease for the first
time in 2004. An enhanced surveillance system exists for
Haemophilus influenzae disease and data obtained through
this surveillance system are presented as a separate chapter
elsewhere within this document.
Hepatitis A (acute)
Forty-seven cases (1.2/100,000) of hepatitis A (acute) were
notified in 2004 compared to 25 cases (0.6/100,000) in 2003.
A comprehensive report on viral hepatitis is presented as a
separate chapter within this document.
Hepatitis B (acute and chronic)
Hepatitis B notifications continued to increase in 2004 with
797 notifications (20.3/100,000) compared to 547 and 458
notifications in 2003 and 2002, respectively. A comprehensive
report on viral hepatitis is presented as a separate chapter
within this document.
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Hepatitis C
There were 1154 (29.5/100,000) notifications of hepatitis C in
2004. Hepatitis C was specified as a notifiable infectious
disease in Ireland for the first time in 2004. Prior to 2004
hepatitis C was only notifiable under the disease category
viral hepatitis unspecified. In 2003, of the 85 viral hepatitis
unspecified notifications 77 were reported as hepatitis C, one
as hepatitis E while the organism was not reported for seven
cases. A comprehensive report on viral hepatitis is presented
as a separate chapter elsewhere within this document.
Influenza
Influenza was first specified as a notifiable infectious disease
in 2004. Eighty cases of influenza were notified in 2004,
giving a notification rate of 2.0 per 100,000 population. Of
the 80 influenza notifications, 40 were reported as influenza A
virus, 30 as influenza B virus while organism details were not
reported for the remaining 10 cases. A report on influenza
activity during the 2004/2005 season is included elsewhere in
this document.
Legionellosis
Four cases of legionellosis were notified in 2004. All four
cases were aged greater than 44 years. Three of the cases
were male and one was female. Three of the cases were
classified as confirmed while one was classified as probable.
There was one death. Of the four cases one was community-
acquired in Ireland, one was hospital-acquired while two were
travel-associated (Ireland and USA). A case of Legionnaires’
disease is defined as travel-associated if the patient spent one
or more nights away from their home in accommodation
used for commercial or leisure purposes e.g. hotels, holiday
apartments etc. in the 10 days before the onset of illness.
Travel-associated cases may involve travel within Ireland or
travel abroad. Both travel-associated cases in 2004 were
notified to the European Working Group for Legionella
Infections (EWGLI) surveillance scheme. The aim of this
surveillance scheme (EWGLI) is to detect cases of travel-
associated Legionnaires’ disease and thereby rapidly identify
outbreaks and implement control measures. 4
Table 4. Number of notifiable infectious diseases by case classification in 2004   
Inectious disease Confirmed Probable Possible Not Specified Total
Acute infectious gastroenteritis 1357 297 0 263 1917
Bacterial meningitis (not otherwise specified) 8 6 23 0 37
Brucellosis 2 57 0 1 60
Campylobacter infection 1286 0 0 425 1711
Clostridium perfringens (type A) food-borne disease 4 0 0 1 5
Creutzfeldt Jakob disease 4 0 0 0 4
Cryptosporidiosis 280 1 0 151 432
Enterohaemorrhagic Escherichia coli 66 0 0 1 67
Giardiasis 39 0 0 14 53
Haemophilus influenzae disease (invasive) 38 0 0 0 38
Hepatitis A (acute) 36 0 5 6 47
Hepatitis B (acute and chronic) 570 13 0 214 797
Hepatitis C 1006 0 0 148 1154
Influenza 74 0 1 5 80
Legionellosis 3 1 0 0 4
Leptospirosis 10 0 0 5 15
Listeriosis 9 0 0 2 11
Malaria 12 0 0 15 27
Measles 156 0 150 24 330
Meningococcal disease* 171 3 25 0 199
Mumps 85 13 82 244 424
Noroviral infection 1000 27 0 101 1128
Paratyphoid 2 2 0 0 4
Pertussis 42 1 21 29 93
Q fever 1 4 0 2 7
Rubella 4 1 32 12 49
Salmonellosis 242 74 0 99 415
Shigellosis 55 0 0 2 57
Staphylococcal food poisoning 0 0 0 3 3
Streptococcus group A infection (invasive) 32 0 0 3 35
Streptococcus pneumoniae infection (invasive) 160 0 4 10 174
Tetanus 0 0 0 1 1
Toxoplasmosis 26 0 0 7 33
Typhoid 6 0 0 1 7
Viral encephalitis 2 0 0 3 5
Viral meningitis 4 2 0 17 23
Yersiniosis 4 0 0 2 6
Total 6796 502 343 1811 9452
*As per the case definitions, meningococcal disease notifications are classified as definite, presumed and possible. For convenience they are reported in this table as confirmed, probable 
and possible, respectively.     
Please note the EARSS, STI and TB data are not included in this report.  Data on these diseases can be found in separate chapters in this document   
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Leptospirosis
Fifteen cases of leptospirosis were notified in 2004, an
increase of 66% on 2003 (n=9). This increase may be a
reflection of laboratories becoming notifiers for the first time
in 2004. All except one of the cases were male (93%) and all
were aged between 18 and 57 years (mean age, 36 years;
median age, 33 years). Information on the possible source of
infection was received for 11 cases; five were believed to be
leisure-acquired, five occupationally and one could have
acquired the illness either through work or leisure. The ERHA
reported six cases while each of the other health boards
reported between one and two cases each. A cross health-
board outbreak (reported by the ERHA) among canoeists
accounted for five of the cases with exposure through leisure
activities.5 All five were admitted to hospital. Gardening was
the exposure for the remaining leisure-acquired case. Among
the occupational exposures reported, four cases had contact
with livestock through the course of their work and two with
construction sites. The species implicated was reported as
Leptospira interrogans icterohaemorrhagiae for one case;
species was not reported for the remaining 14 cases.
Listeriosis 
Eleven cases of listeriosis were notified in 2004. Three were
pregnancy associated, one resulting in an intrauterine death.
The remaining eight cases were non-pregnancy-associated
adult cases. In this group, 63% (5/8) were male and the age
range was 41-86 years (mean age, 63 years). Five were
reported either as elderly (>65 years) or as suffering from an
underlying illness that predisposed them to listeriosis. No
information on risk factors was available for the remaining
three cases but two were aged over 55 years.
Listeriosis was first specified as a notifiable infectious disease
in 2004; prior to 2004 listeriosis was only notifiable under the
disease category food poisoning (bacterial other than
salmonella). In 2003 four listeriosis cases were notified under
this category.
Malaria
During 2004, twenty-seven cases of malaria were notified, a
29% increase on the number reported in 2003 (n=21). It is
generally recognised that malaria has been under notified and
this increase may be a reflection of laboratories becoming
notifiers for the first time in 2004. Fourteen of the reported
cases were male, twelve were female and the sex of the
remaining case was not reported. Cases ranged in age from
two to 73 years, with a median age of 30 years.
Malaria is not indigenous in Ireland and cases are usually
associated with recent exposure in an endemic country or are
relapses of earlier illness. However, one case in 2004 was
reported as a congenital case. Countries where exposure to
malaria occurred included Nigeria (n=9), and Tanzania,
Uganda, Brazil, Chile/Africa and Ethiopia (n=1 each): country
of exposure was not reported for the remaining 13 cases. The
reasons for travel to a malarious region were: holiday (n=1),
business/professional travel (n=1), new entrant to Ireland
(n=5), visiting family in country of origin (n=2), other (n=3,
which includes aid/development workers) and unknown
(n=15).
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In 14 cases (70%), Plasmodium falciparum was the causative
organism, P. vivax in four cases (20%), P. ovale in one case
(5%), a mixed infection in one case (5%): the malarial parasite
was not reported for the remaining seven cases. Information
on malaria prophylaxis was available for eleven of the cases,
of these nine (82%) did not take any malaria prophylaxis
while the remaining two cases (18%) discontinued
prophylaxis before one month after their return to Ireland.
Measles
During 2004, 330 measles cases (8.4/100,000) were notified,
a decrease compared to 2003 when 572 (14.6/100,000) cases
were notified. Case classification was provided for 93%
(n=306) of measles notifications in 2004, of these 51%
(n=156) were classified as confirmed and 49% (n=150) were
classified as possible. Enhanced details including laboratory
and hospitalisation data were obtained on some of the
measles notifications in 2004, these data are discussed further
in a separate measles report in this document.
Meningococcal disease
One hundred and ninety-nine cases of meningococcal disease
were notified in Ireland in 2004, giving a notification rate of
5.1 per 100,000 population. A comprehensive report on
meningococcal disease is presented as a separate chapter in
this document.
Mumps
During 2004, 424 cases of mumps were notified, giving a
notification rate of 10.8 per 100,000 population. This
represents a 10-fold increase compared to 2003 when 40
cases were notified. This increase in mumps was associated
with a national mumps outbreak that began in early
November 2004 and predominantly affected university/
college-going students (figure 3). Three hundred and fifty one
(83%) of the mumps notifications in 2004 were in November
and December (Weeks 44-52) with 49% in the age group 17-
21 years. The mumps outbreak continued into 2005 with 784
cases (provisional figure) notified between January and
September 2005.
Mumps became a notifiable disease in 1988. Mumps
outbreaks occurred in 1988-89, 1996-97 and recently in
2004-2005 (figure 4; data up to 30/09/2005).
Noroviral infection
There were 1128 noroviral infection notifications during 2004,
giving a notification rate of 28.8 per 100,000 population. The
majority (n=765, 68%) of notifications were in those aged
greater than 64 years followed by those in the age group 0-4
years (n=95, 8%). The highest age specific incidence rates
were also in those aged greater than 64 years (175.5/
100,000) followed by those in the age group 0-4 years
(34.2/100,000). Six hundred and forty seven cases (57%)
were female and 481 were male (43%).
Noroviral infection was first specified as a notifiable infectious
disease in 2004; prior to 2004 norovirus was only notifiable
under the disease category gastroenteritis (when contracted
by children under two years of age). There were 14 noroviral
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Figure 3. Mumps notifications received by week of notification in 2004 
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Figure 4.  Mumps notifications received, 1988-2005  
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notifications in 2003 under the disease category
gastroenteritis, whereas 75 cases were notified in children less
than two years of age in 2004. However, 1053 noroviral
notifications (93%) in 2004 were in those greater than or
equal to two years, such cases were not previously notifiable.
Paratyphoid
Four cases of paratyphoid were notified during 2004. All four
cases were in the age group 15-34 years. Three of the four
cases were male. The countries of infection were Germany
(n=1), India (n=1), Nepal (n=1), and not reported (n=1). Prior
to 2004 paratyphoid was notifiable under the disease
category typhoid and paratyphoid. During 2003 four cases of
paratyphoid were notified under typhoid and paratyphoid, this
is identical to 2004.
Pertussis
Notifications of pertussis had fallen to the lowest number on
record (n=40) during 2003. Pertussis notifications increased
again in 2004 with 93 cases reported (2.4/100,000). The
majority (91%) of cases in 2004 were aged less than 15 years
with 70% of cases in the age group 0-4 years. Fifty-one cases
were female while 42 were male.
Q Fever
Seven cases of Q fever were notified during 2004. Four cases
occurred in females and three in males. The cases ranged in
age from two years to 67 years (mean age, 31 years; median
age, 36 years). This is the first year Q fever was specified as a
notifiable infectious disease in Ireland.
Rubella
During 2004, 49 cases (1.3/100,000) of rubella were notified,
compared to 59 in 2003 and 33 in 2002. Case classification
was provided for 37 (76%) of the rubella notifications, of
these four were classified as confirmed, one as probable and
32 as possible. Forty-five of the cases (92%) notified in 2004
were less than 15 years, with 38 (78%) of the cases aged less
than five years. Twenty-two cases were female and 27 cases
were male. One of the rubella notifications in 2004 was a
case of confirmed congenital rubella syndrome in a newborn
baby.
Salmonellosis (other than typhoid or paratyphoid)
There were 415 Salmonella notifications in 2004
(10.6/100,000) a slight decrease compared to 449 in 2003. In
2004, the highest number of cases (n=82) and the highest
age specific incidence rate (29.5/100,000) were in those aged
less than five years. In 2004, Salmonella Enteritidis accounted
for 32% (n=134) of the notifications, S. Typhimurium
accounted for 18% (n=73) while serotype details were not
provided for 31% (n=127). A separate and comprehensive
report on Salmonella is presented elsewhere within this
document.
Shigellosis
Fifty-seven cases (1.5/100,000) of shigellosis were notified in
2004 compared to 36 cases in 2003. The majority of cases
(70%) in 2004 occurred in those aged 20 years or older. Of
the 57 cases notified, 38 were due to Shigella sonnei, 15 due
to Shigella flexneri and four due to Shigella boydii. For
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comparison, of the 36 cases notified in 2003, 13 were due to
S. sonnei, 12 due to S. flexneri, one due to S. boydii, one due
to Shigella dysenteriae while species was not reported for nine
cases. This indicates a slight increase in the number of S.
sonnei reported in 2004 compared to 2003.
Staphylococcal food poisoning
Three cases of staphylococcal food poisoning were notified
during 2004. All three cases occurred in females aged 10
years and younger. Staphylococcal food poisoning was first
specified as a notifiable infectious disease in 2004; prior to
2004 food poisoning due to staphylococcus was only
notifiable under the disease category food poisoning (bacterial
other than salmonella). In 2003, two notifications of food
poisoning were reported as Staphylococcus species; both were
aged greater than 30 years.
Streptococcus group A infection (invasive)
Thirty-five cases of Streptococcus group A infection (invasive)
were notified during 2004. The majority (77%) of cases were
aged greater than 20 years with 37% aged greater than 64
years. Nineteen cases were male while 16 cases were female.
Streptococcus group A infection (invasive) was not notifiable
prior to 2004.
Streptococcus pneumoniae infection (invasive)
During 2004, 174 cases of Streptococcus pneumoniae
infection (invasive) were notified. The majority of cases
(71%) were aged greater than 20 years with one third of
cases aged greater than 64 years. Ninety cases were male
while 84 cases were female. S. pneumoniae infection
(invasive) was specified as a notifiable infectious disease for
the first time in 2004. Prior to 2004, cases of S. pneumoniae
were only notifiable under the disease category bacterial
meningitis (including meningococcal septicaemia). In 2003,
25 cases of S. pneumoniae were notified under bacterial
meningitis (including meningococcal septicaemia) while in
2004, 22 cases of S. pneumoniae were notified. S.
pneumoniae infection (invasive) is discussed further in a
separate chapter in this document.
Tetanus
One tetanus case was notified during 2004 in a patient aged
45-54 years. The case survived the infection. The case had
occupational exposure to soil and animals and had no record
of ever receiving tetanus vaccination. Tetanus is a vaccine
preventable disease; tetanus vaccine was introduced into
Ireland in the 1930s and is currently part of the childhood
immunisation schedule. Primary immunisation consists of
three doses of a tetanus toxoid-containing vaccine, routinely
administered at 2, 4 and 6 months of age. A booster dose is
given at school entry with a further dose between the ages of
11-14 years.6 Further boosters may be required at the time of
injury. In Ireland, those considered most at risk of developing
tetanus are in the older age groups, many of whom never had
active immunisation. Tetanus is relatively uncommon in
Ireland; however, nine cases were notified in the last 16 years
with seven of these notified since 1998.
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Toxoplasmosis
During 2004, 33 cases of toxoplasmosis were notified. The
majority of cases (64%) were female. The cases were aged
between 9 and 75 years (mean age, 32 years; median age, 30
years). Toxoplasmosis was not specified as a notifiable
infectious disease in Ireland prior to 2004.
Typhoid
Seven cases of typhoid were notified during 2004. The cases
ranged in age from 4 to 40 years (mean age, 19 years; median
age, 18 years). Four of the cases were male and three were
female. The countries of infection were India (n=2), Pakistan
(n=1), Philippines (n=1), Nigeria (n=1) and not reported
(n=2). Prior to 2004 typhoid was notifiable under the disease
category typhoid and paratyphoid. During 2003 seven cases
of typhoid were notified under typhoid and paratyphoid, this
is identical to 2004.
Viral encephalitis
Five cases of acute encephalitis were notified in 2004, similar
to six cases in 2003. Case classification was provided for two
notifications in 2004; both cases were classified as confirmed.
Details of the causative organisms were not reported for any
of the five cases. Age was reported for four cases, all four
were aged less than 14 years.
Viral meningitis
In 2004, 23 (0.59/100,000) cases of viral meningitis were
notified compared to 39 cases in 2003. Over sixty percent of
cases in 2004 occurred in those aged less than 15 years with
over 30% in the age group 0-4 years. The majority of viral
meningitis notifications in 2004 were male (n=19). Of the 23
notifications, four were classified as confirmed, two  as
probable while case classification was not specified for the
remainder. The causative organisms were not reported for
any of the acute viral meningitis notifications in 2004. The
low number of cases reported in 2004 is considered an
underestimate of the true incidence of disease.
Yersiniosis
Six cases of yersiniosis were notified during 2004. The cases
ranged in age from 9 months to 85 years with three of the
cases aged less than two years. Prior to 2004 yersiniosis was
only notifiable under the disease category food poisoning
(bacterial other than salmonella). For comparison, during
2003, three cases of yersiniosis were notified under food
poisoning.
Discussion
There were important changes in the infectious diseases
legislation when the Infectious Diseases Regulations
(Amendment) (No.3) 2003, S.I. No. 707 of 2003, came into
operation on the 1st January 2004. The changes to the
legislation were based on recommendations from a subgroup
of the Scientific Advisory Committee following a review of the
notification system in Ireland.7 This review was carried out at
the request of the Department of Health and Children. These
amended regulations specified a new and expanded list of
notifiable diseases. The changes to the list of notifiable
diseases are consistent with a European Commission Decision
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on the communicable diseases to be progressively covered by
the Community network (Decision no. 2000/96/EC, under
Decision no. 2119/98/EC of the European Parliament and of
the Council). The amended regulations require all diagnostic
laboratories to report cases of notifiable infectious diseases
identified in their laboratories. This change in the notification
system must be taken into account when interpreting trends
in disease in 2004 compared to previous years.
In total there were 9452 notifications in 2004, a 62% increase
compared to 2003 (these figures exclude the EARSS, STI and
TB data which are presented elsewhere in this document).
This rise in notifications during 2004 is attributed
predominantly to an increase in hepatitis C and noroviral
infection notifications. In 2004, there were 1154 and 1128
notifications of hepatitis C and noroviral infections,
respectively. In comparison, during 2003, there were 77
hepatitis C notifications in the disease category viral hepatitis
unspecified and 14 noroviral notifications in the disease
category gastroenteritis  (when contracted by children under
two years of age). The increase in hepatitis C and noroviral
infection notifications is in part attributed to both being
specified as notifiable diseases in their own right and to
laboratories being legally required to notify infectious
diseases, for the first time in 2004. The fact that notifications
were no longer restricted to children under two years of age
would also account for the increase in noroviral notifications.
During 2004, 1053 noroviral notifications were in those
greater than or equal to two years; such cases would not have
been previously notifiable.
The increase in mumps notifications in 2004 also contributed
to the increase in total notifications in 2004 compared to
2003. Mumps notifications increased ten-fold in 2004
compared to annual figures for 2001-2003 (range 32 to 40
notifications). This increase in mumps was due to an outbreak
that started towards the end of 2004 and affected
predominantly those aged 17-21 years. The mumps outbreak
continued during 2005.
Notifications due to Streptococcus pneumoniae infection
(invasive) also contributed to the increase in notifications in
2004. This disease was first specified as notifiable in its own
right in 2004. There were 174 notifications of S. pneumoniae
in 2004 compared to 2003 when 25 cases were notified
under the disease category bacterial meningitis (including
meningococcal septicaemia). S. pneumoniae appears,
however, to be under-reported, as indicated by comparisons
with the EARSS data. Four hundred S. pneumoniae
bacteraemia cases were reported through the EARSS system
in 2004 as opposed to 174 notifications through the weekly
infectious disease notification system. Cases of invasive S.
pneumoniae that are reported through the EARSS system
should also be reported through the weekly infectious disease
notification system.
There were also increases in notifications of brucellosis,
hepatitis A, leptospirosis, malaria, pertussis and shigellosis in
2004. Perhaps some of these increases may be attributed to
laboratories becoming notifiers for the first time in 2004. It is
also important to recognise that of the 60 brucellosis cases
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57 were classified as probable. Brucellosis cases classified as
probable may be cases of past infection rather than acute
infection as laboratory results for these notifications were
based on an isolated high titre.
There were no apparent increases in diseases such as
meningococcal disease and salmonellosis in 2004 despite
laboratories becoming notifiers for the first time. Perhaps this
is a reflection that laboratories already had informal
arrangements in place to report infections such as these to
public health prior to the changes in legislation.
There were significant and welcome changes in infectious
disease surveillance in Ireland during 2004 with the amended
legislation (S.I. No. 707 of 2003) coming into effect at the
beginning of the year. These changes are in line with EU
requirements on surveillance. The inclusion of laboratories as
notifiers means a more complete picture of the burden of
infectious diseases is now available for Ireland. The successful
piloting of the electronic surveillance system (i.e. CIDR) in
2004 followed by the commencement of national rollout of
the system to laboratories and public health in 2005 is also
helping improve infectious disease surveillance in Ireland. For
CIDR users data is now available in a more timely manner. In
addition, the use of a single data repository is helping improve
data quality and the efficiency with which data is managed.
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Immunisation Uptake 
in Ireland, 2004
Key Points
• Immunisation uptake rates at both 12 and 24 months
improved in 2004
• Uptake of D3, T3, P3, Hib3, Polio3 and MenC3 at 12
months was 83%
• Uptake of D3, T3, P3, Hib3 and Polio3 at 24 months was
89%
• Uptake of MenC3 at 24 months was 88%
• Uptake of MMR1 at 24 months was 81%
Introduction
Widespread access to lifesaving vaccines is considered one of
the great public health achievements of all time.
Immunisation is a simple, safe and effective way of protecting
children against certain diseases. Immunisation programmes
against childhood vaccine-preventable diseases is one of the
most cost-effective health strategies, leading to improved
health, reduced mortality and morbidity and resulting in huge
savings to society and to the health care system.
Through immunisation it is possible to eradicate or eliminate
certain childhood infectious diseases. Nine diseases can
currently be prevented by routine childhood immunisation in
Ireland – diphtheria, tetanus, pertussis, poliomyelitis,
Haemophilus influenzae type b (Hib) disease, meningococcal
group C disease, measles, mumps and rubella. All these
diseases are capable of causing serious complications and
sometimes death. Immunisation against tuberculosis is also
provided in the form of BCG vaccination.
The current Irish childhood immunisation schedule
recommends that newborns should receive one dose of BCG
and that infants receive three doses of DTaP/IPV/Hib and
MenC at two, four and six months of age. Between 12 and 15
months these children should receive the first does of MMR.
Immunisation uptake/coverage statistics for 2004 are
presented in this report.
Materials and Methods
Each health board maintains a childhood immunisation
register. In 2004, health boards provided immunisation
HPSC Annual Report 2004 117
uptake data on a quarterly basis. These data related to
children who reached their first or second birthday in that
quarter and had completed the primary immunisation
schedule i.e. immunisation uptake at 12 and 24 months,
respectively. Data on the number of children eligible for
immunisation in each cohort, the number immunised and the
percentage immunised were provided. Data were collected on
children who had received three doses of diphtheria (D3),
pertussis (P3), tetanus (T3), poliomyelitis (Polio3), H. influenzae
type b (Hib3), meningococcal group C (MenC3), one dose of
vaccine against measles, mumps and rubella (MMR1; uptake at
24 months only) and one dose BCG vaccine (uptake at 12
months only).
Using MS Excel, these data were collated and analysed by
HPSC. Quarterly reports were produced and are available on
the HPSC website.1 Annual immunisation uptake rates
presented in this report were calculated by collating the
quarterly data provided by the health boards. These statistics
relate to children who were 12 and 24 months of age in
2004, i.e. birth cohorts born between 01/01/2003 &
31/12/2003 and 01/01/2002 & 31/12/2002 and who
completed the immunisation schedule outlined above.
Results
Immunisation uptake rates at 12 months
In 2004, national immunisation uptake rates at 12 months
were 83% for D3, P3, T3, Hib3, Polio3 and MenC3. This was an
improvement of 2.5% when compared to 2003 and of 8%
when compared to 2002 (Figure 1). Immunisation uptake
rates in Ireland have been steadily rising each year since 2001,
when uptake of vaccines was between 68-70%. In 2004,
uptake of the above vaccines ranged from 78-79% in the
ERHA to 90% in the MHB. Five of the eight health boards
had uptake rates at 12 months of greater than 85% (Table 1).
BCG uptake rates were available for the first time in 2004 for
an entire year. Five of the eight health boards were in a
position to provide figures (representing a third of the
national birth cohort), and uptake was 90.5%. BCG uptake
ranged from 84% in MHB to 96% in SEHB (Table 1).
Quarterly immunisation uptake rates steadily rose throughout
2004 from 81.6% in Q1-2004 to 84.5% by Q4-2004 (Figure
2). The highest uptake rate at 12 months since the collation
of these data commenced in Q3-2000 was actually reported
in Q4-2004 (84%). This is in contrast to the low that was
seen in Q2-2001 when uptake rates were 65-67% (Figure 2).
Immunisation uptake rates at 24 months
In 2004, an improvement in immunisation uptake rates at 24
months was also seen. National uptake for D3, P3, T3, Hib3
and Polio3 was 89%, 88% for MenC3 and 81% for MMR1
(Figure 3). Compared with 2003, uptake of D3, T3, Hib3 and
Polio3 improved by 3%, P3 by 3.6%, MenC3 by 4% and MMR1
by almost 3%. MMR1 uptake in 2004 was the highest
recorded since the collation of these statistics commenced in
1999 (Figure 3). Uptake of D3, P3, T3, Hib3, Polio3 and MenC3
ranged from 84-86% in the ERHA to 93-95% in the NWHB
(Table 2). Five of the eight health boards reached ≥90%
uptake for D3, T3, Hib3, Polio3, while four health boards also
did so for MenC3 (Table 2). Only one health board, namely
the NWHB, reached the target 95% uptake rate, this was
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Figure 1.  Annual immunisation uptake rates at 12 months in Ireland, 2001-2004
Note scale ranges from 65-95%
T  uptake identical to D  uptake, therefore T  uptake not presented in this chart
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 Table 1. Immunisation uptake rates in children 12 months of age in 2004
       % Uptake at 12 months
                       Cohort born between 01/01/2003 – 31/12/2003
Health Board No. in cohort D  P  T  Hib  Polio  MenC  BCG
ERHA 22,399 79 79 79 79 79 78 na*
MHB 3,820 90 90 90 90 90 90 84
MWHB 5,086 86 86 86 86 86 86 89
NEHB 6,054 86 86 86 86 86 86 na*
NWHB 3,225 89 89 89 89 89 88 91
SEHB 6,760 86 86 86 86 86 86 96
SHB† 8,508 83 83 83 83 83 83 86‡
WHB 5,501 81 81 81 81 81 79 na*
Ireland 61,353§ 83 83 83 83 83 83 91
* Data not available at this time
† As the denominator/number in cohort varied according to vaccine, most commonly 
used number is presented here.  The number in cohort eligible for BCG vaccine was 1332
‡ SHB: part coverage of neonatal BCG, Kerry only
§ Number in cohort eligible for BCG vaccine was 19,925
3 3 3 3 33
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achieved for D3, T3, P3 and Polio3. MMR1 uptake ranged from
76% in the ERHA to 91% in the MHB. The MHB was the only
health board to reach a MMR1 uptake rate of greater than
90% in 2004. No health board reached the target rate of 95%
(Table 2).
Throughout 2004 there was a steady rise in the national
immunisation uptake rates, rising from 88% in Q1-2004 to
93% in Q4-2004 for D3 and T3 (Figure 4). Q4-2004 was the
first quarter since the collation of these data commenced in
Q1-1999, that national uptake rates broke the 90% level,
achieved for D3, P3, T3, Hib3, Polio3. This is in marked contrast
to two to three years previously, quarterly uptake rates had
dropped to 83% and remained consistently at this low from
Q3-2001 until Q3-2002, inclusive (Figure 4).
Discussion
An improvement in immunisation uptake rates at both 12 and
24 months was seen in 2003.2 This improvement continued
in 2004, with even higher rates recorded. The 2004 uptake
figures at both 12 months and 24 months are the highest
reported since collation of these data commenced in 2001
and 1999, respectively. For all the vaccines with the exception
of MMR1, immunisation uptake rates at 24 months was 90%
or greater in four of the eight health boards. These
improvements are very encouraging and are a reflection of
the work done by health care professionals and allied staff in
the regions in promoting immunisation, making updates to
the immunisation registers and undertaking data cleaning on
these systems. It is vital that these improvements can be
built on, so that the required 95% target rate can become a
reality. MMR1 uptake levels still need improving, as uptake
remains 14% below the target rate, with the result that
measles and mumps outbreaks continue to occur.
Complete national immunisation uptake figures on neonatal
BCG, MMR2 and the booster doses i.e. D4, P4, T4 and Polio4
would be useful so that immunisation uptake in Ireland for all
the childhood vaccines can be effectively monitored.
Unfortunately, many of the regional systems do not support
the provision of these additional data in the format required
for meaningful analysis. Initiatives currently being undertaken
by the Programme of Action for Children which include
defining the requirements of a proposed national IT system to
register and track immunisations, producing immunisation
health promotion materials and providing support for regional
immunisation initiatives, will undoubtedly have a very positive
impact in maximising immunisation uptake in Ireland and
ultimately in the elimination and eradication of some
childhood infectious diseases.
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Table 2. Immunisation uptake rates in children 24 months of age in 2004
        % Uptake at 24 months
                Cohort born between 01/01/2002 – 31/12/2002
Health Board No. in cohort D  P  T  Hib  Polio  MenC  MMR
ERHA 22,522 86 86 86 86 86 84 76
MHB* 3,828 94 93 94 94 94 94 91
MWHB 5,038 89 88 89 89 89 88 84
NEHB 5,823 93 93 93 93 93 92 83
NWHB 3,127 95 95 95 94 95 93 87
SEHB 6,657 92 91 92 91 91 90 87
SHB* 8,597 89 89 89 89 89 88 83
WHB 5,476 90 89 90 90 90 87 78
Ireland 61,068 89 89 89 89 89 88 81
       
3 3 3 3 3 3 1
* As the denominator/number in cohort varied according to vaccine, most commonly used 
number is presented here
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Computerised Infectious 
Disease Reporting System (CIDR)
What is CIDR?
• Computerised Infectious Disease Reporting (CIDR) is a
new information system developed to manage the
surveillance and control of infectious diseases in Ireland
• CIDR is a web-based system. All information in CIDR is
held in a single shared national information repository
• CIDR is a shared national information system for the
CIDR partners - the HSE Areas, the Health Protection
Surveillance Centre (formerly NDSC), the Food Safety
Authority of Ireland (FSAI), the Food Safety Promotion
Board (FSPB) and the Department of Health and
Children (DoHC)
CIDR Implementation -progress
• CIDR pilot implementation started in May 2004 in
NDSC, all laboratory and public health sites in the NEHB,
and in national reference laboratories. During the period
of pilot implementation CIDR system was found to be
robust, secure and flexible.
• CIDR was recommended for national implementation in
November 2004 
• National roll-out commenced in January 2005 and by
October 2005 CIDR was being used in four of the HSE
areas (Midlands, South, South-East and North East) in
addition to the reference laboratories. The remaining
HSE areas (West, Mid-west, North-west, and Eastern
region) are expected to implement CIDR in 2006.
(Figure 1)
Introduction
Computerised Infectious Disease Reporting (CIDR) is a system
that has been developed by the HPSC in collaboration with its
partners; the DoHC, the Health Boards, the FSAI and the FSPB.
CIDR utilises modern internet-based technologies. When fully
implemented throughout the country CIDR will provide an
integrated and standardised electronic surveillance system to
collect, collate, analyse and disseminate good quality
laboratory-based and clinical notification data on
communicable disease in a timely manner in Ireland. CIDR
will:
• Provide timely and comprehensive information to facilitate
public health action in individual cases of infectious disease
• Provide standard reports on the incidence and burden of
infectious diseases and antimicrobial resistance nationally,
regionally, and locally
• Allow users to build reports defined by their needs
• Evaluate the effectiveness of prevention and control
programmes nationally, regionally and locally 
CIDR System 
CIDR was designed in 2002, and development and testing of
the system took place between 2003-2004.
The CIDR system uses the latest .NET development
environment with SQL Server 2000 as the backend database
and makes extensive use of XML technology, in line with the
inter-operability requirements of e-government initiatives.
Ensuring that information within CIDR is stored and accessed
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appropriately is key to CIDR. A number of data security
protection systems are in place; access to the system is
provided via the Government Virtual Private Network (G-
VPN); the core system is  firewall-protected; information is
encrypted before being transferred from local PCs to the core
system; and access to the system is limited to authorised
users (username, password and user authentication required
by unique key fobs).
Public health departments and clinical microbiology
laboratories enter and retrieve infectious disease information
from CIDR via standard browser software on their personal
computers. No additional software is required.
The information collected and stored by CIDR is available for
analysis utilising a report writing / business intelligence
application called ‘Business Objects’. This software enables
information to be retrieved from complex relational databases
in a user-friendly fashion yet leaves the underlying data safe.
CIDR pilot in 2004 
During CIDR pilot in the NEHB, the NDSC and in national
reference laboratories in May 2004, CIDR was evaluated by
the Pilot Implementation Evaluation Committee for
performance, functionality, and security. CIDR was found to be
robust, secure and flexible.
The CIDR Project Board recommended national CIDR
implementation at their November 2004 meeting. The board
recommended CIDR roll-out in a phased manner, to each of
the HSE areas, starting with Departments of Public Health
and followed by the local laboratories as closely as possible.
CIDR national implementation (roll-out)
CIDR national roll-out commenced in January 2005, is
continuing throughout 2005 and is expected to be completed
in 2006 (Figure 1). Rolling CIDR out nationally has required an
on-going and close collaboration between the different HSE
areas (Departments of Public Health, and regional
laboratories, IT staff) and the national CIDR team.
As part of CIDR national rollout activities, CIDR team has met
with each HSE area regional implementation committee
(representing public health departments, regional laboratories
and IT management) in the country. These meetings have
provided a forum to update CIDR partners on CIDR
implementation progress, identify local needs for CIDR
implementation, and overall, to assess preparedness for CIDR
implementation. Following these meetings each HSE area
identifies local CIDR users, ensures that local IT systems are in
place and functioning, with Government VPN access, reviews
local business processes and data security measures, and
provides local data protection training. CIDR ‘go live’ date is
then agreed and CIDR application training is scheduled to
precede ‘go live’ (with a short time interval between training
and implementation).
By August 2005, meetings had been held between national
CIDR team with all HSE areas and all areas were preparing for
CIDR implementation. Delays in CIDR implementation were
experienced in a number of HSE areas due to changes in
Public Health structures e.g. organisation and staffing changes.
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Many of these difficulties were resolved in the latter half of
2005. Those areas that were able to resolve these issues early
in 2004 were the first to implement CIDR.
CIDR implementation in laboratories
CIDR implementation in the laboratories requires close liaison
with relevant laboratory personnel to review and document
current processes in relation to infectious disease notification,
and to document the expected practice when each laboratory
participates in CIDR. The laboratory then decides whether
entry of data to CIDR will be manual or via upload from a
Laboratory Information Management System (LIMS). If entry
will be via LIMS, then a LIMS data extract questionnaire is
completed, as well as a data availability analysis, a data
capture analysis, and a data mapping exercise. Based on the
data analysis documentation, CIDR is configured uniquely for
each laboratory. Rules for extracting data, the format of the
data to be imported, and in some cases the type and content
of data may vary. CIDR is designed to facilitate all of this. It is
important to note that the CIDR System is the only software
required to upload data from LIMS systems. The CIDR design
is open and flexible enough to accept data from systems
other than LIMS e.g. Access databases. CIDR currently uploads
delimited text files from other systems. The system imposes
very few restrictions on data entry and/or upload and the
number of mandatory data items is minimised.
By mid 2005, in addition to the laboratories in the North-east
and the reference laboratories, CIDR had been introduced into
all reporting laboratories in the Midlands. Preparations were
taking place for CIDR implementation in the Southeast, the
South, and the Midwest. By the latter half of 2005 senior
scientific laboratory staff in the other regions had met with
the CIDR team and were beginning to work together in
laboratory information system user groups to pool knowledge
and to identify how transition CIDR could be achieved in the
most efficient manner.
CIDR Business Rules 
For the shared national database to function effectively and
efficiently as a surveillance tool for public health action, all
partners/participants in CIDR need to agree and adhere to
principles of participation, or business rules. A National
Business Rules Committee was established in 2001 to provide
a forum for feedback from regional business rules committees
in each health board. Business rules have been agreed by all
CIDR partners. These rules provide a framework which
provides a template of the general principles for participation
in CIDR by all partners.
The business rules template stipulates that information in
CIDR will be:
• Held securely and confidentially
• Obtained fairly and efficiently
• Recorded accurately and reliably
• Used effectively and ethically
• Shared appropriately and lawfully
CIDR communications
Information and updates about CIDR are provided through a
variety of channels. CIDR newsletter, initiated in 2004, is
regularly (approximately bi-monthly) distributed electronically
to all CIDR users and other individuals involved in the
Figure 1. CIDR National implementation progress by HSE area  (September 2005)
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infectious disease notification process (not yet on CIDR). The
newsletter is also posted on the HPSC website for open
access to all interested individuals. The HPSC/CIDR website
also includes sections on Frequently Asked Questions (FAQs)
as well as CIDR presentations to national or international
audiences.
CIDR Disaster Recovery / Business Continuity
The core CIDR system is physically located within the
premises of HPSC. Data is backed up daily and stored securely
off-site. As part of a business continuity plan, in the event of
unanticipated loss of equipment or access to that equipment,
a disaster recovery / business continuity solution was
developed, in conjunction with Fujitsu. This Business
Continuity solution replicates data via the Government VPN
to a Disaster Recovery CIDR environment hosted in the Fujitsu
data centre in Swords, Co. Dublin. The Disaster Recovery
system has been tried and tested and has demonstrated that
this solution can support business continuity in the event of
the main system being down.
HPSC Annual Report 2004124
Measles, 2004
Key Points
• There were 330 measles notifications in 2004
• The crude incidence rate of measles per 100,000
population in 2004 was 8.4 compared to 14.6 in 2003
and 6.2 in 2002
• 47% of the measles notifications in 2004 were classified
as confirmed, 45% were classified as possible while 7%
had no case classification assigned
Introduction
Measles is an acute viral infectious disease characterised by
high fever, cough, conjunctivitis, coryza (runny nose) and rash.
Complications of measles include otitis media, pneumonia,
croup, diarrhoea and encephalitis. Measles results in death in
approximately one to two cases per 1000 population. In
Ireland, three measles deaths were reported during 2000. Two
of these deaths were as a result of pneumonia complicating
measles and one was due to post-measles encephalitis.
Measles is highly contagious but can be prevented by
vaccination. Measles vaccine in Ireland is currently available
as part of the combined measles-mumps-rubella (MMR)
vaccine. More than 99% of individuals who receive two MMR
doses (provided the first dose is given after their first
birthday) develop immunity to measles. Two doses of MMR
are required to ensure protection, as two to five percent of
children fail to respond to one dose of MMR. In Ireland,
vaccination with the first dose of MMR (MMR1) is
recommended at twelve to fifteen months and the second
dose (MMR2) at four to five years.
Measles is a notifiable disease in Ireland and since 2000 is
notified weekly to HPSC. In 2004 there were 330 measles
notifications, a decrease compared to 2003 when 572
measles cases were notified.
Materials and Methods
Measles 2004 notification data, obtained through the weekly
infectious disease notification system, are presented in this
report. A dataset, including identification number, date of
birth, age, sex, date of onset, date of notification/week of
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notification, Community Care Area, county, health board, case
classification, diagnostic specimen type and vaccination
status, is collected through the weekly notification system for
each case. In addition, for a number of measles cases in 2004,
enhanced details, such as information on hospitalisation
status, were reported.
The following case definition is used for measles in Ireland:
Clinical description
Clinical picture compatible with measles i.e. a generalised
erythematous rash lasting greater than three days and a
temperature greater than 38ºC and one or more of the
following cough, coryza (rhinitis), Koplik’s spots or
conjunctivitis.
Laboratory criteria for diagnosis
One of the following:
• Detection of measles IgM antibody in absence of recent
vaccination
• Four-fold or higher rise in measles IgG antibody level in
absence of recent vaccination
• Detection of measles virus (not vaccine strains) in a clinical
specimen.
Case classification
Possible: Clinically compatible cases
Confirmed: A case that is laboratory confirmed or a
clinically compatible case which is
epidemiologically linked to a confirmed case. A
laboratory-confirmed case does not need to
meet the clinical case definition.
A measles case is epidemiologically linked if there was
exposure to a laboratory confirmed case during the infectious
period (four days before to four days after rash onset) and
this exposure occurred within the expected incubation period
of the case under investigation – 7 to 18 days (mean 14 days)
before rash onset.
Measles data presented in this report were taken from the
Computerised Infectious Disease Reporting (CIDR) system on
the 7th October 2005. Analysis of measles data was carried
out using Business Objects and Microsoft Excel. Incidence
rates were calculated based on population data taken from
the 2002 census.
Results
Incidence
A total of 330 measles cases were notified during 2004, giving
a crude incidence rate of 8.4 per 100,000 population. This
rate is lower than the crude incidence rate of 14.6 per
100,000 in 2003 but higher than the incidence rate of 6.2 per
100,000 in 2002. The breakdown of measles cases by health
board and the crude incidence rates by health board during
2003 and 2004 are presented in table 1. In 2004, the highest
number of notifications was in the ERHA (n=223, 68%)
followed by the SHB (n=26, 8%). The highest crude incidence
rate in 2004 was in the ERHA (15.9/100,000) followed by the
NWHB (9.9/100,000).
Case classification 
Case classification was provided for 93% (n=306) of measles
notifications in 2004. Of the 330 notifications, 156 (47%)
were classified as confirmed, 150 (45%) as possible while case
        
Table 1. Numbers of measels notifications and crude incidence rates (CIR) per 100,000 
population by health board in 2003 and 2004 
Health board                      2003                  2004
 Number CIR Number CIR
ERHA 363 25.9 223 15.9
MHB 123 54.6 10 4.4
MWHB 24 7.1 10 2.9
NEHB 15 4.3 17 4.9
NWHB 1 0.5 22 9.9
SEHB 6 1.4 9 2.1
SHB 5 0.9 26 4.5
WHB 35 9.2 13 3.4
Total 572 14.6 330 8.4
Table 2.  Number of measles notifications and rate per 100,000  population by age group 
in 2003 and 2004
Age group (years)        2003                  2004
 Number      Rate Number    Rate
<1 109 200.0 96 176.2
1-2 207 185.3 118 105.6
3-4 61 54.7 38 34.1
5-9 107 40.5 49 18.6
10-14 60 21.0 12 4.2
15-19 6 1.9 3 1.0
20-24 13 4.0 5 1.5
25+ 0 0.0 7 0.3
Unknown 9 - 2 -
Total 572 14.6 330 8.4
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classification was not provided for 24 notifications (7%). Of
the 156 notifications classified as confirmed, 145 were
laboratory confirmed while the remaining 11 were
epidemiologically linked to a laboratory confirmed case.
Age and sex distribution
A breakdown of measles notifications by age group and the
age specific incidence rates per 100,000 population in 2003
and 2004 are presented in table 2. Measles cases were
reported in both children and adults in 2004. The highest
number of notifications (n=118, 36%) in 2004 was in the age
group 1-2 years followed by those aged <1 year (n=96, 29%)
and those aged 5-9 years (n=49, 15%). The highest incidence
rates in 2004 were in the age groups <1 year (176.2/100,000)
and 1-2 years (105.6/100,000). Of the 330 measles
notifications, 167 were female, 159 were male, while sex was
not reported for four notifications.
Seasonality, increased activity and outbreaks
Measles notifications by week of notification are shown in
figure 1. An increase in measles notifications commenced in
early June 2004 (Week 22 2004) with the number of measles
notifications remaining high throughout June, July and August.
It was the beginning of September (Week 35 2004) before
weekly measles notifications dropped to five cases or fewer
for two consecutive weeks. During June, July and August
(Weeks 22 -34) 226 measles cases were notified, this is 68%
of the notifications for the entire year. The majority of these
notifications during the period June-August were notified in
the ERHA (n=162, 72%) followed by the SHB (n=18, 8%) and
the NWHB (n=16, 7%). During the period June to August,
twelve epidemiologically linked measles notifications were
reported by the NWHB, seven by the SHB, while three linked
notifications were reported by the NEHB.
Laboratory data
Laboratory confirmation of acute measles infection is
recommended for all sporadic cases and to confirm the
existence of outbreaks. Diagnosis can be confirmed by testing
oral fluid specimens or serum specimens.
Oral fluid specimens are collected using a foam swab, which
provides a non-invasive method for the confirmation of
measles. Oral fluid specimens should be obtained between
one and five weeks following the appearance of the rash.
Specimens obtained less than one week after rash onset may
lead to a false negative result. Measles can also be confirmed
serologically by detecting measles specific antibodies. In
2004, laboratory results were provided to HPSC for 156
(156/330, 47%) measles notifications.
One hundred and forty-five notifications were laboratory
positive for measles (table 3). Forty-six percent (67/145) of
the laboratory confirmed cases were diagnosed based on tests
of oral fluid specimens, 29% (42/145) were diagnosed using
serum specimens, and 23% (34/145) were diagnosed on both
oral fluid and serum specimens. Eleven notifications were not
lab confirmed but the cases were considered to fit the clinical
criteria for measles.
As measles vaccine induces a positive measles IgM response a
positive IgM test cannot be used to confirm the diagnosis of
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measles in individuals who received measles vaccine six to 45
days before rash onset. Of the 145 laboratory positive
measles notifications 14 had received at least one dose of
vaccine (table 4). The date of vaccination in relation to onset
of disease was not provided for 13 of these. The remaining
case was vaccinated (MMR1) six months prior to onset of
illness.
Vaccination data
Vaccination status was reported for 180 (55%) of the 330
notifications. One hundred and forty-one (141/180, 78%)
notifications were unvaccinated. Fifty percent (71/141) of
those unvaccinated were aged greater than 15 months and
therefore, were potentially eligible for vaccination with MMR1
(assuming there were no contraindications to vaccination).
Nine cases (9/180, 5%) were vaccinated with MMR1 only.
Two of these cases were aged greater than five years;
therefore, they were not age appropriately vaccinated. Of the
nine cases vaccinated with MMR1; two received the vaccine
less than 18 days prior to onset suggesting the possibility
they may have been incubating measles at the time of
vaccination; four were vaccinated greater than two months
prior to onset; the date of vaccination in relation to disease
onset was not reported for three cases. An additional 24
notifications received at least one dose of MMR; however,
cases may have received two doses. The MMR1 vaccination
dates were not reported for these notifications.
Six cases received MMR2; however, it is important to note
that none of these cases were reported as laboratory
confirmed (table 4). The MMR2 vaccination date was reported
for four cases, two of these were vaccinated less than 20 days
prior to onset of illness. Therefore, none of these six cases are
known to be, or can be, classified as vaccine failures based on
the data provided.
Hospitalisation data & complications of measles
Information on hospitalisation status was available for 178
notifications (178/330, 54%). Forty-one cases were
hospitalised representing 23% (41/178) of all cases with
known hospitalisation status (table 5). The length of hospital
stay was only reported for six notifications, with the length of
stay ranging from one to five days. The hospitalised cases
were aged between 6 months and 53 years (mean age, 5
years; median age, 2 years). Twenty-nine of the hospitalised
cases (29/41, 71%) were unvaccinated. Twenty-one (72%) of
these unvaccinated cases were aged greater than 15 months
and so were potentially eligible for vaccination. Six
hospitalised cases had received at least one dose of MMR
(dates of vaccination were not provided for any of the six
cases), one of these was aged greater than five years and so
was not age-appropriately vaccinated. Vaccination status was
not provided for the remaining six hospitalised cases.
Laboratory results were reported to HPSC for 37 of the
hospitalised cases, all 37 were laboratory confirmed.
Information on measles associated complications was
reported for 31 (31/330, 9%) notifications. Seizures were
reported as a complication for two cases. Hypertension was
reported as a complication for one older case (<50 years of
age) but it is unlikely to have been related. The 28 remaining
cases were reported to have no complications.
Table 3. Measles laboratory test results (n=156)
Specimen type   Laboratory result Total
   
* Specimen date in relation to onset date not reported for 2 cases, and for 3 cases the       
specimen was taken <7 days after rash onset   
 †One case that was negative based on an oral fluid specimen (taken < 7 days after onset) but serum 
positive is reported here as laboratory positive   
‡Specimens taken on day of rash onset   
§Laboratory results were only provided for 156 of the 330 notifications   
   
   
          
Oral fluid 67  10 *  77
Serum 42  0   42
Oral fluid and serum 34 † 1 ‡  35
Type not reported 2  0   2
Total 145  11   156§
Positive Negative
Table 4.  Laboratory results and vaccination status of measles notifications in Ireland during 2004
Vaccination status    Laboratory result  Total
 Positive Negative Not Tested/Unknown   
MMR * 14 † 4 15 33 ‡
MMR § 0 0 6 6 §
Nil 74 5 62 141
Not Reported 57 2 91 150
Total  145^ 11 || 174 330  
*24 of the 33 cases known to have at least one dose of MMR may have received two doses     
†For 13 cases date of vaccination in relation to disease onset not provided, 1 case vaccinated 6 months prior to onset     
‡For 27 cases date of vaccination in relation to disease onset not provided, 2 cases were known to be vaccinated <18 days prior to onset     
§MMR2 vaccination dates reported for 4 cases, 2 of these were vaccinated < 20 days prior to onset     
^One case that was negative based on an oral fluid specimen(taken < 7 days after onset) but serum positive is reported here as laboratory positive
||4 possible false negative as specimens taken < 7 days following onset 
1
2
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Discussion
In Ireland, despite the dramatic reduction in measles cases
following the introduction of a measles vaccine in 1985 and
MMR in 1988, measles continues to be a problem with
recurrent outbreaks. Measles outbreaks occurred in 1993 and
2000 with 4328 and 1603 cases notified, respectively.
Following the measles outbreak in 2000 measles notifications
had declined during 2001 and 2002 but measles activity
increased again in 2003 with 572 notifications. In 2004, while
there were fewer notifications compared to 2003, increased
measles activity was observed between June and August. The
majority of notifications during this time were in the ERHA
(n=162). However, epidemiologically linked notifications were
also reported by the NEHB (n=3), NWHB (n=12) and SHB
(n=7) during this time. Since the national collation of cohort
based immunisation uptake data commenced in Ireland in
Quarter 1 1999, MMR1 uptake at 24 months has never
reached the WHO target of 95%.1 While the uptake of MMR
remains below the target of 95% required to prevent the
spread of measles outbreaks will continue to occur.
Ireland continues to have a high incidence of measles
compared to a number of other European countries. In 2004,
the measles incidence was 8.4 per 100,000 in Ireland,
compared with a measles incidence of less than one per
100,000  (as derived from the number of laboratory
confirmed cases) in England and Wales.2 The incidence of
measles in Ireland, in 2004, ranked us second highest
compared to 16 other regions reporting complete data to
WHO Europe.3
The WHO has targeted 2010 for the elimination of measles
and congenital rubella in the WHO European Region. In order
to achieve measles elimination in Ireland a measles
elimination committee was established during 2004 with the
aim of producing a five-year elimination plan. The elimination
plan will place particular emphasis on improving MMR uptake
rates in Ireland. Strengthening of measles surveillance in
Ireland will also be a critical component in the control and
elimination of measles. Measles surveillance is required to
detect cases and to understand the reasons for the occurrence
of the disease so that appropriate and timely control
measures can be implemented. Surveillance also detects
trends and risk factors thereby guiding and monitoring the
effectiveness of control and elimination efforts.
One of the limitations of measles surveillance data provided
to HPSC in 2004 was the incompleteness of data. Laboratory
confirmation of measles is an important aspect of surveillance
but less than half of notifications had laboratory testing
performed. Vaccination status was provided for just over half
the notifications. In addition, for a number of cases, where
vaccination status was provided, the date of vaccination in
relation to disease onset was not reported making
interpretation of the vaccination data difficult. Nearly a
quarter of cases in 2004, where hospitalisation status was
reported, were hospitalised. However, the duration of stay
was not reported for the majority of these cases. Information
on hospitalisation status was not provided for 46% of
notifications, thus limiting interpretation of this data in
relation to all measles notifications. However, it highlights
the severity of measles infection and clearly indicates that
measles causes substantial morbidity for the individual, with
substantial implications for families and health services.
Table 5.  Number of measles notifications in Ireland by age group and hospitalisation status during 2004       
Age group (years)  Hospitalisation status                    Total
 Hospitalised Not hospitalised Not reported
<1 6 41 49 96
1-2 16 47 55 118
3-4 7 17 14 38
5-9 8 21 20 49
10-14 0 7 5 12
15-19 0 1 2 3
20-24 2 0 3 5
25+ 2 2 3 7
Unknown 0 1 1 2
Total 41 137 152 330
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Incomplete surveillance data poses problems during analysis
and interpretation. As measles surveillance and data quality
are improved so to will the ability to control and prevent
measles cases thereby aiding elimination.
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Antibiotic Consumption in 
the Community, 2004
Key Points
• In 2004 comprehensive outpatient (primary care) and
hospital care antibiotic usage data became available for
the first time
• Outpatient antibiotic consumption rose to 20.9 DDD per
1000 inhabitants per day, which is mid-range in Europe,
although strong seasonal fluctuations and regional
pockets of high usage remain. Reliance on broad-
spectrum penicillin was consistent with other countries
where antimicrobial resistance in important pathogenic
bacteria is high
• Hospital antibiotic consumption was estimated at 77
DDD per 100 bed days, which is equivalent to mid-range
of usage in Europe. While differences in usage pattern
are consistent with hospital function, the overall
reliance on third-generation cephalosporins and
fluoroquinolones was high
Introduction and Methods
Surveillance of antimicrobial utilisation has been identified as
a key component of the Strategy for the Control of
Antimicrobial Resistance in Ireland (SARI) and Ireland now
fully participates in the European Surveillance of Antimicrobial
Consumption (ESAC). This report covers antibiotic
consumption in both outpatient (sometimes referred to as
ambulatory, community or primary care) and hospital care
areas collected under ESAC guidelines for 2004 in Ireland.1
ESAC uses the WHO Anatomical Therapeutic Chemical (ATC)
index to classify drugs through five hierarchical levels. For
example, all anti-infective systemic drugs are grouped under J,
antibacterial agents (antibiotics) are denoted as J01,
penicillins are classed as J01C, broad-spectrum penicillins as
J01CA and Amoxicillin as J01CA04. Consumption is measured
in Defined Daily Dose (DDD), which is the assumed average
maintenance dose per day for a drug used for its main
indication in adults. Rates are expressed as DDD per 1000
inhabitants per day (DID) for outpatient consumption and
DDD per 100 bed days used for hospital consumption.
HPSC has purchased Irish pharmaceutical sales data from a
commercial organisation specialising in pharmaceutical
market research, IMS Health. This dataset contains regional,
monthly wholesaler to retail pharmacy sales data for 2004
from over 95% of the wholesalers and manufacturers in
Ireland. Hospital prescribed antibiotics data were supplied
directly by clinical pharmacists from a representative sample
of 14 Irish hospitals for each quarter of 2004.
An automated data-extraction protocol was devised at HPSC
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to obtain the ATC/DDD outputs for antibiotics. The WHO
ATC/DDD version 2005 was used throughout and
retrospective data were re-analysed accordingly.
Results
The overall outpatient antibiotic consumption for Ireland in
2004 was 20.9 DID, a slight rise from the previous year’s rate
of 20.6 DID. Figure 1 shows the breakdown by antibiotic class
for each health board and for Ireland as a whole. Penicillins
accounted for the largest class used (48% of total at 10.1
DID), followed by tetracyclines (19%, 3.9 DID), macrolides
(14%, 3.0 DID), cephalosporins (9%, 2 DID), quinolones (4%,
0.8 DID) and sulphonamides (4%, 0.8 DID). “Others”
comprising aminoglycosides (J01G) and miscellaneous (J01X)
accounted for 2% at 0.3 DID.
The overall hospital antibiotic consumption for Ireland in
2004 is estimated at 76 DDD per 100 bed days. Figure 2
shows the breakdown by antibiotic class for each hospital in
the sample and the mean estimates for Ireland as a whole.
Again penicillins accounted for the largest class used (48% of
total at 37 DDD per 100 bed days), followed by macrolides
(16%, 21), quinolones (10%, 8), cephalosporins (9%, 7),
sulphonamides (5%, 4) and tetracylcines (2%, 2). “Others”
comprising amphicols (J01B), aminoglycosides (J01G) and
miscellaneous (J01X) accounted for 9% at 7 DDD per 100 bed
days.
While there was a wide variation in terms of total antibiotic
consumption in the different hospitals (range 51 to 110 DDD
per 100 bed days), there was little variation in outpatient
antibiotic usage among the different health boards (19.9 to
24.0 DID). However, as shown in figure 3, there was
considerable variability in outpatient antibiotic usage at
county level (16.0 to 29.7 DID).
Penicillins and cephalosporins 
Figure 4 shows breakdown of penicillin usage by subclass.
Penicillin in combination with beta-lactamase inhibitor (such
as amoxicillin/clavulanate) accounted for the largest
proportion of penicillins in both outpatient (48%) and
hospital (57%) care. The proportion of broad-spectrum
penicillins (such as ampicillin and amoxicillin) was next
highest in outpatient care (35%), but not in hospital care
(9%). The second highest proportion of penicillin subclass
used in hospitals was beta-lactamase resistant penicillins
(such as flucloxacillin) at 22%, which was third in outpatient
care (9%). The narrow-spectrum penicillins, such as
benzylpenicillins formed the smallest proportion of total
penicillin usage in both outpatient (8%) and hospital (11%)
care.
Figure 5 shows the breakdown of cephalosporin usage by
generation. Second-generation cephalosporins (such as
cefuroxime) accounted for the largest proportion of
cephalosporins in both outpatient (75%) and hospital (56%)
care. The proportion of first-generation cephalosporins (such
as cefalexin) was next highest in outpatients (17%) but
remained low in hospitals (6%), while the proportion of third-
generation cephalosporin (such as cefotaxime) usage was next
highest in hospital care (38%) and lowest in outpatients (8%).
Table 1. The top ten combined outpatient and hospital care antibiotics used in Ireland for 
2004: Rank (percent) within each healthcare area.  
Antibiotic Outpatient Hospital
J01CR02 Amoxicillin and enzyme inhibitor 1 (23%) 1 (23%)
J01FA09 Clarithromycin 3 (10%) 2 (12%)
J01CA04 Amoxicillin 2 (16%) 6 (4%)
J01CF05 Flucloxacillin 7 (5%) 3 (10%)
J01MA02 Ciprofloxacin 12 (2%) 4 (7%)
J01AA02 Doxycycline 4 (7%) 18 (14%)
J01AA08 Minocycline 5 (7%) 28 (5%)
J01CE02 Phenoxymethylpenicillin 8 (4%) 13 (2%)
J01DC02 Cefuroxime 13 (2%) 5 (4%)
J01FA01 Erythromycin 10 (3%) 12 (2%)
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Figure 1. Outpatient antibiotic consumption by therapeutic class in each health
board in Ireland, 2004.
J01A Tetracyclines
J01C Penicillins
J01D Cephalosporins, Monobactams and Carbapenems
J01E Sufonamides and Trimethoprim
J01F Macrolides, Lincosamides and Streptogramins
J01M Quinolones
Others (J01B + J01G + J01X)
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Commonly used antibiotics
Table 1 shows the top ten, combined outpatient and hospital
care, antibiotics used in Ireland for 2004. At 23%, amoxicillin
and enzyme inhibitor was the most commonly used antibiotic
in both healthcare areas. The fluoroquinolone, ciprofloxacin
was more commonly prescribed in the hospital setting, while
the tetracyclines, doxycycline and minocycline, were more
frequently employed among outpatients. The ten antibiotics
accounted for 78% of outpatient antibiotics but only 67% of
the antibiotics used in hospitals.
Time series analysis
Figure 6 shows consumption of antibiotics in outpatient care,
in DID, for Ireland by quarter since 1993. Antibiotic usage has
been rising steadily and rose to 24.2 DID for the last quarter
of 2003 and 24.3 DID for the last quarter of 2004. These rates
are the highest recorded for any quarter in the entire study
period (12 years). Overall antibiotic use was highest during
the winter months. The mean difference between troughs
(quarters 2 and 3) and peaks (quarters 1 and 4) in antibiotic
use was 23% (range 12% - 34%) and 19% for 2004.
The fluctuation in outpatient antibiotic utilisation during the
course of a year is further demonstrated in figure 7. The mean
monthly rate for the last five years (2000 – 04), dropped
steadily from 21.6 DID in January to 15.2 DID in July and
stayed low for August. The level rose sharply to a plateau in
September, October and November to about 21 DID, then
peaked to 23.2 DID in December.
There was no demonstrable seasonal fluctuation among
hospital antibiotic consumption data.
Discussion
In 2004, comprehensive antibiotic usage data from both
outpatient and hospital healthcare areas for Ireland became
available. Some limitations of the data collection process still
remain. Firstly, the IMS dataset is based on pharmacy
wholesale figures rather than individual prescriptions and may
be subject to bias arising from stockpiling and wastage of
drugs. Secondly, among the hospital antibiotic usage data, a
few outpatient prescriptions could be included; therefore this
section of the analysis may not reflect true inpatient usage
statistics. Lastly, there may be a small number of patients who
fall between outpatient and hospital care areas for which
antibiotic usage data are not available. Nevertheless the data
do show reliability over time and similar data sources have
been successfully used to calculate antibiotic consumption in
other countries. Furthermore, the figures are in line with
previous analyses from the of drugs prescribed under the
reimbursement schemes of the General Medical Services
Payments board.2
In a recent publication on aggregate outpatient antibiotic use
in 32 European countries (2002 data) consumption rate
ranged from 10.0 DID (the Netherlands) to 32.3 DID (France).3
Figures in this report therefore show outpatient usage in
Ireland (20.9 DID for 2004 and consistently around 17-20 DID
over the last 5 years) to be mid-range in Europe. However, the
strong seasonal fluctuation coupled with the reliance on
broad-spectrum penicillins in outpatient antibiotics usage in
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Figure 2. Hospital antibiotic consumption by therapeutic class in each 
institution in the survey for 2004  
J01A Tetracyclines
J01C Penicillins
J01D Cephalosporins, Monobactams and Carbapenems
J01E Sufonamides and Trimethoprim
J01F Macrolides, Lincosamides and Streptogramins
J01M Quinolones
Others (J01B + J01G + J01X)
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Figure 3. Total outpatient antibiotic consumption in Defined Daily Doses per 1000 Inhabitants 
per Day by county in Ireland, 2004
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Figure 4. Relative proportions of penicillins used in outpatient and hospital care
in Ireland, 2004
J01CE Beta-lactamase sensitive penicillins
J01CA Penicillins with extended spectrum
J01CR Combinations of penicillins incl. 
beta-lactamase inhibitors
J01CF Beta-lactamase resistant penicillins
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Figure 5. Relative proportions of cephalosporins used in outpatient and hospital
care in Ireland, 2004
J01DB First-generation cephalosporins
J01DC Second-generation cephalosporins
J01DD Third-generation cephalosporins
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Figure 6. Seasonal variation in outpatient antibiotic consumption in Ireland, 1993-2004
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Figure 7. Variation in outpatient antibiotic consumption by month in Ireland, 2000-2004.
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Ireland is consistent with those countries having a higher level
of resistance among key indicator pathogens, as in Belgium,
Greece and the UK, and much lower than the Nordic
countries, which generally have low levels of resistance.
Furthermore, the overall primary care usage is rising year-on-
year and was highest for the last quarter of 2004 in any year
in Ireland. The usage in regional pockets appears to be
considerably different from the national rate and this regional
variability, though not displaying any obvious geographical
pattern, may reflect differences in socio-economic factors and
regional prescribing practices. Seasonal fluctuation has been
seen every year in outpatient antibiotic consumption and is
probably related to over-prescribing of antibiotics for
respiratory tract infections in winter months.
The pattern of antibiotic usage in hospitals is different from
primary care usage but again the consumption in Ireland
appears to be mid-range in Europe according to ESAC data
(unpublished). Aggregate data from 15 countries in 2002
produced a median of 2.1 with a range of 1.3 to 3.9 DDD /
1000 inhabitants / day. [This unit of measure was employed
as the recommended bed-days denominator is not obtainable
in some countries. The figure is based on the catchment
population of each hospital studied and can be only roughly
estimated for the Irish data]. The equivalent rate for hospital
antibiotic consumption in Ireland is 2.1 DDD / 1000
inhabitants / day, which is the same as the EU median,
although variation in therapeutic choice was observed. The
reliance on fluoroquinolones and third-generation
cephalosporins, as preferred here, has been shown to exert
constant pressure for the selection of resistant strains of
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bacterial pathogens. The variation of antibiotic use between
hospitals in Ireland is in line with the diversity of the type of
hospitals taking part in the survey which included data from
small single-specialist to large teaching hospitals as well as
public, voluntary and private facilities from different
geographical settings. The inclusion of a larger number of
hospitals in the future will lead to improved analyses based
on hospital type and location.
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ACE – Assistant Chief Executive
AMO – Area Medical Officer
ASIR – Age Stanardised Incidence Rate
CIR – Crude Incidence Rate
CFR – Case Fatality Rate
CSF – Cerebo Spinal Fluid
CSSD – Central Sterile Suppliers Department
EARSS – European Antimicrobial Resistance Surveillance System 
ECEH – European Centre for Environment and Health
EHSS – Eastern Health Shared Services
ERHA – Eastern Regional Health Authority - HSE Eastern Region
since 2005. (Dublin, Kildare,Wicklow)
EISS – European Influenza Sureveillance Scheme
ESAC – European Surveillance of Antimicrobial Consumption
ESBL – Extended Spectrum Beta-lactamase
ESEN – European Sero-Epidemiology Network
FBHM – Faculty of Public Health Medicine
FSAI – Food Safety Authority of Ireland
FSPB – Food Safety Promotion Board
GBS – Guillain Barré Syndrome
HAART – Highly Active antiretroviral Therapy
HSE – Health Services Executive
HPA – Health Protection Agency
HUS – Haemolytic Uraemic Syndrome
IBTS – Irish Blood Transfusion Service
ICGP – Irish College of General Practioners
IDU – Injecting Drug User
IMMRL – Irish Meningococcal and Meningitis Reference
Laboratory
IMU – Information Management Unit
MDR – Multi-Drug Resistant
MHB – Midlands Health Board - HSE Midlands Area since 2005.
(Laois, Offaly, Longford, Westmeath)
MMR – Measles Mumps Rubella
MSM – Men who have Sex with Men
MWHB – Mid Western Health Board - HSE Mid Western  
Area since 2005. (Clare, Limerick, Tipperary NR)
NASC – National AIDS Strategy Committee
NDSC – National Disease Surveillance Centre
NEHB – North Eastern Health Board - HSE North Eastern 
Area since 2005. (Cavan, Monaghan, Louth, Meath)
NGO – Non-Governmental Organisation
NSRL – National Salmonella Reference Laboratory
NTBSS – National Tuberculosis Surveillance System
NVRL – National Virus Reference Laboratory
NWHB – North Western Health Board - HSE North Western 
Area since 2005. (Donegal, Sligo, Leitrim)
OLHSC – Our Lady’s Hospital for Sick Children
PCR – Polymerase Chain Reaction
PFGE – Pulse Field Gel Electrophoresis
RCPI – Royal College of Physicians Ireland
RCSI – Royal College of Surgeons in Ireland
RSV – Respiratory Syncytial Virus
SAC – Scientific Advisory Activity
SARI – Strategy for the control of Antimicrobial Resistance
in Ireland
SARS – Severe Acute Respiratory Syndrome
SEHB – South Eastern Health Board - HSE South Eastern Area
since 2005. (Carlow, Kilkenny, Tipperary SR, Waterford,
Wexford)
SHB – Southern Health Board - HSE  Southern Area 
since 2005. (Cork, Kerry)
STI – Sexually Transmitted Infection
TCD – Trinity College Dublin
TTP – Thrombotic Thrombocytopenic Purpura
UCD – University College Dublin
UCH – University College Hospital
WHB – Western Health Board - HSE Western Area 
since 2005. (Galway, Mayo, Roscommon)
WHO – World Health Organisation
Glossary of Terms 
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